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The human body is continuously exposed to a variety of environmental  insults at 
mucosal surfaces via inhalation or ingestion. The immune system has developed 
mechanisms to discriminate between danger, such as bacteria or viruses, and 
self-antigens or harmless substances. At mucosal surfaces, dendritic cells (DCs) 
are constantly patrolling the environment, looking for danger signals. DCs 
express evolutionary conserved pattern-recognition receptors (PRRs) such as 
Toll-like receptors (TLRs), NOD-like receptors, or C-type lectin receptors (CLRs), 
which recognize specific sets of pathogen-associated molecular patterns (PAMPs) 
on invading pathogens. When activated, DCs take up and process antigens into 
small peptides and present those via major histocompatibility complexes (MHC) 
class I and II molecules (1;2). Next, activated DCs migrate towards the draining 
lymph nodes, where they will present peptides to naive T cells and based on the 
expression of different sets of polarizing molecules, drive their development into 
effector T helper cells, such as Th1, Th2, Th17, Th22 or regulatory T (Treg) cells. 
The T-cell polarizing capacity of the DCs is determined by the type of molecules 
they have encountered in the peripheral tissues. For example, DC exposure to 
intracellular microorganisms typically leads to the development of Th1 cells, 
instrumental in cell-mediated defence against viruses and intracellular bacteria, 
while exposure to helminth molecules primes DCs to drive polarized Th2 cells, 
which play a role in immunity against multicellular pathogens such as helminth 
parasites. Likewise, fungi or certain extracellular bacteria activate DCs and 
enhance their capacity to drive Th17 or Th22 cells, which contribute to protective 
immunity against such pathogens (3;4).
 An essential part of T-cell-mediated immunity is the development of non-
responsiveness toward naturally occurring self-antigens or harmless substances, 
such as common environmental allergens (e.g. house dust mite (HDM) or pollen), 
a process which is called immunological tolerance. Tolerance can be divided into 
central tolerance, which is induced in the thymus and bone marrow and where 
the immune system learns to discriminate self from non-self, and peripheral 
tolerance, which occurs in the periphery and prevents over-reactivity of the 
immune system to environmental entities. DCs play a crucial role in determining the 
immune outcome after presenting peptides from harmless molecules. In healthy 
individuals, DCs induce tolerance via induction of anergic T cells, characterized 
by a hypo-responsive status, or via the induction of Treg cells such as FoxP3+ Treg 
cells or IL-10 and/or transforming growth factor-β (TGF-β)-producing T cells (Tr1 or 
Th3 cells) (5). FoxP3+ Treg cells reduce the magnitude of the immune response by 
suppressing effector T-cell responses as well as the activity of other immune cells 
by the secretion of elevated levels of anti-inflammatory cytokines and/or contact-
mediated suppression. The mechanism of suppressive effects with Tr1 and Th3 




Th3 cells (6). In genetically predisposed people, an impaired or weakly developed 
tolerance may result in responses towards self-antigens and the development 
of auto-immune diseases, characterised by aberrant Th1 responses or immune 
responses towards normally harmless allergens, resulting in Th2-polarized allergic 
inflammation. Well-known allergens are derived from house dust mite, cockroach, 
grass pollen, animal and fungal molecules. Interestingly, these allergens share 
common intrinsic biological properties to increase the capacity to penetrate 
the epithelial barrier, such as serine and cysteine protease enzymatic activity or 
the capacity to induce the secretion of angiogenic cytokine vascular endothelial 
growth factor (VEGF). Subsequently, the allergens activate the immune system 
through interactions between epithelial cells and immune cells (7-9). Allergic 
inflammation can be found in various mucosal tissues, resulting in different, but 
related allergic diseases: allergic asthma, atopic dermatitis, allergic rhinitis, toxin 
and food allergies, in which similar but aberrant immune responses can be found. 
In this thesis, we focused on respiratory allergic diseases in the upper and lower 
airways, namely allergic rhinitis and allergic asthma.
Asthma
Asthma is a chronic inflammatory disease in the lower airways of the lungs 
characterized by bronchial hyper-responsiveness, a variable degree of airway 
obstruction which is partially reversible with medication and shows symptoms 
such as shortness of breath, coughing, and wheezing (10). In allergic rhinitis 
(hay fever), allergen exposure leads to irritation and inflammation of the nasal 
airways, including excessive mucus production, itching, conjunctival swelling, 
and eyelid swelling. Allergic rhinitis is very common in patients with allergic 
asthma. Recent investigations have demonstrated that allergic and non-allergic 
upper airway disease are both strong risk factors for developing asthma and 
the current concept is that rhinitis precedes asthma in most patients (11-14). 
Furthermore, exposure to environmental stimuli, such as cigarette smoke, 
diesel particles, ozone and (viral) infections are a known risk factor for asthma 
in genetically susceptible individuals (15). Clinically, at least two forms of the 
disease can be distinguished, allergic and non-allergic (intrinsic) asthma, of which 
the latter represents symptomatic asthma in the absence of eosinophilic airway 
inflammation and is not triggered by allergens, but by other factors such as air 
pollution or viral infection (16). Here, we will discuss allergic asthma, which is 
characterized by the presence of IgE antibodies specific for common allergens in 
the lungs and is mediated for a larger part by Th2 immune responses. 
Inflammatory immune responses in asthma
Barrier epithelial cells make up the first line of defence against inhaled pathogens, 
but also express pattern recognition receptors such as TLRs, CLRs, and protease 
activated receptors (PARs), which recognize PAMPs, such as microbial motifs and 
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allergens (17;18). Interestingly, genome-wide association (GWAS) studies have 
identified some genes involved in regulation of the epithelium barrier function to 
be linked with a higher susceptibility to develop atopy and asthma (19;20). Related 
to this, some allergens have the potential to increase the permeability of the 
epithelium barrier and/or to activate airway epithelial cells to produce cytokines 
and chemokines that attract and activate innate cells (18;21-25). As a consequence, 
passage of inhaled allergens into the airway tissue is facilitated, leading to a 
higher risk of airways sensitization in genetically predisposed individuals, as the 
allergens are sensed by an elaborate network of DCs underneath the epithelial 
layer. Importantly, airway epithelial cells (AECs) have been demonstrated to 
be key modulators of DC behaviour upon allergen exposure via the release of 
chemokines, cytokines and danger signals (26;27), priming activated DCs to drive 
the polarization of naive T cells towards effector Th2 cells (26). Next, Th2-cell-
associated cytokines orchestrate the allergic inflammatory cascade that occurs 
in asthma, including promoting immunoglobulin class-switching to the IgE heavy 
chain, allowing for the production of IgE by B cells (by IL-4 and IL-13), mast cell 
differentiation and maturation (by IL-3, IL-9 and IL-13), Th2 cell survival (by 
IL-4), while IL-5 is solely responsible for eosinophil maturation and survival. IgE, 
once formed and released into the circulation, binds through its Fc portion to 
high affinity receptors on mast cells and basophils, leaving its allergen-specific 
receptor site available for future interaction with allergens (28).
 Once sensitized, re-exposure to the allergen leads to effector responses, 
which can be divided into immediate and late phase reaction. The immediate 
allergic inflammatory reaction is initiated by allergens cross-linking allergen-
specific IgE molecules bound to high-affinity IgE Fc-receptors on mast cells 
and basophils. Consequently, these cells will degranulate and release products 
such as histamine, leukotriene, and prostaglandins, causing immediate vascular 
permeability, mucus production, bronchoconstriction, and constriction of airway 
smooth muscle cells, which are all responsible for the clinical symptoms of 
allergic responses (10;29;30). The early-phase asthmatic reaction is 4-6 hours 
later followed by the late-phase asthmatic reaction induced by the recruitment 
and activation of inflammatory cells such as eosinophils, macrophages or DCs, 
attracted by products released by airway smooth muscle cells and bronchial 
epithelial cells in the early phase. The activated eosinophils produce chemokines 
and inflammatory mediators, which induce substantial damage to the endothelial 
cells but also lead to further recruitment of eosinophils and Th2 cells to the airway 
(31;32), responsible for ongoing and chronic inflammatory processes in the lungs. 
In severe forms of asthma, IL-17-producing T cells are found, which can enhance 
the Th2-mediated inflammation and recruit neutrophils and other inflammatory 
leukocytes into the airways (33;34). The interaction of activated effector Th2 and 
Th17 cells, and structural cells such as AEC and smooth muscle cells will result in 
extracellular matrix formation, hyperplasia of mucus producing goblet cells, basal 





The prevalence and severity of hyper-inflammatory disorders such as allergies, 
but also auto-immunities has dramatically increased in the Western world over 
the last 50 years (35;36). Although genetic predisposition is a risk factor for hyper-
inflammatory disorders (37-39), only sudden changes in environmental factors 
may explain the recent rise in these diseases. In 1989, David P. Strachan was one 
of the first to suggest that infections in early childhood transmitted by unhygienic 
contact with older siblings or acquired prenatal from a mother infected by contact 
with her older children may confer protection against hay fever (40). He proposed 
that the increase in prevalence of allergic disease could be explained by a reduced 
exposure to infectious agents, which were attributed to declining family sizes, 
improvements in household amenities, and increased personal hygiene over the 
past century (40), also known as the ‘hygiene hypothesis’. Initially, an insufficient 
stimulation of Th1 responses due to a limited exposure to bacterial and viral 
pathogens, which in turn cannot counterbalance the expansion of overactive 
Th2 responses, was thought to result in predisposition to allergy (41). However, 
the distorted Th1/Th2 balance hypothesis could not explain the simultaneous 
increase in several Th1-mediated auto-immune diseases, such as type 1 diabetes 
(T1D), multiple sclerosis (MS) and inflammatory bowel disease (IBD) together 
with increases in allergic disorders in the same countries (42;43). Moreover, 
individuals infected by helminths, which are the most potent natural inducers 
of Th2 responses, were paradoxically less likely to have allergic disorders, and in 
some studies anti-helminth treatment even led to increased allergic sensitization 
(35;44).
The ‘Old friends hypothesis'
A more rational explanation for the link between microbial exposure and 
inflammatory diseases in the hygiene hypothesis was proposed in 2003, based on 
several epidemiological studies pointing towards a reversed relationship between 
hyper-inflammatory disorders and vital microbial exposures (35;45). These 
exposures were not the common childhood- and/or other infections, which have 
evolved relatively recently over the last 10,000 years, but rather the microbes 
which were already present in hunter-gatherer times, accompanying mammalian 
evolution and therefore have been tolerated (46-48). These ‘Old Friends’ mostly 
include normal microbiota of the human skin, gut and respiratory tract and that 
of the animals we are closely living with and certain environmental bacteria and 
fungi that inhabit our indoor and outdoor environments. For example, various 
cross-sectional studies demonstrated that children living in farming environments 
were protected from childhood asthma and allergy and this correlation has been 
attributed to contact with livestock (49;50), hay and the consumption of raw 
cow’s milk (51-54). In farming environments, both outdoor and indoor microbial 
exposure are higher and more diverse compared to non-farming environments 
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(50;55;56). Interestingly, a more detailed analysis of the dust composition 
showed that a lower risk of asthma was associated with fungi of the Eurotium 
and Penicillium species (50). Furthermore, ingestion of orofecal microbes (57) 
or colonization of certain probiotic bacteria stimulating the gut associated 
lymphoid tissue (GALT) are also associated with reduced allergic responses or 
certain auto-immune conditions. An association between the composition of the 
gastrointestinal microbiome and the prevalence of allergies has been described in 
several studies, suggesting that Lactobacilli and Bifidobacterium bifidum may have 
a protective effect (58;59). In line with these data, changes in faecal microbiota 
were detected in auto-immune patients suffering from Crohn’s disease and 
ulcerative colitis (60;61). In models of IBD and allergic asthma, germ-free mice 
were more susceptible to pathology and showed higher inflammatory responses 
compared to specific pathogen-free mice (62;63). Furthermore, a link between 
microbiota and dietary fibres was recently described in a HDM allergic airway 
inflammation model showing that fermentable fibres in the diet promoted the 
outgrowth of bacteria from the Bacteroidetes phylum, and thereby increased 
levels of circulating short-chain fatty acids, which influenced DC hematopoiesis 
and functionality in the lungs together with a reduced susceptibility to AAI (64).
 Other ‘Old Friends’ pathogens that are capable of suppressing of Th1 and 
Th2 responses within the host immune system, are those that establish chronicity, 
such as hepatitis A virus and helminths. In contrast to the high prevalence in 
the Western world, it has been documented that children, living in different 
geographical areas endemic for parasitic infection, show a lower prevalence of 
allergic symptoms and atopic sensitization (65). For example, chronic infections 
with intestinal helminths, such as Ascaris Lumbricoides, Trichuris trichiura and 
hookworms, were reported to protect against allergic reactivity in Venezuela 
(66), Gambia (67), Ethiopia (68), Taiwan (69), and Ecuador (70;71). In addition, 
individuals from Gabon (72), Brazil (73), Ghana (74) or Indonesia (75) infected 
with tissue helminths such as schistosomes, filarial worms, and tapeworms, 
all showed a lower skin prick test (SPT) reactivity to allergens compared to 
population studies in areas where the prevalence of helminth infections was 
low or absent (72;76). Strikingly, long-term anti-helminth treatment resulted in 
increased atopic reactivity to HDM, supporting a direct link between helminth 
exposure and protection against allergic diseases (44;77). In addition, helminth-
infected patients with MS showed better clinical disease outcome compared to 
control patients with MS (78). A causal relationship between helminth infections 
and protection against hyper-inflammatory disorders has also been established in 
various mouse models for food allergy (79), asthma (80-82), T1D (83;84), collagen-
induced arthritis (CIA) (85) and experimental auto-immune encephalomyelitis 
(EAE) (86;87).
 Some studies, however, have suggested that infections with helminths 
show no relationship with the incidence of allergy. A study with school children 
in Ecuador reported no change in either SPT reactivity to allergens or allergic 




population living in an area of Indonesia where soil transmitted helminths are 
highly prevalent, showed no statistically significant increase in SPT reactivity 
after two years of three-monthly albendazole treatment (89). Furthermore, 
Trichuris infection was reported to increase cockroach SPT sensitivity in Ethiopia 
(90) and Ascaris lumbricoides was associated with increased risk of asthma and 
an increased number of SPT reactivity to aeroallergens in some areas (91). The 
nematode Toxocara canis exacerbates the development of experimental allergic 
airway inflammation in mice, which is similar to the enhanced allergic responses 
reported in epidemiological studies in humans infected with T. canis (92). Finally, 
infection with Trichinella spiralis and Ascaris suum resulted in enhanced allergy in 
mice (93;94). A possible explanation for this heterogeneity is variation between 
studies in the species of helminth, the age when infections were acquired, but 
also the intensity of infection. A systematic review and meta-analysis of 30 cross-
sectional studies found an inverse relationship between asthma and hookworm 
infection, predominantly the N. americanus species, which was correlated with 
infection intensity (95). Smits et al. demonstrated that lung lavage eosinophilia, 
peribronchial inflammation, and OVA-induced allergic airway inflammation were 
increased during acute Schistosoma (S.) mansoni infection, but significantly 
decreased when infection progressed intro chronicity (80). Furthermore, this 
suppression was correlated with the intensity of infection, showing the highest 
suppression in the high-intensity infected group.
 Altogether these findings indicate that microbial exposure, especially 
during early life, seems to be important to prevent hyper-inflammatory 
conditions. The Th1 versus Th2 imbalance cannot explain the escalation of both 
allergic and autoimmune disorders and imply common underlying mechanisms in 
a deregulated immune system that is increased or activated by pathogens. In this 
thesis, we focussed at immuno-regulatory processes induced during Schistosoma 
helminth infections and the consequences for protection against allergic diseases.
Helminth infections
Immune responses during helminth infections
Schistosomiasis is caused by infection with helminth parasites of the genus 
trematode, Schistosoma. Five species, endemic in different parts of the world, 
and are responsible for over 200 million infected individuals. Most schistosomiasis 
is caused by S. mansoni (present in Africa, South America, Middle East, and 
Caribbean), S. haematobium (Africa and Middle East), and S. japonicum (China 
and Asia). Less prevalent species are S. intercalatum and S. mekongi. Depending 
on the species, different organs are infected, e.g S. mansoni and S. haematobium 
infect the venules of the intestinal mesentery or the bladder, respectively.
 Field studies in endemic areas and animal experiments, mostly considering 
S. mansoni and S. haematobium infections, showed that these schistosomes cause 
two immunologically distinct phases, namely acute and chronic schistosomiasis. 
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Acute schistosomiasis is initiated by immune responses primarily directed 
against worm antigens and mainly Th1 in nature (96). When the first eggs are 
produced by matured worm pairs 5-6 weeks post-infection, the immune response 
switches towards strongly polarized Th2 cell responses. This Th2 response is egg 
antigen-specific, and predominates the worm antigen-specific Th1 response that 
preceded it (96). Increased numbers of circulating eosinophils, basophils and 
mast cells, and high plasma levels of IgE are found during acute phase of infection 
(97;98). The eggs are the major cause of pathology for several reasons, because 
their released products contain hepatotoxic molecules (e.g. omega-1, and IPSE/
alpha-1). However, most morbidity is associated with pathology caused by eggs 
trapped in the gut and liver when infected with S. mansoni or S. japonicum or 
by eggs trapped in the urogenital tract when infected with S. haematobium. The 
induction of type 2 immune responses is an important mechanism that minimizes 
immunopathology in a setting where the immune response is incapable of 
clearing the helminth infection. The formation of type 2-mediated granulomatous 
lesions around the tissue-trapped eggs serves an important host-protective role, 
preventing the released toxins from reaching surrounding tissue cells (99). In IL-4-/- 
mice, infection is acutely lethal and accompanied by excessive tissue injury in the 
liver and intestines (100;101). Type 2 responses during infection promotes wound 
healing via the IL-4- and IL-13-dependent development of alternatively activated 
(AA) macrophages, which can inhibit classical pro-inflammatory macrophage 
activation, responsible for oxidative tissue damage (102;103). Furthermore, 
arginase 1 (Arg1) is an enzyme produced by AA macrophages that is involved in 
down-regulation of inflammation and facilitates tissue remodeling (104). Mice 
lacking Arg1 showed more severe intestinal inflammation following infection with 
S. mansoni (105). Infected RELM-α-deficient mice, another molecule secreted by 
AA macrophages, showed more severe intestinal inflammation or granulomatous 
inflammation and fibrosis around schistosome eggs.
 AA macrophages also shown a role in resolution of acute inflammation 
through the production of immunosuppressive cytokines IL-10 and TGF-β, which 
inhibit IL-17-associated neutrophilia and tissue injury (106-109). Indeed, a 
correlation was found between a higher frequency of Th17 cells during human 
schistosomiasis and severe pathology (110;111). When the organ damage is not 
sufficiently repaired or the inflammation uncontrolled, especially during the latter 
stage of disease, the granulomatous lesions can lead to gross periportal liver 
fibrosis and life-threatening hepato-splenomegaly in severe cases in S. mansoni 
infections (112) or cancer of the urinary bladder in S. haematobium infections 
(113). 
 After reaching the peak of infection at approximately 8 weeks post-
infection, a decline, over time, in proliferation and responsiveness of Th2 cells and 
in the size of granulomas forming around eggs newly deposited in tissues occurs 
and the infections reaches a phase of chronicity (114). In endemic areas most 
individuals infected with Schistosoma exhibit a chronic, relatively asymptomatic 




IL-10 levels and regulatory T-cell frequencies forming a regulatory network that 
can alter immune response to both parasite and harmless antigens (35;115-117).
Regulatory network during chronic helminth infection
Observations that helminths down-modulate inflammation were already 
described in the 1970s for individuals infected with S. mansoni or bancroftian 
filariasis, showing a general hypo-responsiveness in lymphocyte proliferation 
(118;119). Three decades later, human and murine studies revealed that helminths 
are capable of inducing and expanding naturally occurring CD4+CD25+FoxP3+ Treg 
cells (72;120-122), and thereby restraining immune responses against the parasite 
while at the same time protecting the host against excessive inflammation and 
tissue damage (123-125). In humans, S. mansoni-infected patients with high 
proportions of naturally regulatory T cells showed a decrease in the frequency 
of these cells after effective treatment (126). Adoptive transfer experiments 
demonstrated that CD4+CD25+ Treg cells markedly protect against exacerbated 
pathology in murine schistosomiasis (127). Depletion of Treg cells, using anti-CD25 
treatment, increased the anti-parasitic responses in murine Brugia pahangi 
(128), S. mansoni (127) and S. japonicum (129). Evidence that helminth-induced 
CD4+CD25+ T cells can induce spill-over suppression against other diseases such 
as allergies comes from studies showing that depletion of Treg cells, using either 
anti-CD25 antibodies (121;130) or DEREG mice (131), resulted a higher OVA-
induced allergic airway infiltration and eosinophilia in helminth-infected mice. 
 Next through induction of Treg cells, elevated levels of anti-
inflammatory cytokine IL-10 have been reported in many human and murine 
studies in the context of helminth infections and shows pleiotropic effects in 
immunoregulation (132). IL-10 seems to be a key immune modulator in the loss 
of T-cell responsiveness during infection (72;123;133). For example, the loss of 
IL-10 was shown to exaggerate Th2 responses during the acute phase (109;134), 
while others studies reported IL-10 was essential for down-modulation during 
the chronic phase (135). This is however partly debated by a study where they 
showed that IL-10 was responsible for liver pathology, but not so much for immune 
hypo-responsiveness (136). Furthermore, IL-10 promoted AA macrophages 
activation in schistosomiasis, a process which can inhibit Th2 cell proliferation 
by competing for arginine (137), enhance Treg cell development/activity, but 
limit Th17 differentiation and dampen antigen-specific T cell proliferation (105). 
Macrophage maturation and DC differentiation were suppressed in the presence 
of IL-10, thereby limiting their ability to activate effector T cells (138;139). IL-10 
also inhibited the production of pro-inflammatory cytokines, such as TNF-α 
(138;140). 
 Some murine experimental models suggested that not only Treg cell-
derived IL-10, but also non-T-cell derived IL-10 played an essential part in immune 
modulation (141;142). Studies in auto-immunity models have indicated that B 




The concept of regulatory B cells
B cells represent a major component of the immune system and their best 
understood effector functions are antibody production, presentation of antigens 
to T cells and the modulation of immune responses via cytokine production. 
Although, most of these functions serve to amplify immune responses, B cells 
with regulatory capacity have become the focus of intense investigations in 
recent years. However, the general concept that B cells might have the ability 
to induce tolerance, was introduced already in the 1970s by Katz et al., who 
demonstrated that depletion of B cells from splenocytes abolished their ability to 
inhibit an inflammatory reaction in a delayed-type hypersensitivity (DTH) model 
(145;146). More than 20 years later, Janeway and co-workers were the first to 
demonstrate a role of B cells in protection from auto-immunity, showing that B 
cell-deficient mice failed to undergo spontaneous remission from EAE (147). The 
term ‘regulatory B cells’ was introduced shortly afterwards, by Mizoguchi and 
Bhan, who identified an IL-10-producing B-cell subset in gut-associated lymphoid 
tissues (GALT) with up-regulated CD1d expression, which suppressed progression 
of intestinal inflammation by down-regulating inflammatory cascades (148).
Different regulatory B cell populations in mice and humans
Although nowadays the existence of a regulatory subset of B cells is generally 
accepted, there is still some controversy concerning their origin and relationship 
to other B-cell populations (149). In mice, B cells are classified according to their 
developmental origin, into B1 and B2 cells. B1 are considered an innate type of 
lymphocytes and arises early in embryonic development and originate from the 
fetal liver. They produce antibodies with a limited diversity to common pathogens 
and can respond quickly and independently of T cells (150;151). B1 B cells reside 
in the peritoneal and pleural cavities and in the spleen in smaller numbers. They 
are distinguished from the other B cell subsets by expression of CD5, a cell-surface 
glycoprotein.
 B2 lymphocytes on the other hand originate from adult bone marrow and 
populate secondary lymphoid organs. As immature transitional B cells migrate 
from the bone marrow, they will enter the spleen and emigrate to the splenic 
peri-arteriolar lymphatic sheath (PALS). These transitional type I cells (T1) having 
a CD21negCD23negCD24hiIgMhiIgDlow phenotype will develop into transitional type 
2 cells (T2) with a CD21+CD23+CD24hiIgMhiIgD+ phenotype that take residence 
in the spleen primary follicles. T2 B cells differentiate either into mostly sessile 
marginal zone (MZ) B cells or into follicular (FO) B cells depending on the B cell 
receptor (BCR) signal strength. FO B cells represent 60-80% of the B cells and are 
characterized by a CD21int CD23hi phenotype (152). They reside in follicles of the 
spleen, circulate between lymphoid organs and populate lymph nodes where they 




MZ B cells are long-lived cells with a CD21hiCD23-/low phenotype that remain in 
the marginal zone of the spleen (153). They respond to a wide spectrum of T-cell 
dependent and T-cell independent antigens, such as blood-borne pathogens, by 
migrating into the follicle (154) where they activate naive T cells more efficiently 
than follicular B cells and differentiate into plasma cells (155).
 Regulatory B cells or their precursors seem to be able to arise from 
different subpopulations of both B1 and B2 cells. As shown in Table 1, several 
Breg cell populations with varying surface phenotypes have been identified in 
various mouse model systems as well as in different human disease conditions. 
Some regulatory B-cell populations have also been shown to be induced in 
diverse disease settings and in response to many different exogenous and 
endogenous stimuli. Toll-like receptor signalling via TLR-2, -4 and -9 as well as BCR 
signalling and co-stimulation mediated by CD40, CD80/CD86 or B-cell activating 
factor (BAFF) has been demonstrated to induce B cells with suppressive activity 
(144;156-160). One prominent type of ‘natural’ B cells with regulatory capacity 
has been isolated from naive mouse spleens and termed B10 cells by reason of 
their IL-10-dependent suppressive function. Phenotypically, these B cells seem 
to be predominantly CD1dhiCD5+, thus they share surface markers with CD5+ B1 
cells (CD21hiCD23+IgMhiCD1dhiCd93int), MZ B cells (CD1dhiCD21hiCD23loIgMhi) and 
transitional 2 (T2)-MZ precursor B cells (CD1dhiCD21hiCD23hiIgMhi), but do not 
exclusively belong to one of these B cell subpopulations (161).
 So far most evidence comes from murine models and needs to be 
confirmed in humans. Nevertheless, the human equivalent to mouse B10 cells has 
been identified, mainly in a disease setting. A small population within peripheral 
blood CD24hiCD38hiB cells showed impaired IL-10 production and reduced 
suppression of CD4+ T cell cytokine responses in systemic lupus erythematosus 
(SLE) patients (162) and impaired regulatory function in rheumatoid arthritis 
patients (163). Additional, in helminth-infected individuals an increased population 
of CD1dhi B cells was found in peripheral blood, which expressed elevated levels 
of IL-10 (78). B cells expressing CD24hiCD27+ (164) was also associated with IL-10 
production and immune regulation, whereas B cells secreting both IgG4 and IL-10 
were sharing a CD25+CD71hi phenotype in healthy donors, of which the latter 
was reduced in frequency in bee venom allergic individuals(165). Next to IL-10-
secreting, also an enhanced frequency of CD5+ TGF-β-secreting B cells have been 
identified in response to milk allergens in healthy donors, whereas the frequency 
was lower in milk-allergic donors (166;167). Although a number of distinct human 
Breg cell populations have been identified and clear parallels can been drawn in 
function and phenotype with several mouse Breg subsets, one specific marker 
that characterizes human Breg cells has not been identified yet.
 Because of the variety of Breg cell populations and inducing factors, 
several models have been proposed that try to explain their origin and 
development. The first model put forward by Mizoguchi et al. states that distinct 
Breg cell populations are generated from already existing B cell subsets depending 
on distinct activation processes (143). According to this hypothesis, innate type 
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regulatory B cells are generated from MZ B cells in the spleen upon stimulation 
with inflammatory signals such as lipopolysaccharides (LPS) or CpG via toll-like 
receptors. On the other hand, acquired type regulatory B cells develop from 
follicular B cells following activation with CD40 ligand and/or B cell receptor (BCR) 
ligation with self-antigen. A second model proposed by Lampropoulou et al. states 
that all B cells have the capacity to become regulatory B cells due to a hierarchical 
process of stepwise B cell activation, with TLR ligands initiating the process and 
BCR and CD40 engagement serving to further reinforce this differentiation (159). A 
third model, based on shared phenotypic markers between most described IL-10-
producing B cell populations, claims that all different B-cell populations contain 
their own distinct Breg cell precursors, which mature to IL-10-producing cells 
upon activation (168). Taken together, currently available information suggests, 
that in addition to distinct ‘natural’ Breg cell populations arising from specific 
Breg cell progenitors, members of many B cells subsets potentially are able to 







Mouse B10 Yanaba, Bouaziz 2008 Spleen IL-10 CHS
Mouse TZ MZ Carter, Vasconcellos 2011 
Evans, Chavez-Rueda 2007
Spleen IL-10 Arthritis
Mouse MZ Gray, Miles 2007 Spleen IL-10 CIA
Mouse B1 Nakashima, Hamaguchi 2010 Peritoneum IL-10 CHS
Mouse CD1dhi Amu, Saunders 2010
Mizoguchi, Mizoguchi 2010
Spleen IL-10 AAI, IBD, 
anaphylaxis
Mouse CD23+ Wilson, Taylor 2010 Mes. LN ? AAI, EAE





Blair, Norena 2010 Blood SLE
Human CD24hiCD27+ Iwata, Matsushita 2011 Blood IL-10 Healthy and 
auto-immune
Human CD1dhi Correale, Farez 2008 Blood IL-10 MS
Human 'Br3' Lotz, Ranheim 1994 Blood TGF-β CLL
Human 'Breg' Noh, Choi 2010 Blood FoxP3 Healthy
Human CD73-
CD25+CD71+





Table 1. B cell populations with regulatory phenotypes in different species.
B cell populations with regulatory capacity have been identified in various different experimental settings 
or disease conditions in mice, humans and sheep. CHS: contact hypersensitivity, T2-MZ: transitional 2 
marginal zone, CIA: collagen induced arthritis, AAI: allergic airway in-flammation, IBD: inflammatory 
bowel disease, mes.LN: mesenteric lymphnodes, EAE: experimental auto-immune encephalomyelitis, MS: 




acquire suppressive functions as a negative feedback mechanism in response to 
activation.
Immunological effector functions of regulatory B cells
Breg cells are now considered a key regulatory cell type capable of suppressing 
effector functions of various target cells including T cells, DCs and macrophages, 
and can even convert effector T cells into regulatory T cells (169-172). As depicted 
in Figure 1, many Breg cell functions have been demonstrated to be mediated by 
the release of immunosuppressive cytokines. IL-10 is the hallmark cytokine of 
regulatory B cells. It has been shown to be essential for the Breg cell suppressive 
functions in many auto-immune models. Accordingly, the protective function 
of Breg cells in CIA, EAE, non-obese diabetes (NOD), spontaneous and induced 
models of colitis, and IBD is abrogated if B cells are deficient in IL-10 production 
(144;156;173-176). Breg cells controlling homeostasis were also detected in 
adipose tissue, showing that B-cell-specific IL-10 deletion enhanced adipose 
inflammation and insulin resistance in diet-induced obese mice (177). B-cell 
derived IL-10 efficiently suppresses proliferation and inflammatory cytokine 
production of T cells (144;156) and can also induce FoxP3+ regulatory T cells 
(157;178). Some of these effects might be indirect and due to the effects of IL-10 
on innate cell types, as IL-10 is well known to inhibit antigen presentation and pro-
inflammatory cytokine production by DCs, monocytes and macrophages (179).
 In addition to IL-10, TGF-β is the second immunosuppressive cytokine 
found to be secreted by some Breg cell populations to down-regulate inflammatory 
immune responses (166;169;180;181). Similar to IL-10, TGF-β controls 
Figure 1. Suppressive functions of Breg cells mediated by the release of cytokines. Breg cells secrete 
immunosuppressive cytokines causing downregulation of antigen presenting cell function, inhibition of 
T effector cell function and induction of regulatory T cells. Breg: regulatory B cells, Teff/reg: effector/
regulatory T cells, APC: antigen presenting cells.
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inflammation via suppression of Th1 and Th2 inflammatory cytokine production, 
maintenance of Treg cells, and inhibition the function of antigen presenting cells 
(APC) (182). In addition, TGF-β induces apoptosis in target effector cells and acts 
as a negative regulator of mucosal immune responses (183).
 Interestingly, although not generally considered suppressive, IL-12 
production by B cells has also been demonstrated to have immunomodulatory 
capacity in a T-cell receptor (TCR)α knockout mouse model of Th2-mediated 
colitis. In this model, IL-10-mediated induction of IL-12-secreting B cells is 
involved in protection from colitis, as blocking IL-12 using IL-12p35-deficient 
double knockout mice as well as mice treated with anti-IL-12p40 antibodies, 
developed a more severe colitis compared to control mice (184).
 Independent of cytokine secretion, several B cell surface molecules 
have been implicated in the suppressive functions of regulatory B cells (Fig. 2). 
CD1d is not only a major phenotypic marker highly expressed on many Breg 
cell populations, it has also been suggested to have an active role in Breg cell-
mediated suppression. CD1d is a major histocompatibility complex (MHC) class 
I-like molecule and is responsible for the presentation of lipid antigens to Natural 
Killer T (NKT) cells (185;186). Mizoguchi et al. showed that upregulation of CD1d 
on B cells is associated with B cell-mediated protection against intestinal mucosal 
inflammation (148).
 As NKT cells had earlier been shown to be protective in mouse models of 
diabetes (187) and colitis (188), it was feasible to assume that the activation of 
NKT cells was the underlying mechanism of protection in these models. However, 
Figure 2. Suppressive functions of Breg cells mediated by cell contact-dependent mechanisms. Breg cells 
express several cell surface molecules that cause inhibition of T effector cell function, induction of target 
cell apoptosis and induction of regulatory T cells. Breg: regulatory B cells, Teff/reg: effector/regulatory T 
cells, TCR: T cell receptor, PD-1: programmed death-1, PD-L1: programmed death-ligand1, FasL: Fas-Ligand, 




as the TCRα knockout mice used in the studies by Mizoguchi et al., do not have 
NKT cells, the protective effect in this experimental setting has to be mediated 
by another CD1d responsive cell type. Amu et al. later confirmed a CD1dhigh Breg 
cell-dependent, but NKT cell-independent mechanism of protection in a model of 
worm-mediated protection from allergic airway inflammation (81). Another group 
reported, that CD1d expression on APC and splenic MZ B cells was necessary for 
efficient generation of regulatory T cells in CD1d-reactive NKT cell-dependent 
tolerance in immune privileged sites suchsi as the eye (189).
 As described earlier, CD40-CD40L interaction seems to play an important 
role in the differentiation of regulatory B cells. In addition, there are reports 
indicating that CD40 signalling on target cells might also be involved in the 
suppressive mechanisms of B cells. Upon activation, B cells express CD40L on 
their surface (190) and CD40-CD40L interaction has been shown to mediate 
suppression of colonic inflammation by inhibition of T cells (191). Other co-
stimulatory molecules involved in cell contact-dependent suppressive functions 
of B cells, are the B7 co-stimulatory receptors CD80 and CD86. Interaction of B7 
surface receptors with their inhibitory ligands cytotoxic T-lymphocyte protein 
Figure 3. Regulatory B cells in homeostasis and disease. Under normal conditions regulatory B cells control 
T effector cell activation and proliferation in response to harmless self-antigens and allergens, and induce 
and activate regulatory T cells. If this Breg cell mediated control fails, effector T cells can proliferate and 
activate antibody-producing B cells as well as innate immune cell types causing tissue damage. Beff/reg: 




4 (CTLA-4) or CD28 on target cells is crucial in regulating T cell activation and 
peripheral tolerance (192). Expression of B7 molecules has been shown to be 
essential for recovery from EAE due to B cell-mediated generation and recruitment 
of Treg cells (193) as well as for the suppression of colonic inflammation through 
inhibition of effector T cell proliferation (191).
 Moreover, evidence exists that Breg cells upregulate surface molecules 
like Fas ligand (FasL) and programmed death-ligand 1 (PDL-1), which upon 
interaction with their receptors can directly induce apoptosis or inhibition in 
target cells, respectively. Lundy and Fox demonstrated that in a mouse model 
of rheumatoid arthritis, splenic CD5+ B cells express high levels of FasL and that 
induced T cell apoptosis indeed was due to FasL-mediated direct killing by B cells 
(194;195). In EAE, Bodhankar et al. showed that the well-established protective 
effect of estrogen is mediated by B cells. The treatment, in addition to increasing 
the percentage of IL-10-producing regulatory B cells, also induced upregulation 
of PD-L1 expression on B cells (196). Furthermore, in murine experimental 
stroke, PD-L1 and PD-L2 expressing B cells were found to be protective due to 
their capacity to inhibit the activation of inflammatory T cells, macrophages and 
microglial cells through upregulation of PD-1 expression (197).
The role of regulatory B cells in helminth infections
One of the first observations that helminths, such as S. mansoni, could induce 
suppressive B cells was made in μMT mice, which lack mature B cells. These 
mice show increased S.mansoni-induced tissue pathology compared to infected 
wild-type mice (198). Subsequent studies with S. mansoni demonstrated that B 
cells isolated from helminth-infected mice could play a protective role in allergy, 
as transfer of B cells protected recipient mice against systemic fatal anaphylaxis 
or OVA-induced airway inflammation (81;141;199). Interestingly, these regulatory 
mechanisms were only active during the chronic phase of infection, where a 
higher frequency of IL-10 producing B cells was detected (80). Similar results were 
obtained in Heligosomoides polygyrus-infected mice, where CD19+CD5-CD23hi B 
cells isolated from mesenteric lymph nodes of chronically infected mice were able 
to suppress Derp1-induced airway inflammation, although independently of IL-10 
(86). Interestingly, in a worm-only infection of S. mansoni, Breg cells also incurred 
protection against allergic airway inflammation via the induction of regulatory T 
cells (81). In addition, B cell expressed FasL-mediated apoptosis of CD4+ T cells 
appeared to be another mechanism used by Breg cells to control inflammation 
during schistosome infections (200).
 Helminth-induced Breg cells also ameliorated symptoms of several auto-
immune diseases. Adoptive transfer of B cells isolated from H. polygyrus infected 
mice, dramatically reduced EAE severity in uninfected recipients (86) and B cells 
from helminth infected MS patients suppressed T cell activation in vitro (78). 
The production of B-cell IL-10 and the induction of Treg cells were important 
in the reduction of inflammation. Treg cell induction was further shown to be 




failed to efficiently recruit Treg cells into the CNS and mediate recovery from EAE 
clinical disease (193). Overall, there is a strong case for the capacity of helminths 
to induce functional Breg cells that are protective against inflammation-driven 
pathology (Fig. 3).
Pathogen-driven pathways for the induction and expansion of Breg cells
Several studies have highlighted the relevance of Breg cells in down-modulating 
inflammation in both auto-immune and allergic disorders. In addition to the direct 
effects via cytokine production, Breg also function indirectly via the induction or 
recruitment of regulatory T cells and therefore may have promising therapeutic 
potential. However, the mechanism underlying the formation of regulatory B cells 
and their implications in existing therapies must be fully understood, before these 
pathways can be exploited for therapeutic purposes. As demonstrated in Figure 
4, Breg cells can be induced by bacterial or parasitic infections. Therefore, the 
identification of the secreted or excreted pathogenic compound(s) driving Breg 
cell induction provides useful information for the development of therapeutic 
interventions. Indeed, the fact that live schistosome worms could induce IL-10 
producing Breg cells from splenic B cells in an in vitro culture system, suggests 
that helminth antigens have a direct effect on B cells (81). Helminth-related 
TLR ligands may be a likely candidate responsible for helminth-induced Breg 
cell formation, given the implication of certain TLR ligands in the induction of 
Figure 4. Pathways for the induction and expansion of Breg cells. Different secreted or excreted (non)
pathogenic compounds of bacteria, parasites or their eggs can drive Breg cell induction. These compounds 
have been shown to bind to TLR and, thereby induce Breg cell development. As a consequence, Breg 
cells start to produce anti-inflammatory cytokines IL-10 and TGF-β, inhibit effector T cell proliferation and 
induce Treg cells. PAMPs: pathogen associated molecular patterns, TLR: Toll-like receptor, Breg: regulatory 
B cells, Teff/reg: effector/regulatory T cells, LNFPIII: lacto-N-fucopentaose-III, SEA: soluble egg antigens.
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Breg cells in auto-immune models (Fig. 4). Notably, lacto-N-fucopentaose-III 
(LNFPIII), a milk-derived sugar similar to those found on soluble egg antigens 
(SEA) interacts with TLR-4 and stimulates splenic B cells to produce IL-10 (201). 
Likewise, microfilarial extracts from Leishmania major, and Brugia malayi, which 
both bind to TLR-4, can induce IL-10 production by B cells (202). Furthermore, 
lyso-phosphatidylserine, a lipid derived from S. mansoni worms ligated TLR-2 on 
human monocyte-derived DC and promoted Treg cell activity (203). Although it 
is unclear whether this TLR-2 ligating molecule has an effect on the formation of 
Breg cells, SEA stimulation of human B cells did result in TLR-2 mediated elevated 
IL-10 production (204). Overall, the identification of the secreted or excreted 
pathogenic compound(s) driving Breg cell induction provides useful information 
for the development of therapeutic interventions.
Scope of this thesis
In the last few decades, childhood allergy has alarmingly increased to epidemic 
levels not only in westernized countries, but is now also rising in middle-income 
countries. An explanation is suggested by the 'hygiene hypothesis', stating that 
this increase may be in part the result of a decreased exposure to microbial agents, 
leading to reduced education of the regulatory arm of the immune system and 
allowing the development of more inflammatory responses to essentially harmless 
entities, such as allergens. Indeed, epidemiological field studies and experimental 
murine models have pointed at an important role for helminth parasites such as 
schistosomes in protection against allergic diseases. During chronic schistosome 
infections, a profound T-cell hypo-responsiveness is found preventing excessive 
inflammation and tissue damage and in which the induction of a strong regulatory 
network and the cytokine IL-10 are central. Several immune cells can be the 
source of this protective IL-10, including Treg cells. However, studies with auto-
immune models have suggested that also B cells can be an important source for 
IL-10. These IL-10-producing B cells inhibit T-cell proliferation, induce Treg cells 
and, therefore, were named regulatory B cells.
 Regulatory B cells are an exciting new player on the regulatory side, 
however, most data are obtained from auto-immune models. In the context of 
helminth infections, the possible roles of schistosome-induced IL-10-producing 
B cells are unknown, what their role is in protection against allergic airway 
inflammation and how this may be exploited for therapeutic intervention. The 
work in this thesis tries to address several of these questions and aims to improve 
our understanding of these cells which forms a relatively young field of research 
and explores its future applications in controlling allergic diseases.
 In Chapter 2, we first addressed the question whether IL-10-producing 
B cells, when developed during chronic schistosomiasis, can contribute to 
protection against allergic airway inflammation in mice. Next to splenic IL-10-




provided protection against airway inflammation, although independently of 
IL-10. The characteristics and regulatory activities of these pulmonary B cells are 
discussed in Chapter 3.
 Targeting Breg cells for therapeutic applications holds great promise for 
future treatment of autoimmune and allergic inflammatory conditions, however, 
conditions to promote IL-10-producing B cells are still ill defined. Pathogen-
associated molecular patterns, such as Toll-like receptor ligands can stimulate a 
regulatory function in B cells by inducing IL-10. We have optimized in vitro assays 
to investigate which TLR ligands can stimulate B-cell IL-10 and to assess whether 
these IL-10-producing B cells have functional regulatory activities (Chapter 4).
 Since schistosomes were capable of inducing IL-10-producing B cells in 
both mice and men (chapter 2), we next investigated the functional characteristics 
of human regulatory B cells in Gabonese individuals with S. haematobium, 
focusing on their influence on effector T-cell cytokine secretion and regulatory 
T-cell induction in vitro (Chapter 5).
 Allergic disorders are less frequent in individuals with schistosomiasis. 
In addition, allergic responses were suppressed by schistosome-induced Breg 
cells in mice and increased Breg cell frequencies are found in a schistosome-
infected individuals. The question remains whether in people with allergies their 
regulatory compartment, including Breg cells, is less well developed. Indeed, a 
reduced frequency of IL-10-producing peripheral blood B cells in response to the 
milk or bee venom antigens was found in allergic subjects compared to healthy 
tolerant (exposed) individuals (165;167), supporting the notion that Breg cells 
may be weakened in some allergic disorders. Here, we studied the frequency of 
IL-10-producing B cells in peripheral blood of HDM-allergic asthmatic patients 
compared to healthy controls and investigated their inhibitory potential of 
allergen-specific immune responses (Chapter 6). Finally, the main findings 
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Chronic helminth infections, such as schistosomes, are negatively associated with 
allergic disorders. Here, using B cell IL-10-deficient mice, Schistosoma mansoni-
mediated protection against experimental ovalbumin-induced allergic airway 
inflammation (AAI) was shown to be specifically dependent on IL-10-producing B 
cells. To study the organs involved, we transferred B cells from lungs, mesenteric 
lymph nodes or spleen of OVA-infected mice to recipient OVA-sensitized mice, 
and showed that both lung and splenic B cells reduced AAI, but only splenic B 
cells in an IL-10-dependent manner. Although splenic B cell protection was 
accompanied by elevated levels of pulmonary FoxP3+ regulatory T cells, in vivo 
ablation of FoxP3+ T cells only moderately restored AAI, indicating an important 
role for the direct suppressory effect of regulatory B cells. Splenic marginal zone 
CD1d+ B cells proved to be the responsible splenic B cell subset as they produced 
high levels of IL-10 and induced FoxP3+ T cells in vitro. Indeed, transfer of CD1d+ 
MZ-depleted splenic B cells from infected mice restored AAI. Markedly, we found 
a similarly elevated population of CD1dhi B cells in peripheral blood of Schistosoma 
haematobium-infected Gabonese children compared to uninfected children and 
these cells produced elevated levels of IL-10. Importantly, the number of IL-10-
producing CD1dhi B cells was reduced after anti-schistosome treatment. This study 
points out that in both mice and men schistosomes have the capacity to drive the 
development of IL-10-producing regulatory CD1dhi B cells and furthermore, these 
are instrumental in reducing experimental allergic inflammation in mice.
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Introduction
The prevalence and severity of allergic diseases and asthma has increased over 
the last five decades in industrialized countries (1). Conversely, lower prevalence 
of allergic diseases is seen in low income countries. Many epidemiological studies 
have reported an inverse association between helminth infections, which are 
highly prevalent in developing countries, and allergic or auto-immune disorders 
(2–4). In order to study the interaction between helminth infections and protection 
against allergic diseases, murine models of allergic airway inflammation (AAI) and 
helminth infection have been developed. For example, H. polygyrus or T.  spiralis 
infections protected against house dust mite-induced and/or ovalbumin (OVA)-
specific AAI (5;6). In addition, S. mansoni infection protected mice against OVA-
induced airway hyperresponsiveness (AHR) (7); protection was optimal during 
the chronic stage of infection, but not the acute stage (8). 
 Helminth infections are characterized by potent type 2 effector responses 
and a strong regulatory network (9). Regulatory T (Treg) cells are well-known for 
their suppressive capacity, but recent studies in auto-immunity models have 
indicated that also B cells can be important players in immune regulation (10). 
These so-called regulatory B cells are known to influence the immune system 
by the regulatory cytokines IL-10 and TGF-β, influencing T cell proliferation, 
downregulating CD4+, CD8+, NK T cell activation and promoting FoxP3+ Treg cell 
induction (11). Interestingly, a number of studies have reported that B cells may 
have an active regulatory role in various parasitic infections. For example, IL-10-
producing B cells in L. major-infected BALB/c mice are essential in suppressing 
type 1 responses that are necessary to clear infection (12) and S. mansoni-
infected B cell-deficient μMT mice show more extensive hepatic granulomas 
(13). In addition, in a model of systemic anaphylaxis or AAI, in combination with 
S. mansoni infection with adult stage worms only, B cells appeared to be major 
players in addition to IL-10 and Treg cells (7;14). 
 In auto-immunity models several Breg subsets have been identified, 
including marginal zone (MZ), transitional or CD5+CD1dhi B cells (15). Recent 
studies in human auto-immune diseases have substantiated these findings by 
showing human Breg cells in peripheral blood characterized as CD24hiCD38hi (16), 
CD24hiCD27+ (17) or CD1dhi B cells (18). 
 Here, we investigated both in mice and humans whether schistosome 
infections can induce functional Breg cells. Indeed, we identified for the first time 
in peripheral blood of S. haematobium-infected children elevated numbers of IL-
10-producing CD1dhi regulatory B cells, which were decreased after treatment. 
The functional capacity of those schistosome-induced Breg cells was confirmed 
in a mouse model of allergic airway inflammation where Breg-derived IL-10 and 





Mice were housed under SPF conditions at the animal facilities of the Leiden 
University Medical Center in Leiden, the Netherlands. All animal studies were 
performed in accordance with the guidelines and protocols (DEC-07062, 07152, 
08034, 09141) approved by the Ethics Committee for Animal Experimentation 
of the University of Leiden, The Netherlands. The human study was conducted 
according to the principles expressed in the Declaration of Helsinki. The study 
was approved by the “Comité d’Ethique Regional Independent de Lambaréné” 
(CERIL). Written informed consent was obtained from parents or legal guardians 
of children participating in the study.
Animals 
Six week-old female C57/Bl6 OlaHsd mice were purchased from Harlan. For the 
generation of chimeric IL-10-producing B cell-deficient mice, B cell-deficient 
μMT mice were irradiated to remove the bone marrow (BM). Subsequently, the 
irradiated mice were reconstituted with 80% of μMT BM and 20% IL-10-/- BM cells 
(IL-10-deficient) or with 80% of μMT BM and 20% wild-type (WT) BM as described 
(10). DEREG (DEpletion of REGulatory T cells) mice were kindly provided by Dr. T. 
Sparwasser (19). 
Parasitic infection and AAI induction
Mice were infected percutaneously with 40 S. mansoni cercariae and the infection 
lasted until 14 weeks (chronic phase starts around week 12) (8). For AAI induction, 
mice were sensitized twice by i.p. injections of OVA (10 μg/mL, Worthington 
Biochemical Corp) in Imject Alum (2 mg/ml; Pierce) at 17 and 10 days before 
challenge. Sensitization was initiated during week 11 and 12 after the start of 
infection. Ten days after the last injection, mice received OVA aerosol challenges 
(10 mg/ml in PBS) for three consecutive days in the 14th week of infection. Mice 
were sacrificed 24 hours after the last challenge. BAL fluids were collected and 
phenotyped by flow cytometry (8).
Study population
Venous blood was obtained from 20 school children living in Lambaréné (Gabon) 
or from a nearby village (PK15) where Schistosoma haematobium is endemic. S. 
haematobium infection was detected by examining 10 ml of urine passed through 
a 12-µm-poresize filter (Millipore) and the eggs were stained with a ninhydrin 
solution. Children were classified as ‘infected’ if at least one S. haematobium 
egg was detected in the urine or ‘uninfected’ if three consecutive urine samples 
were negative. Infections with intestinal helminths A. lumbricoides, T.  trichiura 
and hookworm were determined by analyzing one fresh stool sample using the 
Kato-Katz method (20). Infection with P. falciparum was determined by PCR (21). 
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S. haematobium-infected children were treated with three doses of praziquantel 
(40 mg/kg) every two months. Intestinal helminth and malaria infected children 
received respectively a single dose of albendazole (400 mg) and an artemisinin-
based combination therapy as per the local guidelines. 
Mouse cell purification and cell sorting
Single cell suspensions were prepared from the spleens, mesenteric lymph 
nodes, and mediastinal lymph nodes by dispersion through a 70-µm cell sieve 
(Becton Dickinson). Perfused lungs were minced to ~1 mm pieces and digested by 
collagenase II/Dnase for 1 hour in 12-well plates (Greiner Bio-One). The digested 
lungs were sequentially dispersed through 70- and 40-µm sieves. Erythrocytes 
were removed from the spleen and lung single cell suspensions by lysis. B 
cells were purified using anti-CD19 MicroBeads (Miltenyi Biotec). Follicular B 
cells (CD21intCD23hi) and marginal zone B cells (CD21hiCD23int/low) were stained 
with antibodies against CD19-PE (MB19-1, eBioscience), CD21-APC (7G6, BD 
Pharmingen), and CD23-FITC (B3B4, eBioscience) in 15 ml tubes (Greiner Bio-One)
and separated using FACSAriaII cell sorting (Becton Dickinson). The sorted 
subsets were routinely ~95% pure. For the depletion of MZ B cells, splenocytes 
were first incubated with CD19-PE (6D5, Miltenyi Biotec), followed by anti-PE 
multisort beads (Miltenyi Biotec) to isolate the B cells. Next, these beads were 
enzymatically removed and the isolated B cells were incubated with CD21-FITC 
(7G6, BD Pharmingen) antibody for 20 minutes. The CD21hi MZ B cell fraction was 
depleted using anti-FITC magnetic beads (Miltenyi Biotec). For the total CD19+ B 
cells, the CD21hi B cells were added back to the CD21neg B cells (mock depletion). 
The depletion of MZ B cells was ~92% pure. CD4+CD25- T cells were enriched using 
anti-CD4 and anti-CD25 MicroBeads with a purity of 96% (Miltenyi Biotec).
Human B cell isolation and characterization
PBMCs were isolated by Ficoll-Hypaque density gradient centrifugation from 
20 ml of heparinized blood. B cells were isolated with anti-CD19 MicroBeads 
(Miltenyi Biotec) with a purity of ~95%. For immunophenotyping different B cell 
subsets, isolated PBMCs were fixed in 2.4% PFA and stained for CD19-PB (HIB19, 
eBioscience), CD1d-PE (51.1, eBioscience), CD5-APC (UCHT2, BD), CD24-PeCy7 
(ML5, ITK Diagnostics), CD27-APCeFluor780 (O323, eBioscience), and CD38-FITC 
(HIT2, BD).
Adoptive transfer of isolated mouse B cells
Recipient mice were sensitized with two injections of OVA at day 0 and day 7. Ten 
days after the last injection, the OVA-sensitized animals received i.v. injection of 5 
x 106 pulmonary, mesenteric, splenic total or splenic CD19+ B cells depleted for MZ 
B cells from OVA sensitized-uninfected or OVA sensitized-infected mice. Blocking 
anti-IL-10R antibody (250 µg; kindly provided by Schering Plough Biopharma) or 
isotype control antibody was given i.p., one day before adoptive transfer. DEREG 
mice, which carry a Diphtheria toxin receptor-eGFP transgene under the control 
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of an additional Foxp3 promoter, were treated with two diphtheria toxin (DT, 1 
μg/ml) i.p. injections: one day before and two days after the adoptive transfer 
of B cells in order to deplete the FoxP3+ Treg cells. After two days, mice were 
challenged for three consecutive days and sacrificed 24 hours after the last 
challenge.
In vitro mouse B cell stimulation and co-culture with CD4+CD25- T cells
Mouse CD19+ B cells and B cell subsets (1 x 105 cells) were cultured in medium 
(RPMI 1640 glutamax; Life Technologies), containing 5% FBS (Greiner Bio-One), 5 
x 10-5 M 2-Mercaptoethanol (Sigma-Aldrich) and antibiotics (100 U/ml penicillin 
and 100 μg/ml streptomycin; Life Technologies), in the presence of SEA from 
S. mansoni eggs (20 μg/mL) for five days in 96-well plates (Greiner Bio-One). 
Supernatants were stored for later cytokine analysis by ELISA. For in vitro 
Treg induction, B cells (1 x 105 cells) were first irradiated with 2600 RAD and 
subsequently, co-cultured with CD4+CD25- T cells (1 x 105 cells) in the presence 
of medium or anti-CD3 (1 µg/ml) plus anti-CD28 (1 µg/ml). An isotype control 
anti-β-gal (10 µg/ml), or anti-IL-10 receptor (10 µg/ml) was added. After five days, 
cells were fixed according to the eBioscience FoxP3 fixation/permeabilization kit. 
Proliferation was confirmed by cell counts. Cytokines were measured in the cell 
culture supernatant using Luminex or ELISA (IL-1β,-4,-5,-6, -10, -12p40/70, -13, 
IFN-γ, TNF-α). 
Human B cell stimulation and intracellular staining for IL-10
Freshly isolated B cells (1 x 105) were stimulated for 48 hours with 2.5 µg/ml 
anti-human IgG/IgM (Jackson ImmunoResearch) in the presence or absence of 10 
µg/ml SEA from S. haematobium eggs. For ICS of IL-10, B cells were restimulated 
with PMA (50 ng/ml), ionomycin (2 µg/ml), and LPS (100 ng/ml; Invivogen) for 6 
hours with the final 4 hours in the presence of BrefA (10 µg/ml; Sigma-Aldrich), 
followed by fixation with FoxP3 fixation/permeabilization kit and stained for 
CD1d-PE (51.1, eBioscience), CD20-APCeFluor780 (2H7, eBioscience), and IL-10-
biotin (JES3-12G8, Abd Serotec) followed by second incubation with streptavidin-
Qdot525 (Invitrogen).
Statistical analysis
All murine results are expressed as mean ± SEM and the different groups were 
tested using the Student’s t-test (two-tailed). Differences between infection 
groups in humans were tested by the Mann-Whitney U test. Differences within 
the same group pre- and post-treatment were compared by Wilcoxon matched 
pairs test. Probability values less than 0.05 were considered significant. *** p< 
0.001, ** p<0.01, * p<0.05 and # p<0.1.
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Results 
IL-10-producing B cells are important for protection against allergic airway 
inflammation
Elevated IL-10 characterizes chronic stages of schistosome infection and 
is produced by B cells starting from week 12 during infection (Fig. S1) (8). To 
determine whether B cells are a dominant source of IL-10 and whether this IL-10 
is essential for protection against AAI during chronic schistosome infections, IL-
10-deficient B cell and control wild-type (WT) chimeric mice were generated and 
chronically infected with S. mansoni followed by an allergic OVA sensitization and 
challenge. The IL-10-deficiency was restricted to the B cells population (confirmed 
by intracellular flowcytometry) as described before (10). In the uninfected 
allergic groups (OVA-uninfected) for both WT and IL-10-/- B cell chimeric mice, the 
bronchoalveolar lavage (BAL) fluid contained significantly more eosinophils (Fig. 
1A), lymphocytes and macrophages compared to uninfected non-allergic groups 
(PBS-uninfected) (data not shown). Nevertheless, in OVA-infected WT mice 
significantly less eosinophils were found compared to OVA-uninfected WT mice 
(Fig. 1A), as previously described (8). In contrast, eosinophilia in the OVA-infected 
group of the IL-10-/- B cell mice was restored and was similar to the OVA-uninfected 
IL-10-/- B cell group and significantly higher compared to the OVA-infected WT 
group. Interestingly, in the PBS-infected group, eosinophilia was equally high, 
suggesting that IL-10-producing B cells were involved in controlling non-allergic 
inflammatory processes during natural infections as well. Furthermore, IL-5, IL-13 
and/or IL-10 were equally elevated in the BAL fluid and mediastinal lymph nodes 
(MedLN) of OVA-infected IL-10-/- B cell mice compared to OVA-uninfected IL-10-/- 
B cell group, whereas these Th2 cytokines were reduced in OVA-infected WT mice 
(Fig. 1B, C). The IL-5 production in the BAL fluid and by T cells in the MedLN was 
also significantly increased in the OVA-infected IL-10-/- B cells mice compared to 
the OVA-infected WT mice as well. As expected, IL-4 remained at low levels due 
to the C57/Bl6 background of the chimeric mice (Fig. 1C). These results indicate 
that IL-10-producing B cells are critically involved in the downmodulation of 
eosinophilia and the Th2 response against OVA antigen leading to protection 
against AAI during chronic schistosomiasis. 
Pulmonary and splenic B cells produce IL-10 and protect against AAI
In order to identify the dominant organ with IL-10-producing B cells during 
infection, we isolated B cells from organs that have previously been described to 
harbor regulatory B cells (spleen), drain schistosome infection sites (mesenteric 
lymph nodes, MLN) or are the effector site where allergic inflammation is found 
(lung). Both pulmonary and splenic B cells, but not mesenteric B cells, from 
chronically-infected mice were able to produce IL-10 upon soluble egg antigen 
(SEA) stimulation, with highest production by splenic B cells (Fig. 2A). To study the 
suppressive activity of isolated B cells from different organs in downmodulating 
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AAI, we adoptively transferred CD19+ B cells from OVA-infected mice into OVA-
sensitized recipient mice. AAI was reduced by pulmonary or splenic but not by 
mesenteric B cells (Fig. 2B). Interestingly, the protective effect of the transfer of 
splenic B cells, but not of pulmonary B cells, was abolished by administering a 
Figure 1. Role of IL-10-producing B cells on OVA-specific AAI during chronic S. mansoni infection. Chimeric 
WT and IL-10-/- B cell mice were infected with S. mansoni and sensitized and challenged for OVA at week 
11 and 12 after the start of infection. BAL fluid was collected and total BAL cells (A) and eosinophils were 
determined. (B) In the BAL fluid, IL-5 and IL-13 were measured by ELISA. (C) MedLN cells were collected and 
restimulated by OVA (10 μg/mL) for four days and IL-4, IL-5, IL-10, and, IL-13 production was determined 
using ELISA. Results are from two independent experiments and each group consists of 6 PBS- and 6 OVA-
uninfected, 8 PBS- and OVA-infected mice.
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blocking IL-10 receptor antibody (Fig. 2C). Furthermore, we observed increased 
percentages of CD4+CD25+FoxP3+ T cells in the lungs of recipient mice, but only 
after administering splenic B cells (Fig. 2D). This data indicate that pulmonary B 
cells can drive IL-10 and Treg cell-independent protection against eosinophilic 
AAI, while splenic B cells protect via an IL-10-dependent mechanism and enhance 
local Treg cell numbers in the lungs.
Figure 2. IL-10 production by B cells from different organs during chronic schistosomiasis and their role in 
protection against AAI. (A) WT mice were treated as in Fig 1A. Splenic, pulmonary or mesenteric B cells 
(1 x 105) were isolated and cultured in the presence of SEA (20 µg/ml) for five days. IL-10 production was 
measured using ELISA and medium value was subtracted. (B) OVA-sensitized recipient mice received 5 x 
106 B cells from different organs. After challenge, BAL cell numbers and eosinophils were determined (C) 
BAL numbers and eosinophilia of mice that received 250 µg isotype control or anti-IL-10R abs per mouse 
one day before the adoptive transfer. (D) The percentage of CD4+CD25+FoxP3+ Treg cells was determined 




Splenic B cells induce Treg cells, which support reduction of AAI 
Regulatory B cells are known to regulate inflammation by recruitment and 
generation of Treg cells in auto-immune disorders (10). Therefore, we cultured 
irradiated splenic B cells from OVA-uninfected or OVA-infected mice with 
CD4+CD25- T cells from naive mice to evaluate Treg cell development. Splenic B 
cells from OVA-infected mice doubled the percentage of CD4+CD25+FoxP3+Treg 
cells (Fig. 3A), while pulmonary B cells did not change the level of Treg cells, as 
already confirmed in vivo. In addition, no shift towards Th1 or Th2 cytokines was 
found during the co-culture showing that the splenic B cells primarily influenced 
the development of Treg cells but not of other T cell subsets (data not shown).  
 Next, we studied the contribution of B cell-induced Treg cells in 
protection against AAI in vivo using OVA-sensitized FoxP3-DTR transgenic DEREG 
mice (19). The temporal loss of FoxP3+ Treg cells during allergen challenge only 
Figure 3. Treg cell induction by IL-10-producing Breg cells. (A) Irradiated splenic B cells (1 x 105) were 
cultured with CD4+CD25- T cells (1 x 105) for 5 days in the presence of anti-CD3 and anti-CD28. Induction 
of CD4+CD25+FoxP3+ Treg cells (in %) by PBS-uninfected B cells was set at one. Fold change in Treg cell 
percentage for OVA-uninfected and OVA-infected B cells was calculated. Graph expresses results from 
three independent experiments. (B) OVA-sensitized DEREG mice were treated as in Fig. 2B in addition 
to a DT or PBS injection. This graph expresses two experiments, consisting of five mice per group. (C) WT 
and IL-10-/- B cell chimeras were treated as in Fig. 1A. The MedLNs were collected and the percentage 
of CD4+CD25+FoxP3+ Treg cells was determined. Figure contains two independent experiments and each 
group consists of 6 to 8 mice. (D) In vitro co-culture were performed as described in (A) in the presence 
of blocking anti-IL-10R or isotype control antibodies. Percentage of Treg cells induced in the presence of 
isotype control was arbitrarily set at 1. Fold change in Treg cell induction in the presence of anti-IL-10R was 
calculated. Graph represents three independent experiments.
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partly restored AAI, showing that in the group with transferred B cells from OVA-
infected mice, B cell-induced Treg cells are only partially involved in protection 
against AAI (Fig. 3B).  
 A causal relationship between IL-10-producing B cells and Treg cells 
has been suggested in antigen-induced arthritis model utilizing similar chimeric 
mice, where loss of IL-10-producing B cells led to significant reduction of Treg 
cells in draining inguinal LN (22). In OVA-infected WT mice, we found more 
CD4+CD25+FoxP3+ Treg cells in the lung-draining MedLN compared to OVA-
uninfected mice, which was not found in OVA-infected IL-10-/- B cell mice (Fig. 3C). 
Using the same in vitro co-culture as describe above, significantly less Treg cell 
induction by splenic B cells was found when anti-IL-10R antibodies were added 
compared to isotype control (Fig. 3D), underlining the role of IL-10 for Treg cell 
induction both in vivo and in vitro.
Schistosome-induced MZ B cells exhibit regulatory activities
We compared the two main splenic B cell subsets, the follicular (FO) B cells and 
the MZ B cells (which are high in CD1d, Fig. S2) for their ability to produce IL-10 
during chronic infection. Sorted subsets from uninfected and infected mice were 
cultured in the presence of SEA, showing that the MZ B cells from infected mice 
produced high IL-10 levels, while FO B cells produced only low levels (Fig. 4A). 
Production of IL-12 and IL-1β remained low in both subsets of infected mice, 
while production of TNF-α and IL-6 was increased in FO cells, but remained low 
in MZ B cells from infected mice (Fig. S3). Based on our findings regarding Treg 
cell induction by total splenic B cells, we questioned whether MZ B cells, as the 
strongest IL-10 producers, were also responsible for Treg cell induction in vitro. 
Therefore, irradiated FO and MZ B cells were cultured with CD4+CD25- T cells and 
Figure 4. MZ B cells show regulatory features. (A) MZ and FO B cells from PBS-uninfected and PBS-infected 
were sorted using flow cytometry and cultured for 5 days in the presence of SEA for IL-10 production as in 
Fig. 2A. (B) Irradiated MZ B cells or FO B cells (1 x 105) were co-cultured with CD4+CD25- T cells as described 
in Fig. 3A. Treg cell induction by MZ or FO B cells from uninfected mice was set at one. Subsequently, 
fold change in Treg cell induction by MZ or FO B cells from OVA-uninfected and OVA-infected mice was 
calculated. Each graph contains three independent experiments with five mice per group. 
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the highest percentage of FoxP3+ T cells was observed in co-culture with MZ B 
cells (Fig. 4B), which was not explained by differences in proliferation as similar 
cell counts were found in cultures with either FO or MZ B cells (data not shown). 
These data indicate that MZ B cells are responsible for the regulatory features 
observed in total splenic B cells by producing IL-10 and by enhancement of FoxP3+ 
T cells. 
 Next, the contribution of the MZ B cells in vivo was investigated by 
depletion of the CD21hi cells from total splenic B cells of OVA-uninfected or OVA-
infected mice by indirect magnetic labeling (Fig. 5A). The transfer of mock-treated 
B cells from OVA-infected mice resulted in a decrease in total BAL cell count and 
eosinophilia (Fig. 5B), as observed before. Importantly, the transfer of CD21+-
depleted B cells restored the severity of AAI and the induction of pulmonary 
FoxP3+ Treg cells was lost (Fig. 5C), confirming the significance of MZ B cells in 
protection against AAI in vivo.
Figure 5. MZ B cells are important in the protection against AAI. (A) Mock-depleted splenic and the MZ-
depleted B cells were injected in OVA-sensitized recipient mice. After challenge, total BAL cell count and 
the number of BAL eosinophils (B) and the percentage of CD4+CD25+FoxP3+ T cells in the lungs (C) was 
measured. Figure is representative of two independent experiments, consisting of five mice per group.
Elevated levels of IL-10-producing CD1dhi B cells in S. haematobium-infected 
Gabonese children
All data regarding schistosome-induced Breg cells stems from mouse models. 
Therefore, we asked whether in humans schistosomes can also induce IL-10-
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 To compare the IL-10 production in B cells from infected and uninfected 
children, total peripheral blood B cells were stimulated with anti-IgG/IgM. 
Subsequent intracellular analysis showed an increase in IL-10-producing B cells 
in the total B cell population of infected children, which was significantly reduced 
after treatment (Fig. 6A,C). Further gating on the CD1dhi B cell subset, confirmed 
that in particular CD1dhi B cells from infected children produce more IL-10 as 
compared to uninfected children (Fig. 6C). Interestingly, we observed a slightly 
different pattern, when the cells were stimulated with anti-IgG/IgM plus SEA (Fig. 
6D). Although also in this condition, both total and CD1dhi B cells from infected 
producing regulatory B cells. PBMC were collected from 20 Gabonese children 
that were either S. haematobium positive or negative (Table 1). All samples were 
simultaneously analyzed for different Breg markers, including CD24hiCD38hi, 
CD24hiCD27+ or CD1dhi(CD5+) (Fig. 6A). No differences were found between 
infected or uninfected donors for CD24hiCD38hi or CD24hiCD27+ B cells (Fig. S4). 
However, significantly higher percentage of CD1dhi B cells was found in infected 
children compared to uninfected children (Fig. 6B). There was also a trend for 
more CD1dhiCD5+ B cells in infected children, however, the total numbers were 
so low (< 1 %) that the reliability of this measurement can be questioned. 
Importantly, after six months of treatment with praziquantel, CD1dhi percentages 
were reduced to levels comparable to the uninfected control group (Fig. 6B). Of 
note, CD1dhi levels in the uninfected control group were significantly increased 
over the same period, which may reflect seasonal changes. Alternatively, 6 out of 
8 donors from the uninfected group had an increased population of plasmablasts 
(CD19+CD24loCD38hi cells; Fig. S5), suggesting a recent, unrelated infection in 
Lambaréné, but not in the nearby village (~15 km, PK15), which may have caused 
the increase in CD1dhi B cells observed in the uninfected children. 
Table 1. Demographic characteristics and infection status of Gabonese children. 
S.h. infected S.h. uninfected
Participants pre-tx/post-tx       10/7       10/8
Mean age in years (range) 10.3 (8-14)  11.2 (8-14)
Sex male/female        5/5        4/6
Mean egg counts (range) 31.7 (1-201)         0
Co-infections:
   Plasmodium falciparum        4/10        1/10
   Ascaris lumbricoides        3/9        3/8
   Trichuris trichiura        3/9        6/8
   Hookworm        1/9        1/8
Co-infections are depicted as number of participants infected out of total number of participants tested.
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children produce significantly more IL-10, this was not downregulated upon 
treatment. This may reflect the presence of a small, but persistent population of 
schistosome-specific B cells in the circulation of previously infected children that 
more readily produce IL-10 in response to SEA, as its cognate antigen, compared 
to the more aspecific stimulation with antibodies directed against IgG/IgM. 
Although it cannot be excluded that SEA may also act as an adjuvant, this seems 
to be less likely as only little IL-10 inducing activity of SEA is found in B cells from 
uninfected children. The fact that somewhat elevated IL-10 levels in anti-IgG/
IgM plus SEA-stimulated B cells from uninfected group at post-treatment are 
observed compared to pre-treatment may again reflect seasonal effects or recent 
unrelated infections, suggested by the enhanced population of plasmablasts in 
this group (Fig. S5). 
 Altogether, these data confirm that also in humans, schistosomes can 
induce IL-10-producing Breg cells, of which the CD1dhi B subset is the most 
prominent. Therefore schistosomes can be recognized as powerful Breg cell 
inducer in both mice and humans.
Figure 6. Presence of IL-10-producing CD1dhi B cells during S. haematobium (S.h.) infection. (A) The CD1dhi 
B cells and the IL-10 production of the total B cells were gated according to the gating strategy depicted 
in this graph. The gating of the IL-10 production of the different Breg subsets is similar as the total B cell 
gating. (B) PBMC were fixed and stained for Breg markers, including CD1d, and analyzed by flow cytometry. 
(C) Total peripheral blood B cells were cultured with anti-IgG/IgM or (D) anti-IgG/IgM plus SEA (10 µg/
ml) for two days. Intracellular IL-10 production of the total B cells and the CD1d+ B cells was determined 
following PMA/Ionomycin/LPS and BrefA stimulation.
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In this study we provide evidence that during chronic schistosomiasis IL-
10-producing CD1dhi B cells are induced in both humans and mice. In mice, 
schistosome-induced IL-10-producing Breg cells were necessary for protection 
against AAI as shown here in chimeric IL-10-/- B cell mice. Splenic B cells were the 
most prominent source for IL-10. Interestingly, the induction of IL-10-producing 
splenic B cells by infectious agents has been previously documented for L. major 
(12), murine cytomegalovirus (23) and for Schistosoma mansoni by our group and 
by Amu et al. (7). These studies favor the concept that chronic infections, drive 
strong immunoregulatory processes in which IL-10-producing B cells seem to be 
important players (reviewed in (24)).
 However, several reports have indicated that B cells can also suppress 
inflammation via IL-10-independent mechanisms. In a colitis model, mesenteric B 
cells were capable of reducing CD4+ T cell-dependent colon inflammation (25) and 
mesenteric CD23hi B cells of H. polygyrus-infected mice were capable of inhibiting 
inflammation both in an EAE model and in an HDM-specific AAI model via an 
unknown mechanism (26). Furthermore, studies in S. mansoni-infected μMT 
mice, where the lack of B cells led to increased liver pathology have suggested 
the involvement of FcR-dependent mechanisms (13). Although their mode of 
action is still unknown, we describe here that transferred pulmonary B cells also 
protected against AAI independently of IL-10 and Treg cells. The putative role of 
antibodies or interaction with FcR has not been studied yet.
 Further, we characterized the phenotype and function of the dominant 
IL-10-producing B cell subset, finding a regulatory function for CD1dhi MZ B cells in 
the spleen of schistosome-infected mice. These data are in line with several other 
studies in auto-immunity models pointing towards MZ B cells as regulators of type 
1 inflammation in SLE, ACAID or CHS (25;27). In addition, it was shown that CD1dhi-
expressing splenic B cells reduced inflammation in a chronic colitis model (25) and 
AAI during ‘worm only’-schistosome infection (7). However, within the spleen, 
other regulatory subtypes have been suggested; a rare CD1dhiCD5+ B cell subset, 
termed B10 cells, which are capable of downregulating inflammatory responses 
in a number of different auto-immune or contact hypersensitivity models (15) 
and transitional type 2 MZ precursor B cells (CD21hiCD23hiIgMhi), described in 
mouse models for CIA (22;25) and SLE (28). It is not fully clear whether these B 
cells are complete unique subsets because there is a substantial overlap between 
the (co-)expression of various markers, such as CD1d, CD5, CD21, CD23 and IgM. 
In addition, local inflammation or chronic infection may change the expression of 
individual markers complicating distinctions between the different proposed cell 
subsets. 
 Here we show that helminth-induced MZ B cells not only reduced allergic 
inflammation via IL-10 but also via the induction/recruitment of active FoxP3+ 
Treg cells. In humans, Treg cells are known to be an important element in reducing 
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allergic inflammation as a mutation in the FOXP3 gene is associated with severe 
eczema, food allergy and high levels of IgE and eosinophilia (29). Furthermore, 
children with asthma show quantitative and functional impairment of CD4+CD25+ 
Treg cells in the BAL fluid (30), while children that have outgrown their allergy 
have increased frequencies of allergen-responsive Treg cells (31;32). Therefore, 
having a system that embraces not only one regulatory system but in fact two 
seems to be a very efficient strategy to develop tolerance to environmental stimuli 
and prevent allergy. Indeed, in several studies Breg function has been linked to 
induction or recruitment of Treg cells, i.e. in a model of ACAID, colitis, EAE, SLE 
(24;25) and allergic inflammation (7). Importantly, in these studies including the 
one presented here, Breg-induced immune regulation does not fully depend on 
Treg cell activity, with the exception of the study by Amu et al. (7), where in fact 
an excess of regulatory CD1dhi B cells was transferred to recipient mice on three 
consecutive days, in contrast to our study with only one B cell injection before the 
challenge.
 Although the majority of studies on Breg cells have been conducted in 
mouse models there are now a few reports that confirm the existence of human 
Breg cells, in which both equivalents of already described ‘mouse’ Breg cells are 
identified in addition to some new subsets. Correale et al. have reported human 
IL-10-producing CD1dhi B cells in helminth-infected MS patients (18). However, 
these patients were infected with a mixture of different helminth species. Here, 
we now have established a causal relation between a single species of helminth, 
schistosomes and increased levels of IL-10-producing CD1dhi B cells, which 
were reduced to ‘normal’ levels after anti-schistosome treatment. Of note, in 
both schistosome-infected and uninfected children, other geohelminths were 
found and for ethical reasons both groups were treated with the antihelmintic 
albendazole in addition to treatment with praziquantel for the schistosome-
infected group. Despite their initial presence, we find reduced numbers of CD1dhi 
B cells after treatment only in the schistosome-infected group but not in the 
schistosome-uninfected group. These data suggest that schistosomes have a 
more dominant effect on Breg cell induction than other gut-associated helminths. 
So far, two other human Breg subsets have been described, namely CD24hiCD27+ 
(17) and CD24hiCD38hi Breg cells in healthy individuals, of which the activity of 
the latter was impaired in SLE patients (16). Interestingly, we did not observe 
differences in these two Breg cell subsets in peripheral blood of infected versus 
uninfected children, indicating that schistosomes primarily induce CD1dhi Breg 
cells. This discrepancy suggests that the various Breg cell subsets described so far 
may require different conditions for their development and activation. 
 As illustrated above, evidence from animal studies and a few human 
studies points towards a significant role for IL-10-producing Breg cells in 
modulating pathogenic hyperinflammatory responses. As such, it would be of 
great therapeutic interest if Breg cell activity could be specifically induced. For 
this, helminth infections may be of particular value, as in vitro exposure of splenic 
B cells to live schistosome worms or peritoneal injection of schistosome egg-
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derived glycans or filarial glycoproteins induces IL-10-producing B cells (7;33). 
However, the identification of the exact helminth-derived molecules involved, is 
a critical step as enhanced activity of Breg cells may form a valuable new target 
for therapy of rhinitis and/or allergic asthma.
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Supplementary figures
Figure S1. IL-10 production by CD19+ B cells during infection. Mouse CD19+ B cells were isolated from the 
spleen at different time points during Schistosoma mansoni infection. The B cells were cultured in the 
presence of SEA from S. mansoni eggs (20 μg/mL) for five days. Supernatants were stored for IL-10 analysis 
by ELISA. This experiment represents one experiment with 3-4 mice per group.
Figure S2. Geometric mean of CD1d fluorescence intensity on total B cells, FO and MZ B cells.
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Figure S4. Percentage of CD24hiCD38hi and CD24hiCD27+ B cells in peripheral blood of Gabonese children 
pre- and post-treatment, performed as described in legend to Fig. 6B.
Figure S5. Percentage plasmablasts in peripheral blood of Gabonese children pre- and post-treatment, 
performed as described in legend to Fig. 6B.
Figure S3. Production of cytokines after 
SEA stimulation. MZ and FO B cells from 
PBS-uninfected and PBS-infected were 
sorted using flow cytometry and cultured 
for five days in the presence of SEA for 
IL-10 production as presented in Fig. 2A. In 
addition, we measured IL1-β, IL-12p40/70, 
IL-6 and TNF-α using Luminex.
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Chronic schistosome infections protect against ovalbumin (OVA)-induced allergic 
airway inflammation (AAI) via the induction of IL-10-producing splenic regulatory 
B (Breg) cells. Previous experiments have demonstrated that schistosome-induced 
pulmonary B cells can also reduce AAI, but they do not act via IL-10. We now have 
further characterized these protective pulmonary B cells phenotypically and in 
their inhibitory capacity.
 We excluded a role for the inhibitory receptor FcγRIIB or Treg cell induction 
as putative AAI-protective mechanisms by schistosome-induced pulmonary B 
cells. However, schistosome-induced B cells showed an increased expression of 
CD86 and reduced cytokine response to TLR ligands compared to control B cells. 
To investigate the consequences for T-cell activation, we cultured OVA-pulsed 
schistosome-induced B cells with OVA-specific transgenic T cells and observed 
less Th2 cytokines and T-cell proliferation compared to control conditions. This 
effect was still there when sufficient co-stimulation or antigen-presentation was 
provided by anti-CD3/28, suggesting that schistosome infections may hamper B 
cells in their T(h2)-cell-stimulatory capacity and induce inhibitory molecules or 
receptors that can suppress Th2 cytokine production. 
 These data suggest that schistosome-induced pulmonary B cells have a 
reduced capacity to support T(h2) cytokine responses which may be achieved by 
the expression of inhibitory molecules and which is not dependent on their APC 
function.
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Introduction
Chronic infections with Schistosoma (S.) mansoni are associated with immune 
hypo-responsiveness and an enhanced regulatory network (1;2). One of the 
regulatory cell types induced by schistosomes are regulatory B (Breg) cells and 
they are characterized by an enhanced production of IL-10 (3-5). They were 
first demonstrated in mouse models, where the absence of B-cell-derived 
IL-10 resulted in exacerbation of auto-immune diseases such as experimental 
autoimmune encephalomyelitis (EAE), collagen-induced arthritis (CIA), lupus, or 
chronic colitis (6-11). Interestingly, also helminth-induced Breg cells can inhibit 
inflammation and were shown to protect against EAE and allergies such as systemic 
fatal anaphylaxis and OVA- or Derp1-induced allergic airway inflammation (AAI) 
(12-16). Part of the Breg cell activity was explained by their capacity to induce 
another regulatory cell type, i.e. Treg cells (3;14;15;17).
 Murine IL-10-producing Breg cells were mostly detected within splenic 
B-cell subsets (18-20). However, some studies suggested that Breg cells may also 
reside within a mesenteric B-cell population, highly expressing the low-affinity IgE 
Fc-receptor CD23 during Heligosomoides polygyrus infection (16), or expressing 
the membrane-bound molecule T-cell Ig domain and mucin domain protein-1 
(Tim-1), important in allograft survival (21) and controlling auto-immune (22) or 
allergic diseases (23). Furthermore, high CD25-expressing B cells were linked with 
Breg activity in humans (24;25) and in mice with inflammatory bowel disease 
(IBD) (26). Lastly, TGF-β-producing Breg cells controlled inflammation in inhalation 
tolerance (27) or diabetes models (28).
 Recently, a number of alternative Breg cell suppressive mechanisms has 
been identified such as production of immunoglobulins with inhibitory actions. 
For example, an inhibitory role in OVA-induced AAI has been suggested for IgG1 
ligating the inhibitory FcγRIIB, the only FcR with an immunoreceptor tyrosine-
based inhibitory motif (ITIM) (29). Likewise, helminths can restrict excessive 
inflammatory responses during chronic infection is via the induction of polyclonal 
IgG molecules (30-32). 
 Another alternative function of Breg cells includes their capacity to 
suppress T-cell proliferation and cytokine production via cell-cell interactions 
that involve inhibitory molecules, or the induction of apoptosis. Examples of such 
inhibitory membrane-bound molecules are PD-1 (on T cells) and its two ligands, 
PD ligand 1 (PD-L1) and PD-L2 (on antigen-presenting cells (APCs)). Murine PD-1 
deficiency resulted in spontaneous autoimmune diseases (33) and PD-L1 was 
shown to regulate Th-1 mediated immune responses, while PD-L2 was more 
involved in regulating mucosal and Th2 responses such as in asthma (34-36). 
Also during helminth infection, PD-L1 and PD-L2 were shown to be upregulated 
and at least important for the induction of Th2 cell exhaustion (37;38). Breg-
driven apoptosis of CD4+ T cells was observed during Schistosoma infection and 
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cockroach-induced asthma by Fas ligand (FasL) expressing CD5+ B cells from the 
spleen or lungs, respectively (39;40).
 B cells can also manipulate T-helper cell responses via antigen-
presentation (41-43) and/or their expression of co-stimulatory signals CD80 and 
CD86, ligating stimulating CD28 or inhibitory CTLA-4 receptor on T cells, resulting 
in T cell proliferation or inhibition (44). For example, down-regulation of B-cell 
CD80 and CD86 expression during Brugia pahangi larvae infection restricted 
T-cell proliferation (45). In contrast, using B-cell B7-/-mice, expression of CD86, but 
possibly also CD80, was essential for B-cell-mediated recovery of EAE (46), and 
human CD25high(hi) Breg cells increased CTLA-4 expression on FoxP3+ Treg cells in 
vitro (24), suggesting that the interaction of some B-cell co-stimulatory molecules 
and CTLA-4 could be important in controlling inflammation.
 We have previously shown that S. mansoni-infected mice are protected 
against OVA-induced AAI and that both splenic and pulmonary B cells from 
infected mice were able to transfer protection against AAI to OVA-sensitized 
mice (15;47). An intriguing finding in our earlier study was that splenic B cells 
inhibited AAI via IL-10 and the induction of Treg cells, while pulmonary B cells 
essentially acted in an IL-10-independent manner (15). In the current study, 
we aim to further explore the effector mechanism by which pulmonary B cells 
can protect against AAI. We demonstrate here that B cells from OVA-sensitized 
and -challenged mice which were infected with schistosomes do neither share 
the markers nor the function of splenic regulatory B cells, but have a reduced 
cytokine response to TLR ligands and reduced capacity to prime T cell into Th2 
cells, which was independent of their antigen-presentation capacity, suggesting 
the involvement of other, yet unidentified, suppressive molecules. 
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Six week-old female C57BL/6 OlaHsd mice were purchased from Harlan. DEREG 
(DEpletion of REGulatory T cells) mice were kindly provided by Dr. T. Sparwasser 
and bred in the animal facilities of LUMC (48). FcγRIIB(CD32)-deficient mice of 
a C57BL/6J background were kindly provided by J. Sjef Verbeek (49). Mice were 
housed under SPF conditions in the animal facilities of the LUMC, Leiden, the 
Netherlands. All animal studies were performed in accordance with the guidelines 
and protocols (DEC-11166, 12182) approved by the Ethics Committee for Animal 
Experimentation of the University of Leiden, The Netherlands.
Parasitic infection and AAI induction
Mice were infected percutaneously with 36 S. mansoni cercariae and lasted until 
the chronic phase of infection (15 weeks) (15;47). For AAI induction, mice were 
sensitized twice by i.p. injections of OVA (10 μg/mL, Worthington Biochemical 
Corp) in Imject Alum (2 mg/ml; Pierce) at week 13 and 14. Seven days after the 
last injection, mice received OVA aerosol challenges (10 mg/ml in PBS) for three 
consecutive days. Mice were sacrificed 24 hours after the last challenge. BAL 
fluids were collected and phenotyped by flow cytometry (15;47).
Mouse cell purification and cell sorting
Perfused lungs were minced to ~1 mm pieces and digested by collagenase III 
(Worthington) and Dnase for 1 hour in 24-well plates (Greiner Bio-One). The 
digested lungs were sequentially dispersed through 70-µm sieves. Erythrocytes 
were removed from the lung single cell suspensions by lysis. Adhesive cells were 
removed from cell suspensions by passage over LS columns (Miltenyi Biotec). 
Next, B cells were purified using anti-CD19 MicroBeads (Miltenyi Biotec). B cells 
were stained with antibodies against CD23-PeCy7 (eBioscience) and separated 
using FACSAriaII cell sorting (BD). The sorted subsets were routinely ~95% pure. 
Untouched splenic CD4+ T cells were enriched using MicroBeads (Miltenyi Biotec) 
and ~95% pure.
Adoptive transfer of isolated pulmonary B cells
Recipient mice were sensitized with two injections of OVA/Alum at day 0 and 
day 7, as described above. Ten days after the last injection, the OVA-sensitized 
animals received an i.v. injection of 5 x 106 CD19+ B cells from OVA-uninfected 
or OVA-infected mice or PBS as a control. DEREG mice were treated with two 
diphtheria toxin (DT, 1 μg/ml) i.p. injections or PBS as a control: one day before 
and two days after the adoptive transfer of B cells in order to deplete the FoxP3+ 
Treg cells. After two days, mice were challenged for three consecutive days and 




Ex vivo pulmonary B cells were characterized using: CD25-FITC, CD86-PerCP5.5 
(both BD) CD40-PE (eBioscience), Tim-1-PE, B220-V510, PD-L1-PeCy7 (all 
Biolegend), LAP-1-PerCPeFluor710, CD23-PeCy7, CD80-APC, FasL-APC, MHC 
Class II-APC-Cy7, B220-APCCy7, life/dead marker Violet 450, and PD-L2 Biotin 
(all eBioscience) combined with streptavidin-Qdot525 (Life Technologies). For all 
flow cytometric measurements, FcγR-binding inhibitor (2.4G2) was added and 
FMOs were used for gate setting for all surface markers and cytokines.
In vitro B cell stimulation
Pulmonary CD19+ B cells and B cell subsets (1x105 cells) were cultured in 
medium (RPMI 1640 glutamax; Invitrogen Life Technologies), containing 
5% heat-inactivated Fetal Bovine Serum (FBS, Greiner Bio-One), 5 × 10−5 M 
2-Mercaptoethanol (Sigma-Aldrich) and antibiotics (100 U/mL penicillin and 100 
μg/mL streptomycin; Invitrogen), in the presence of LPS (100 ng/ml) or CpG1826 
(5 μg/ml) for five days. Supernatants were stored for later cytokine analysis by 
IL-10 and IL-6 ELISA (BD).
Immunoglobulin measurements
Total and OVA-specific IgG1 and IgG2a and total IgA were measured from the first 
1 ml of collected BAL fluid using ELISA kits (BD). 
In vitro B cell stimulation and co-culture with CD4+ T cells
Pulmonary CD19+ B (1x106/ml) cells were loaded with 10 μg/ml OVA17 peptide 
(OVA323-339: ISQAVHAAHAEINEAGR, kindly provided by M.G.M. Camps) for 1 hour at 
37 ° C, washed, and subsequently co-cultured with OT-II CD4+ T cells (1x105 cells/
well) at 1:1 ratio in the presence or absence of anti-CD28 (1 μg/ml). Additionally, 
CD19+ B cells were co-cultured with CD4+ T cells at 1:1, 1:2, 1:4 ratio, in the 
presence of medium or anti-CD3 (1 µg/ml) plus anti-CD28 (1 µg/ml). To assess 
proliferation, T cells (10 x 106/ml) were incubated with CFSE (0.5 μM) for 15 min. 
In some conditions, the following blocking antibodies were added to the cultures: 
10 µg/ml isotype control anti-βGal and anti-TGF-β (kindly provided by L. Boon). T 
cells were incubated for 30 minutes at 37 °C with 10 μg/ml anti-IL-6 receptor-α/
CD126 (eBioscience) or 10 µg/ml anti-IL-10 receptor ((kindly provided by L. 
Boon). After three days, CFSE-labelled T cell co-cultures were stained with anti-
CD3-eFluor450, CD25-PE, B220-eFluor780, 7-AAD, CD4-biotin (all eBioscience) 
with streptavidin-Qdot525 to measure T-cell proliferation of activated T cells. For 
cytokine analysis, the cells were restimulated with 100 ng/ml PMA and 1 μg/ml 
ionomycin for six hours in the presence of 10 μg/ml Brefeldin A (all Sigma-Aldrich) 
for the last four hours, followed by fixation using 1.9% PFA (Sigma-Aldrich). Next, 
the cells were staining for IL-4-PE (BD), CD3-eFluor710, IFN-γ-FITC, IL-17-PeCy7, 
IL-10-APC, IL-13-eFluor450, and B220-eFluor780 (all eBioscience).
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Apoptosis measurement
After 24 and 72 hours of co-culture of pulmonary B cells and CD4+ T cells, T cells 
were stained with anti-CD3-eFluor450, 7-AAD, B220-eFluor780 (all eBioscience), 
CD25-FITC (BD), CD4-biotin with streptavidin-Qdot525, and AnnexinV-PE (BD) for 
30 min at 4 °C in AnnexinV staining buffer (BD). Dead cells were removed from 
analysis on the basis of 7-AAD+ staining.
Statistical analysis
All results are expressed as mean ± SEM and were tested using the independent 





Phenotypic characterization of schistosome-induced pulmonary B cells
We first set out to investigate whether a specific pulmonary B-cell subset or the 
expression of specific surface markers linked to Breg cell activity were selectively 
expanded during schistosome infection compared to uninfected mice. Pulmonary 
B cells did not contain typical Breg populations that have been described in 
the spleen, such as CD1dhi(CD5+), CD21hiCD23lo MZ or CD1dhiCD21hiCD23hiIgMhi 
transition type 2 MZ B cells (less than 0.5% during infection). Therefore, we 
analyzed several other cell-surface markers as putative markers of Breg cell activity, 
i.e. the membrane-bound marker latency-associated peptide (LAP), as part of a 
latent TGF-β complex, Tim-1, CD23 and CD25 (16;21-23;27;28;50). Interestingly, 
pulmonary B cells from chronically S. mansoni-infected, OVA-sensitized and 
-challenged (OVA-infected) mice expressed similar levels of LAP-1 (3%) and CD25 
(0.4%) as found on B cells from uninfected OVA-sensitized and challenged (OVA-
uninfected) control mice (Fig. 1A), suggesting that TGF-β- or CD25-expressing B 
cells are probably not involved in protection. Although the expression of Tim-1 
was slightly increased, the overall expression on schistosome-induced pulmonary 
B cells remained rather low (MFI of 115 compared to an MFI of 79 on B cells from 
OVA-uninfected mice). However, the one marker that was clearly enhanced on a 
large subset of pulmonary B cells in OVA-infected mice was CD23 (approximately 
80%) (Fig. 1B). To investigate whether this subpopulation was responsible for the 
protection against allergy, we sorted CD23low/intermediate(int) or CD23hi B cells from 
OVA-infected mice and transferred those cells to OVA-sensitized mice followed 
by OVA challenge. However, the experiments remained inconclusive so far as the 
outcome varied (data not shown). Though we did observe that CD23low/int B cells 
showed a more anti-inflammatory cytokine profile compared to CD23hi B cells, 
as they produced higher levels of IL-10 upon LPS or CpG stimulation (Fig.1C and 
D). It still remains to be established whether this is decisive for their capacity to 
inhibit AAI or not.
Role of FcγRIIB ligation and immunoglobulins in protection against AAI by 
pulmonary B cells
To investigate the role of immunoglobulins (Igs) in protection against AAI, we 
analyzed several Ig subclasses and detected a general elevated production of 
IgG1 and IgG2a antibodies in the BAL fluid of OVA-infected mice compared to 
OVA-uninfected mice, though this was not reflected in increased OVA-specific 
antibody responses, as described before (47) (Appendix S1A). To investigate 
whether the secretion of schistosome-induced IgGs by pulmonary B cells could 
induce protection against AAI via the FcγRIIB receptor in a similar fashion as 
described for OVA-specific IgGs (29;51), we transferred pulmonary B cells from 
OVA-uninfected and -infected mice into OVA-sensitized FcγRIIB-/- mice followed 
by OVA challenge. However, the loss of the FcγRIIB receptor did not restore AAI 
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upon pulmonary B cell transfer, suggesting that despite the elevated IgG1 and 
IgG2a secretion in OVA-infected mice, protection against AAI was not mediated 
via signaling through FcγRIIB (Appendix S1B). 
Schistosome-induced pulmonary B cells do not drive protection against AAI via 
the induction of Treg cells
One of the major effector functions of murine Breg cells centers around the 
induction and/or recruitment of FoxP3+ Treg cells. In our previous studies, we 
observed that adoptive transfer of pulmonary B cells did not induce increased 
numbers of FoxP3+ Treg cells in vitro nor in vivo (15). However, this does not 
exclude the possibility that, despite equal numbers, the activity of Treg cells 
on a per cell basis had increased. Therefore, to investigate the role of Treg cell 
activity, we transferred pulmonary B-cells to FoxP3-DTR transgenic DEREG mice, 
in which Treg cells can be temporarily depleted by DT injections and, thus allows 
the investigation of the contribution of Treg cell activity during pulmonary B cell-
Figure 1. Characterization of Breg cell markers in schistosome-induced pulmonary B cells and inflammatory 
responses of CD23-sorted B cells after TLR ligation. Mice were infected with S. mansoni until the chronic 
phase (week 15). After sacrifice, the perfused lungs were minced, digested and the single cell suspension 
from 2-3 mice were pooled. Next, B cells were purified using anti-CD19 MicroBeads and stained for 
different Breg-linked markers. (A) The fold change of percentage surface LAP-1- and CD25-expressing B 
cells from OVA-uninfected and OVA-infected mice over control (PBS-uninfected B cells). Data are pooled 
from 4 independent experiments with 3-5 mice per group/experiment. (B) The fold change of geometric 
mean fluorescence intensity (MFI) of CD23 and Tim-1 expression over control (PBS-uninfected B cells). 
Data are pooled from 4 independent experiments with 3-5 mice per group. (C) OVA-infected B cells 
were sorted using flow cytometry based on the expression of CD23. Next, the cells were stimulated with 




induced protection against AAI. However, BAL eosinophil levels remained similarly 
reduced in both PBS- and DT-treated DEREG mice when receiving pulmonary B 
cells from OVA-infected compared to OVA-uninfected mice (Fig. 2). These data 
indicate that AAI is not restored when Treg cell activity is abolished, suggesting 
that schistosome-induced pulmonary B cells do not drive protection against AAI 
via enhanced Treg cell activity.
Figure 2. Role of FoxP3+ T cells in pulmonary B cell-induced protection against AAI during schistosomiasis. 
OVA-sensitized DEREG mice, which carry a diphtheria toxin receptor-eGFP transgene under the control of 
an additional Foxp3 promoter, were treated with two PBS or diphtheria toxin (DT, 1 μg/ml) i.p. injections: 
one day before and two days after the adoptive transfer of B cells in order to deplete the FoxP3+ Treg 
cells. After two days, mice were challenged for three consecutive days and sacrificed 24 hours after the 
last challenge. The number of BAL eosinophils in the PBS-injected DEREG mouse group was set at 100. 
Fold changes in numbers of eosinophils was calculated for the other groups. This graph represents two 
independent experiments.
TLR-responsiveness and antigen presentation by schistosome-induced 
pulmonary B cells
We next aimed to investigate the role of pulmonary B cells as APCs and stimulators 
of effector T-cell activation. Important signals that can influence T-cell activation, 
proliferation and cytokine production are provided by e.g. co-stimulatory 
molecules CD80 or CD86, antigen-presentation molecule MHCII, inhibitory 
receptors such as PD-L1, PD-L2, apoptosis-inducing FasL or various cytokines 
such as IL-10 and IL-6. To investigate a putative role for those (co-)stimulatory 
molecules and/or inhibitory receptors on schistosome-induced pulmonary B 
cells, we analyzed the above mentioned molecules (Fig. 3A and 3B). Pulmonary 
B cells from OVA-infected mice showed a significantly increased CD86 expression 
compared to B cells from OVA-uninfected mice (Fig. 3A). Expression levels of 
MHCII, CD80, PD-L1 and PD-L2 were equal between the groups (Fig. 3A), while 
the percentage of FasL-expressing cells was significantly reduced in OVA-infected 
mice compared to OVA-uninfected mice (Fig. 3B). Furthermore, we analyzed 
the capacity of pulmonary B cells to produce cytokines, which may support or 
suppress T-cell activation following stimulation by Toll-like receptor (TLR)-4 ligand 
LPS and TLR-9 ligand CpG1826 as being strong B-cell activators (Appendix S2). 
Interestingly, B cells from OVA-infected mice produced significantly less IL-10 and 
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Figure 3. Schistosome-induced pulmonary B cells show elevated expression of CD86 and an impaired 
capacity to drive Th2 cytokines. Pulmonary B cells were isolated as described in figure 1. For both 
characterization and co-culture, pulmonary B cells from 2-3 mice were pooled to obtain enough cells for 
performing experiments. (A) Fold changes of geometric MFI expression of activation, co-stimulation, and 
antigen-presentation molecules on B cells from OVA-uninfected and –infected mice over control (PBS-
uninfected B cells). Data are pooled from 4 independent experiments with 3-5 mice per group/experiment. 
(B) Fold change of percentage Fas ligand-expressing B cells in OVA-uninfected and –infected mice over 
control (PBS-uninfected B cells). Data are pooled from 4 independent experiments with 3-5 mice per 
group/experiment. (C) B cells were loaded with OVA17 peptide, washed and co-cultured 1:1 with OVA-
specific CD4+ T cells in the presence or absence of anti-CD28 (1 μg/ml) for three days. As control, non-
loaded B cells were cultured with T cells with anti-CD28 only. Intracellular production of Th2 cytokines 
IL-13, IL-4 and IL-10, Th1 cytokine IFN-γ and Th17 cytokine IL-17 cells was determined after co-culture with 
B cells following PMA/Ionomycin and Brefeldin A stimulation for all groups. Data are expressed as fold 
change over co-culture with B cells from PBS-uninfected mice. This figure represents pooled data from 3 
independent experiments with 3-5 mice per group/experiment.
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IL-6 in response to LPS and/or CpG compared to B cells from OVA-uninfected mice. 
Taken together, these data show that during chronic schistosomiasis pulmonary 
B cells have an increased expression of CD86, equal levels in MHCII and CD80 and 
lower IL-10 and IL-6 production upon TLR ligation, suggesting that pulmonary B 
cells may be modulated in their function as APCs.
Schistosome-induced pulmonary B cells reduce Th2 cytokine secretion in vitro
To assess the quality of schistosome-induced pulmonary B cells as APCs, T-cell 
activation was examined in a condition where antigen-presentation by B cells 
was essential to drive T-cell activation. To this end, we investigated OVA-specific 
T-cell activation of CD4+ T cells from OT-II mice by OVA peptide-pulsed pulmonary 
B cells. After three days, OVA-presentation by B cells from OVA-uninfected or 
–infected mice did not significantly affect T-cell IFN-γ (3.6 vs. 3.9%), IL-17 (1.3 
vs.1.6%) or IL-4 production (3.5 vs 2.1%). In contrast, IL-10 secretion (1.5 vs. 0.8%) 
was slightly down-modulated in co-cultures with OVA-infected B cells, while IL-13 
secretion (1.3 vs 2.5%) was increased in cultures with OVA-infected B cells. We 
also cultured OVA-pulsed B cells and OT-II T cells in the presence of anti-CD28 to 
bypass differences in CD80 and CD86 and ensure optimal co-stimulation. In the 
presence of anti-CD28, OVA-presentation by B cells from OVA-uninfected mice 
increased mostly Th2 cytokines IL-4 (6.8 vs. 3.2%) and IL-13 (10.6 vs. 6.2%), while 
these cytokines were not induced in co-cultures with B cells from OVA-infected 
mice (Fig. 3C). The reduced IL-10 production found in stimulation conditions 
of OVA-infected B cell co-cultures was overcome in the presence of sufficient 
co-stimulation and may point at a hampered expression during sub-optimal 
stimulation. The observed reduction in Th2 cell cytokines despite, or maybe as a 
consequence of, the presence of optimal co-stimulation, may point at an active 
expression of inhibitory molecules by schistosome-induced pulmonary B cells.
Role of inhibitory molecules in the reduction of Th2 cytokines 
We next aimed to investigate what suppressive factors were involved in the above 
described reduced capacity of schistosome-induced pulmonary B cells to induce 
Th2 responses. Therefore, we performed co-culture experiments of pulmonary 
B cells from OVA-uninfected and –infected mice with CD4+ T cells from naive 
C57BL/6 mice in the presence of anti-CD3/28 to bypass MHCII stimulation and 
insufficient co-stimulation and cultured them for three days. We still observed 
higher Th2 cytokine production in co-cultures with B cells from OVA-uninfected 
mice, but also more T-cell CD25 expression and T-cell proliferation compared to 
co-cultures with OVA-infected B cells (Fig. 4A-C). The ability of B cells of OVA-
allergic mice to induce Th2 cytokines was found to be dose-dependent and 
most effective at a 1:1 ratio (Fig. 4D), while the level of Th2 cytokines by OVA-
infected B cells was similarly low at all indicated ratios. It thus may be argued 
that schistosome-induced pulmonary B cells can actively suppress Th2 cytokine 
production by additional factors.
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Figure 4. Role of inhibitory molecules in pulmonary B-cell mediated Th2 suppression. (A) Pulmonary B 
cells (1x105), pooled from 2-3 PBS-uninfected, OVA-uninfected, PBS-infected or OVA-infected mice, were 
cultured with C57BL/6 CD4+ T cells (1x105) from naive mice for three days in the presence of anti-CD3/
CD28. (A) The proliferation of T cells using CFSE staining was measured. The graph shows cumulative data 
of three independent experiments. (B) The expression of CD25 on T cells after three days of co-culture. (C) 
Fold changes of percentage IL-4, IL-13, IL-10, IL-17 and IFN-γ-producing T cells over control (culture with 
PBS-uninfected B cells) was analyzed. Graphs contain 4 independent experiments. (D) 1x105 T cells were 
cultured in 1:1, 1:2 and 1:4 (B cell:T cell) ratios with B cells from OVA-uninfected and –infected mice. Bar 




 We next investigated whether apoptosis, the above described differences 
in cytokine production, or differential expression of cell surface markers on 
schistosome-induced pulmonary B cells might be involved in the suppression of 
Th2 cytokines by CD4+ T cells. First, we evaluated the induction of CD4+ T-cell 
apoptosis by the analysis of the early apoptosis marker Annexin V after 24 and 72 
hours of co-culturing. However, no differences in T-cell apoptosis between OVA-
uninfected and -infected B cells were observed (data not shown). Therefore, the 
role of various soluble mediators was investigated by adding blocking antibodies 
to the IL-10 receptor (αIL-10R), the IL-6 receptor (αIL-6R) or to TGF-β (αTGFβ) 
into the co-cultures of pulmonary B cells and CD4+ T cells (Fig. 5). We focused on 
the production of IL-4 and IL-13 because of the activity of these Th2 cytokines 
in boosting allergic responses in the airways. However, blockage of IL-6R, IL-10R 
or TGF-β, only slightly, though significantly, increased the IL-4, but not IL-13 
production in T cells cultured with schistosome-induced pulmonary B cells, 
suggesting that these cytokines, if anything, only play a very minor role because 
IL-13 production was not affected. Since some obvious B-cell derived cytokines 
tested here, are not involved in controlling Th2 cytokines by schistosome-induced 
pulmonary B cells, other unknown mechanisms could be involved and need to be 
investigated.
Figure 5. Role of putative inhibitory molecules in pulmonary B cell-mediated Th2 suppression. In vitro 
co-cultures were performed as described in figure 4 in the presence of blocking anti-IL-10R, anti-TGF-β, 
anti-IL-6R or isotype control antibodies. Data represents two independent experiment.
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Discussion
Helminths drive strong immunoregulatory processes that limit immunopathology 
during chronic infection in which regulatory B cells seem to be important players. 
Importantly, S. mansoni-induced splenic and pulmonary B cells also attenuate 
allergic diseases such as AAI upon adoptive transfer. While splenic Breg cells 
mediate their suppression effect through IL-10- and Treg cell-dependent 
mechanisms (14;15), here we demonstrated that helminth-induced pulmonary 
B cells mainly have a reduced capacity to initiate Th2 cytokine responses and 
reduce T-cell proliferation.
 By definition, Breg cells suppress inflammatory processes and induce 
tolerance by various mechanisms of which production of immunosuppressive 
IL-10 is the most widely-studied and best understood. While IL-10 has a pleiotropic 
suppressive effect on most hematopoietic cells, such as T cells and APCs, it also 
indirectly suppresses immune responses via supporting the generation and 
maintenance of Treg cell subsets (9;15;52). Recently, it has become evident 
that Breg cells utilize a number of IL-10-independent suppressive mechanisms 
in order to control inflammation. For example, B cells can contribute to the 
maintenance of tolerance via the production of TGF-β, secretory IgA, IgGs (binding 
to FcγRIIB (33;59)), or by induction of T-cell apoptosis (28;53).The schistosome-
induced pulmonary B cells studied here did not utilize any of the Breg effector 
mechanisms described in the above mentioned studies. In our study, we did 
identify an increased population of CD23hi B cells in the lungs of OVA-infected mice 
compared to OVA-uninfected mice. Interestingly, mesenteric lymph node CD23hi 
B cells from H. polygyrus-infected mice were shown to suppress Derp1-induced 
airway inflammation independently of IL-10 (16). However, the adoptive transfer 
experiments of schistosome-induced CD23hi and/or CD23low/int pulmonary B 
cells into sensitized mice were inconclusive in this stage leaving it unclear whether 
CD23 is a marker for regulatory activity or not. Alternatively, CD23 expression 
may not define a specific Breg population but may be more the consequence of 
the local cytokine milieu (54). Indeed, strong signals to drive CD23 expression are 
provided by IL-4 and IgE (55;56). This is further underlined by studies showing 
elevated numbers of CD23-expressing B-cells during Th2 inflammation such as 
during helminth infections (57) or allergic asthma (58;59).
 Schistosome-induced pulmonary B cells expressed enhanced levels of 
CD86, whereas MHC Class II and CD80 were similar. Each of these markers has 
been suggested to affect T-cell activation. Indeed, co-cultures of schistosome-
induced pulmonary B cells presenting OVA to OVA-specific T cells resulted in 
reduced Th2 cytokine production compared to control conditions. However, 
since similar results were observed, including reduced T-cell proliferation, in co-
cultures of B cells from C57BL/6 mice supplemented with anti-CD3/28 to bypass 
the role of B cells as APC, this may suggest the involvement of other molecules or 
mechanisms. An important surface molecule for the Th2 cell suppressive capacity 
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of schistosome-induced pulmonary B cells may be the B7 co-stimulatory molecule, 
CD86. Interestingly, in a TCRα KO mouse model of intestinal inflammation and EAE, 
CD86 has been reported to mediate suppressive effects of B cells via T cells (46;60). 
Furthermore, the ligation of CTLA-4 (expressed on T cells), one of the interacting 
receptors of CD86, was essential for T-cell hypo-responsiveness and reduced 
protective Th2 immunity during filarial infections (61;62) and schistosomiasis 
(63). However, since preliminary results showed that blocking CTLA-4 ligation did 
not restore Th2 cytokine production, this would exclude a potential role for CD86 
in reducing Th2 cytokines, despite its enhanced expression on OVA-infected B 
cells.
 Furthermore, studies in mice with S. mansoni or Litomosoides sigmodontis 
infections showed that PD-1 and interaction with its ligands (PDL-1/2) was 
important for T(h2)-cell hyporesponsiveness (37;64), while other studies actually 
suggested that Th2 hypo-responsiveness during S. mansoni was not related to 
PD-1 (65). The latter is in agreement with the data presented here, as we observed 
that blocking of PD-L1 or PD-L2 expression on OVA-infected B cells by blocking 
antibodies did not restore Th2 cytokine production or proliferation in co-cultures 
with T cells (data not shown).
 It remains to be established what the effector mechanism is by which 
schistosome-induced pulmonary B cells reduce Th2 polarization and inhibit 
AAI. Recently, IL-35-producing B cells were described, which limited EAE by 
reducing the accumulation of pathogenic T cells (66;67). Here, in mice with a 
B-cell specific knock-out of one of the two IL-35 subunits, EBI3 or p35, B cells 
displayed an enhanced APC function, suggesting that IL-35 acts as a regulator 
of the APC function of B cells. However, IL-35 has not been studied yet during 
schistosomiasis and it is unclear whether this cytokine is increased and thereby 
may control the APC function of pulmonary B cells. Alternatively, local Treg 
cells, induced during helminth infection, may influence B cell function leading to 
reduced B-cell activation, antibody production and the APC function of B cells via 
e.g. TGF-β or IL-35 (68-70). Finally, secreted helminth products from Schistosoma 
may also directly attenuate the T-cell stimulatory capacity of B cells as described 
for DCs (71).
 Here, we show that during chronic schistosomiasis the regulatory 
function of B cells may be affected both via the induction of a sessile splenic IL-10-
producing Breg cell population in the spleen and the functional impairment of local 
pulmonary B cells to act as Th2-inducing APC. This suggests that in the spleen and 
in local tissues different B cell subsets can occur with different capacities, though 
eventually with the same net effect: reduction of allergic airway inflammation. 
In search of the most potent B cell subset, we have previously demonstrated a 
dominant role for IL-10-producing (splenic) B cells in the protection against AAI 
during a natural infection using IL-10-/- B cell mice (15). These data suggest that 
the potential of pulmonary B cells to control AAI in that particular model is not 
sufficient to counterbalance the loss of IL-10-producing B cells (15). However, 
although the functionality of these pulmonary B cells has not been investigated 
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in IL-10-/- B cell mice, it is tempting to speculate that the development of these 
pulmonary B cells may be dependent on local (autocrine) B-cell derived IL-10. 
Alternatively, the schistosome-induced pulmonary B cells could arise from a 
common IL-10+ progenitor splenic B cell that migrates to the site of inflammation. 
However, what argues against this is that pulmonary B cells do not resemble 
splenic Breg cells at all, a fact which would require a dramatic change in the B cell 
phenotype. Clearly, we need better markers to identify whether different AAI-
suppressive splenic and pulmonary B cells arise from the same progenitors or 
that these pulmonary B cells are induced by the local inflammatory milieu.
 Recently, various Breg cell populations have been identified in peripheral 
blood of humans infected with schistosomiasis or other helminths (15;72). 
Furthermore, in several inflammatory diseases, Breg cells were impaired in 
number and/or their regulatory function, i.e. in patients with SLE, RA or allergic 
asthma (25;73;74). Since most human studies are restricted to peripheral blood 
B cells, these results might not fully reflect the processes that occur in inflamed 
organs and B cell subsets involved may be different as suggested by the data 
presented here. Therefore, further studies on human B-cell biology and its 
activity in the inflamed organs are needed to better understand the importance 
and relative contribution of the various Breg cell subsets in peripheral blood and 
local tissues. However, what stands out is that during infection with schistosomes, 
potent IL-10-producing suppressive Breg cells in the spleen and impaired Th2-
driving pulmonary B cells in the inflamed tissue are found which are able to 
suppress AAI. Identifying the mechanisms and/or molecules that influence (local) 
B cell function may be an interesting novel strategy to control or prevent allergic 
inflammatory responses at multiple sites at the same time.
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Appendix S1. Role of schistosome-induced IgG1 and IgG2a in protection against AAI. Mice were infected, 
OVA-sensitized and -challenged as described in figure 1. (A) Total and OVA-specific IgG1 and IgG2a were 
measured from the first 1 ml of collected BAL fluid using ELISA. This graph expresses one representative out 
of two independent experiments, consisting of five individual mice per group (B) OVA-sensitized recipient 
FcγRIIB-deficient or control C57BL/6 mice mice received i.v. injection of 5 x 106 CD19+ B cells from OVA-
uninfected or OVA-infected mice or PBS as control. The B cells were derived from 6-8 donor mice to obtain 
enough cells. This graph contains two independent experiments.
Appendix S2. OVA-infected B cells show an impaired cytokine response towards TLR ligation. OVA-
uninfected and -infected B cells were stimulated with medium, LPS (100 ng/ml) or CpG (5 μg/ml) for five 
days to determine (A) IL-10 and (B) IL-6 responses in the supernatant.
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Toll-like receptors (TLRs) are key components for the recognition of micro-
organisms, the initiation of innate immunity and for promoting adaptive immune 
responses. TLR signaling in B cells, in addition to B cell receptor or CD40 ligation, 
plays an important role in B cell differentiation and activation. In contrast, various 
infectious agents and/or TLR ligands can also prime B cells to induce tolerance 
and downregulate inflammatory reactions; those B cells are called regulatory 
B (Breg) cells and are characterized by a dominant IL-10 production. Several 
studies have suggested that Breg cells are impaired in patients with autoimmune 
diseases and allergic asthma. However, the role for TLR ligands in the induction of 
Breg cells as a potential therapy for some of these inflammatory diseases has not 
yet been investigated. Here, we provide detailed instructions how to analyze and 
validate cytokine production in human and mouse B cells in response to various 
TLR ligands. Furthermore, we describe an assay to investigate the suppressive 
properties of TLR-induced B cells to confirm their regulatory B cell status.
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1. Introduction
Toll-like receptors (TLRs) represent one of the most studied classes of pattern 
recognition receptors and are key components for the recognition of micro-
organisms and activation of immune cells. TLR ligands have become of interest 
in B cell research because of their application as potent adjuvants in novel 
vaccine strategies. However, several reports have been published over the past 
years highlighting a role for TLRs in enhancing anti-inflammatory responses 
instead, possibly promoting the development or activation of regulatory B 
(Breg) cells. Several mouse studies have demonstrated a role for signaling via 
TLR2, TLR4, and TLR9, either or in combination with CD40 engagement, CD80/
CD86 or B cell-activating factor (BAFF), to induce optimal IL-10 production by B 
cells with regulatory capacities (1-7). For example, during the bacterial infection 
by Salmonella typhimurium, MyD88-signaling in B cells suppressed protective 
immunity via IL-10, affecting natural killer cells, neutrophils, and effector T cells. 
Prolonged survival upon infection was displayed in mice with a B-cell specific 
deficiency in both TLR2 and TLR4, suggesting that the B-cell-mediated suppression 
resulted from direct microbial sensing by the B cells (8). Furthermore, ligation 
of TLR2 by ligands from Helicobacter felis induced IL-10-producing B cells in a 
MyD88-dependent manner, which suppressed helicobacter-induced pathology 
not through the direct production of IL-10 but via the generation of suppressive 
IL-10 secreting Tr1-like cells (9). Other bacterial antigens, such as the TLR4 ligand 
lipopolysaccharides (LPS) and the TLR9 ligand CpG oligonucleotides (ODN) were 
also described as strong inducers of IL-10 expression in murine B cells (10;11). 
Interestingly, adoptive transfer of LPS-activated B cells reduced the incidence of 
spontaneous type 1 diabetes for about one year in prediabetic NOD mice (12). 
Next to bacterial, also certain parasite-derived molecules, such as extracts from 
Leishmania major and Brugia malayi or milk-derived sugars comparable to the 
ones found in soluble egg antigens (SEA) from Schistosoma mansoni, induced IL-
10-producing B cells most likely via TLR4 (13-15). In addition, CpG treatment of 
mice ameliorated spontaneous type 1 diabetes (16) and allergic conjunctivitis by 
TLR9 ligation and induction of IL-10 in B cells (17). These mouse studies show 
an important role for TLR2, TLR4 and TLR9 ligation in the development of Breg 
cells and highlight its potential to boost Breg cell development for treatment of 
various inflammatory diseases.
 Human IL-10-producing Breg cells share phenotypic and functional 
characteristics with the murine counterpart and have been studied primarily in 
allergic and autoimmune diseases, where they were shown to be functionally 
impaired in their IL-10 response or regulatory activity (18-23). In some of the 
aforementioned cases, Breg cell defects also account for B cell IL-10 responses to 
TLR ligands. For example, CpG induced less IL-10 in B cells from patients affected 
by multiple sclerosis (MS) compared to healthy controls (24), which was also 
confirmed in autoimmune thrombocytopenia (25). Whereas TLR4 stimulation is 
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very potent on mouse B cells, human B cells produce rather modest IL-10 levels 
after exposure to LPS in vitro due to a relatively low TLR4 expression compared to 
TLR2 and TLR9 at least in healthy individuals (20;23;26-28). In several inflammatory 
conditions an upregulated TLR4 expression on B cells was described, suggesting 
a role of TLR4 activated B cells during infection (29-32). In the context of another 
inflammatory disease, i.e. allergic asthma, we showed that LPS-primed IL-10 
from B cells of allergic asthma patients was reduced compared to that of healthy 
individuals and the subsequent induction of IL-10-producing T cells in vitro was 
abrogated as well (23). The impaired LPS response of B cells in allergic asthma 
patients may therefore play a role in the pathophysiology of asthma.
Figure 1. Main phenotypic markers of human and murine Breg cells. (A) Breg cells from human peripheral 
blood are CD24hiCD38hi, CD24hiCD27+ and CD1dhi (pre-gated on CD20+ cells). (B) Murine Breg cells are 
CD21hiCD23low and CD1dhi (pre-gated on CD19+ splenocytes).
 As outlined above, Breg cell function in response to some TLR ligands seem 
to be reduced in human autoimmune and allergic diseases. In contrast, recent 
reports suggest that the development and activity of Breg cells is increased in 
microbial infections, as shown in patients having chronic infections with hepatitis 
B virus (33), Mycobacterium tuberculosis (34) or the helminth Schistosoma 
haematobium (22). Although a direct role for TLR-dependent generation of Breg 
cells in these infections has not yet been established, TLR activation by various 
pathogen-derived ligands such as the TLR1/2 agonist Pam3CysK, a TLR2 ligand 
in SEA, and the TLR2/6 agonist Pam2CGDPKHPKSF were shown to activate IL-10 
production in human B cells (20;35;36).
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 Various distinct and overlapping Breg subsets have been described 
in mice and humans of which the respective roles in response to TLRs can be 
investigated. For example, CD1d expressing B cells are described in both species 
(22), while CD24hiCD38hi, CD24hiCD27+ and CD25hi and CD71hi expression has been 
attributed to human Breg cells only (19;20;37) (as depicted in Fig. 1A) and CD5+, 
CD21hiCD23hi or CD21hiCD23low were shown to be markers expressed by mouse 
Breg cells (Fig. 1B). However, as some of these markers are overlapping or these 
populations still contain non-IL-10-producing B cells, a unique set of markers or 
transcription factors that exclusively identifies Breg cells does not exist. Whether 
or not all B cells can develop suppressive functions following TLR activation is still 
under debate: Mizoguchi et al. proposed that only certain ‘innate’ B cell subsets 
will develop into Breg cells following TLR ligation (38), while others have suggested 
that all immature progenitor cells have the potential to progress into mature IL-
10-producing B cells after ligation by TLRs and CD40 directly (39). Yet another 
hypothesis has been presented by Fillatreau and co-workers, which proposed 
that B cells can acquire only suppressive functions after a stepwise activation 
process initiated by TLR ligands and followed by BCR and CD40 reinforcement 
(40). 
 Most studies investigating the presence and function of Breg cells 
following TLR stimulation limit their analysis to IL-10 as the major anti-
inflammatory and effector cytokine of Breg cells. However, it is often neglected 
that, next to IL-10, TLR ligation can simultaneously contribute to the development 
of inflammatory responses (10;35). For example, CpG, which is a strong 
IL-10 inducer, leads to strong B cell activation, proliferation, immunoglobulin 
production and expression of pro-inflammatory cytokines such as IL-1α, IL-1β, 
IL-6 and TNF-α (41-43). Indeed, elevated numbers of IL-6-producing B cells were 
observed in MS patients after in vitro ligation with CD40 and B-cell receptor with 
CpG, which was demonstrated to have a pathogenic role in the development 
of chronic experimental autoimmune encephalomyelitis in mice (44). Because 
of the recent interest to study the TLR-induced generation of Breg cells, it is 
crucial to use optimized assays for the phenotypic characterization of Breg cells 
and the analysis of both inflammatory and anti-inflammatory responses. Flow 
cytometry and enzyme-linked immunosorbent assay (ELISA) allow the detection 
of cytokines such as IL-10. However, while the qualitative IL-10 contribution of 
each individual Breg subset can easily be monitored by flow cytometry, ELISA 
provides more quantitative information, but requires a preceding cell sorting of 
the subsets before stimulation.
 Although high IL-10 secretion is regarded as being anti-inflammatory and 
a marker for Breg cells, it is possible that the TLR-primed B cells did not acquire 
any immune suppressive activity or act regulatory in an IL-10-independent 
manner. Therefore, it has a strong additive value to investigate whether TLR-
primed B cells show any suppressive capacity on the effector function of other 
cells either in vivo or in vitro. Indeed various studies have shown that Breg cells 
can influence several aspects of innate and adaptive immunity and either one 
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of these or all targets should be included in the study to the development of 
TLR-induced Breg cells: (1) monocyte-induced inflammatory responses are 
suppressed in their release of pro-inflammatory cytokines (20); (2) the Th1/ Th2 
balance is manipulated by inhibition of antigen-specific T cell proliferation in both 
Th1 and Th2 skewed diseases; and (3) regulatory responses are potentiated by 
the induction and/or recruitment of IL-10-producing T cells and FoxP3+ Treg cells 
(19;21-23).
 In conclusion, various TLR ligands can be used as potent B effector or Breg 
cell inducers in vitro. However, to be able to get a better insight in the acquired 
regulatory capacity, a number of parameters needs to be considered, that is (1) the 
culture conditions (cell numbers per well, duration of stimulation, concentration 
of TLR ligands), (2) the method of cytokine detection (flow cytometry and ELISA, 
mimicking T cell interaction or not, see Fig. 2 and 3), (3) the ratio of produced 
anti-inflammatory versus pro-inflammatory cytokines (IL-10 versus IL-6, Fig. 2 and 
3), and (4) a co-culture with other immune cells to evaluate their suppressive 
capacity on the effector function of other immune cells (see Fig. 4).
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2. Materials
2.1 Isolation of B and T cells
1. Lysis buffer: 0.15 M NH4Cl, 1 mM KHCO3, 0.1 mM EDTA, in MilliQ, sterile.
2. MACS buffer: 0.5% BSA, 2 mM EDTA in PBS, sterile.
3. MACS Midi magnets and LS columns (Miltenyi Biotec).
4. Anti-mouse and anti-human CD19 MicroBeads (Miltenyi Biotec). (see Notes 
1 and 2)
5. Anti-mouse and anti-human memory CD4+ isolation MicroBeads (Miltenyi 
Biotec).
6. 100 µm cell strainers used for mashing the spleen in 50 ml tubes (Greiner 
Bio-One.
7. Ficoll/Hypaque.
2.2 Stimulation of B cells
1. Mouse: RPMI 1640 + Glutamax (Invitrogen Life Technologies) supplemented 
with 5% heat-inactivated FCS (Greiner Bio-One), 5 × 10−5 M 2-Mercaptoethanol, 
and antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin).
2. Human: RPMI 1640 supplemented with 10% heat-inactivated FCS (Greiner 
Bio-One), 1 mM pyruvate and 2 mM L-glutamine, 100 U/ml penicillin and 100 
μg/ml streptomycin.
3. 96-well round bottom plates (Greiner Bio-One).
4. TLR ligands (stock concentrations): CpG2006 (1 mg/ml, Invitrogen), CpG1826 
(1 mg/ml, Invitrogen), Ultrapure LPS (2.5 mg/ml, Invitrogen), FSL-1 (1 mg/ml, 
EMC microcollection), PGN (1 mg/ml, Sigma-Aldrich) and Pam3-Cys (1 mg/ml, 
EMC microcollection); store in aliquots at -20 °C.
5. 0.1 mg/ml Phorbol 12-myristate 13-acetate (PMA), 0.5 mg/ml ionomycin and 
5 mg/ml Brefeldin A; store in aliquots at -20 °C.
2.3.1 Quantification of cytokine production by flow cytometry
1. 37% paraformaldehyde.
2. 96-well V-bottom plates (Greiner Bio-One).
3. FACS buffer: 0.5% BSA, 2 mM EDTA in PBS, non-sterile. 
4. Permeabilization buffer: FACS buffer supplemented with 0.5% saponin.
5. Flow cytometer.
6. Mouse antibodies for flow cytometry: anti-mouse CD1d-PE (1B1, ebioscience), 
anti-mouse CD19-APC-Cy7 (1D3, BD Pharmingen), anti-mouse CD21-APC 
(B3B4, ebioscience), anti-mouse CD23-FITC (7G6, BD Pharmingen), anti-
mouse IL-10-PE (JES5-16E3, eBioscience), and anti-mouse FcyRII/III (2.4G2, 
Bioceros). 
7. Live-dead fixable Aqua dead cell staining kit (Invitrogen).
8. Human antibodies for flow cytometry: CD1d-PE (51.1, eBioscience), CD20-
APCeFluor780 (2H7, eBioscience), CD24-PeCy7 (ML5, ITK Diagnostics), 
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CD27-APC (L128, BD), CD38-FITC (HIT2, BD), IL-10-biotin (JES3-12G8, Abd 
Serotec) with streptavidin-Qdot525 (Invitrogen), TNF-α-eFluor450 (MAB11, 
eBioscience) and FcγR-binding inhibitor (eBioscience) (see Note 10).
2.3.2 Quantification of cytokine production by ELISA
1. BD OptEIA mouse IL-10 and IL-6 ELISA sets (BD biosciences).
2. Human IL-10 and IL-6 ELISA sets (Sanquin).
2.4 Detection of Tr1/FoxP3 T cells by flow cytometry after co-culture
1. FoxP3 permeabilization/fixation buffer (eBioscience).
2. Human antibodies: CD3-PerCPeFluor710 (OKT-03, eBiosience), CD20-
APCeFluor780 (2H7, eBioscience), CD25-PE (2A3, BD), IL-10-biotin with 
streptavidin-Qdot525, TNF-α-PeCy7 (MAB11, eBioscience), FoxP3-eFluor450 
(PCH101, eBioscience), and FcγR-binding inhibitor (eBioscience).
Figure 2. IL-10 and IL-6 expression of human B cells in response to TLR stimulation. 3 x 105 isolated 
peripheral blood CD19+ B cells from healthy donors were stimulated with the TLR ligands LPS (100 ng/
ml), Pam3-Cys (5 µg/ml), FSL-1 (5 µg/ml), and PGN (5 µg/ml), or cultured in medium as a negative control. 
(A) The frequency of IL-10+ B cells was determined after 2 days stimulation followed by 6 h culture with 
PMA/ionomycin (BrefeldinA added in the last 4 h) n =6. (B) Secreted IL-10 measured by ELISA after 2 days 
stimulation with TLR ligands n =6-12. (C) IL-10 secretion in the supernatant of B cells cultured with TLR-2 
ligands for 2 days (no restimulation) or restimulated with PMA/ Ionomycin/ BrefA (PIB) for 6 h. The cytokine 
production before the Golgi stop resembles the flow cytometry data (Fig. 2A). In addition, the cells were 
cultured after TLR priming with CD40L expressing cell line (J558) to mimicking B and T cell interaction for 
an additional 24 h. This figure represents 3 independent experiments. (D) IL-6 secretion after 2 days of 
stimulation measured by ELISA n =6.
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3. Methods
3.1.1 Isolation of mouse CD19+ B cells
1. Single cell suspensions are prepared from mouse spleens using 100 µm cell 
strainers.
2. Erythrocytes are lysed from the spleen suspension using 2 minutes incubation 
with lysis buffer.
3. Cells are washed once with MACS buffer and are incubated with anti-mouse 
CD19 magnetic beads in MACS buffer and CD19+ B cells are positively selected 
on LS columns according to the manufacturer’s instructions (see Notes 1 and 
2).
3.1.2 Isolation of human CD19+ B and T cells
1. PBMC are isolated from blood of healthy donors (after their informed consent 
and in accordance with protocols approved by the local authorities) by density 
gradient centrifugation over Ficoll/Hypaque.
2. Cells are incubated with anti-CD19 magnetic beads (Miltenyi Biotech) in MACS 
buffer and positive selection of CD19+ cells on LS/MS columns according to 
the manufacturer’s instructions (see Note 3).




3.2 Stimulation of B cells with TLR ligands
1. MACS isolated B cells are washed twice with complete RPMI. 
2. A minimum of 3.0 x 106 B cells/ml are needed to evaluate secreted cytokine 
levels in response to weak TLR ligands (see Note 4). 
3. TLR ligands are diluted in complete RPMI two-fold concentrated, yielding the 
following final concentrations after addition of cells. Mouse: CpG1826 5 µg/
mL; LPS 100 ng/mL; FSL-1 10 µg/mL; Pam3-Cys 10 µg/mL; PGN 10 µg/mL. 
Human: CpG2006 1 µg/ml; LPS 100 ng/ml, FSL-1 5 µg/ml; Pam3-Cys 5µg/ml; 
PGN 5µg/ml.
4. 100 µl of two-fold concentrated TLR ligands are added per well of a 96-well 
round bottom plate (Greiner Bio-One). Next 100 µl B cells (3x105) are added 
per well (total volume of 200 µl). 
5. Murine cells are incubated at 37°C, 5% CO2 and humidified atmosphere for 
three days (for flow cytometric IL-10 analysis, see Note 6) or five days (for 
ELISAs, see Notes 5 and 7). Human cells are incubated for two days (see Notes 
5 and 7).
3.3.1 Quantification of cytokine expression by flow cytometry
Two different techniques can be applied for cytokine detection in TLR-
activated B cells, however it is important to take into account that intracellular 
cytokine visualization after TLR ligation by flow cytometry needs an additional 
restimulation, such as PMA/ ionomycin/ BrefeldinA (PIB), which is not applied for 
the analysis of secreted cytokine levels in the supernatant by ELISA (see section 
3.3.2). As a consequence the data of the two assays may not be fully comparable 
and the difference in assay processing should be carefully taken into account 
while drawing conclusions. This is highlighted and explained in an example where 
we compared different TLR2 ligands and the TLR4 ligand LPS for their capacity to 
induce IL-10 production in human B cells (see Fig. 2A-C, Note 8). 
1. For flow cytometric detection of IL-10, cells are washed once with complete 
RPMI and restimulated with PMA (100 ng/ml) and ionomycin (1 µg/ml) in 
RPMI at 37°C, 5% CO2 and humidified atmosphere. After two hours, Brefeldin 
A is added at a concentration of 10 μg/ml. In total, the cells are cultured 
under these conditions for six hours. 
2. Optional: After restimulation with PIB, cells are harvested, washed with PBS 
and stained with Aqua dead cell staining kit (diluted 1:400 in PBS) for 15 min 
at room temperature. 
3. The cells are fixed with 1.9% paraformaldehyde for 15 min at room temperature 
and stored at 4°C or -20 °C.
4. For intracellular staining, the cells are first washed once with permeabilization 
buffer, and then apply 50 μl/well antibody mix and incubated for 30 minutes 
at 4°C (see details Section 2.4).
5. After washing once with permeabilization buffer, cells are resuspended in 
FACS buffer and measured on a FACS Canto or similar instrument (see Note 
8, Fig. 2).
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Figure 3. IL-10 and IL-6 expression of murine B cells in response to TLR stimulation. CD19+ sorted splenic B 
cells were stimulated with the TLR ligands LPS (100 ng/ml), Pam3-Cys, FSL-1, and PGN (each 10 µg/ml), or 
cultured in medium as a negative control. (A) The frequency of IL-10 positive B cells was determined after 
3 days stimulation followed by 6 h culture with PMA/ionomycin (BrefeldinA added in the last 4 h). Secreted 
IL-10 (B) and IL-6 (C) was measured by ELISA after 5 days stimulation with TLR ligands. Mean ± SEM of 3 (A) 
or 4 (B, C) independent experiments is given.
3.3.2 Quantification of cytokine expression by ELISA
As TLR ligation not only induces IL-10 but also other pro-inflammatory cytokines 
(e.g. IL-6, TNF-α), cytokine expression of various cytokines (so not only IL-10) 
should be taken into account to determine whether certain TLR ligands truly 
induce an anti-inflammatory response or not. For optimal Breg activity, a TLR 
ligand should display a strong IL-10 and a low IL-6 inducing capacity. For example, 
the TLR2 ligand PGN induced more human B cell IL-10 secretion in the supernatant 
compared to the other TLR2 ligands, but also the highest IL-6 production (Fig. 2B, 
D and Note 9). In contrast, for mouse B cells, while several TLR2 ligands induced 
similar levels of secreted IL-10, IL-6 levels were lowest with PGN, suggesting that 
in this case PGN is a more potent Breg cell inducing TLR2 ligand in mouse cells 
in vitro (Fig. 3). Of note, the TLR4 ligand LPS showed by far the highest IL-10/IL-6 
ratio in murine B cells (Fig. 3 B,C). 
1. Supernatants from TLR-stimulated cells are collected and stored at -20°C (see 
Note 9).
2. Optional: After TLR-priming, the cells are cultured 1:1 with CD40L expressing 
cell line (J558 cells, irradiated with 2600 RAD) to mimicking B and T cell 
interaction for an additional 24 hours. Next, the supernatant is stored at -20 
°C (see Fig. 2C, Note 8).
3. Optional: After TLR-priming, the cells are restimulation with PMA/ionomycin/
BrefA (see section 3.3.1) and supernatant containing cytokines produced in 
two hours after PMA/ionomycin is stored at -20°C. 
4. ELISA coating antibodies, detection antibodies and standards are used in 
concentrations as recommended by the manufacturer.
3.4 Detection of Tr1/FoxP3 T cell by flow cytometry after co-culture
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1. Even when B cells secrete elevated levels of IL-10, it is essential to elucidate 
whether the B cells from the test conditions really have obtained suppressive 
properties to confirm their regulatory B cell status (see Note 11). Most 
studies compared the suppressive activity of B cells from autoimmune or 
allergic patients with healthy controls using different culture systems ex vivo. 
In this context, we have set-up an in vitro co-culture assay with human B cells 
from healthy donors which were first primed with TLR ligands, followed by 
culture with autologous CD4+ memory T cells to investigate their acquired 
function capacities (24) as described below. Figure 4 shows an example of 
LPS- and CpG-primed B cells both induce a clear increase in IL-10-producing T 
cells compared to medium-primed B cells, suggesting they have acquired an 
increased regulatory capacity in B cells as a consequence their TLR ligation 
(see Note 11, Fig. 4). 
2. 1 x 105 human B cells are stimulated via TLR 4 (ultra-pure LPS) or TLR9 (CpG) 
for two days (total volume 200 µl/well) (see Section 3.2).
3. Isolated memory CD4+ T cells (see Section 3.1.2) are stored at 4°C for two 
days.
4. After two days, supernatant is stored, and the cells are washed, and co-cultured 
with autologous memory CD4+ T cells (ratio 1:1) in RPMI supplemented with 
10% FCS for an additional six days.
5. The cells are restimulated by PMA/ionomycin and BrefA (as indicated above) 
and fixated with FoxP3 fixation/permeabilization buffer (eBioscience). The 
cells were stained for flow cytometry as indicated in Section 2.4.
Figure 4. IL-10+ T cells in co-cultures of TLR-primed B 
cells and T cells. B cells were stimulated for 48 h by 
medium, CpG (5 µg/ml) or LPS (100 ng/ml), followed 
by a 1:1 co-culture with autologous memory CD4+ T 
cells for 6 days. Next, the cells were restimulated with 
PMA/ionomycin (BrefeldinA added in the last 4 h) for 
6 h. Percentage of IL-10 producing CD4+ T cells was 
determined by flow cytometry.
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4. Notes
1. Isolation of B cells using e.g Miltenyi Biotec beads reaches approximately 
95-98% purity. Check for each isolation the contamination of other cells, 
especially dendritic cells and monocytes, as they being very responsive to 
TLR ligand stimulation. Depletion of other cells, prior to CD19+ B cell isolation, 
should reduce their putative contamination. 
2. The concentration of anti-mouse CD19 magnetic beads used for isolation 
can be reduced after empirical testing of the sorting efficiency. For C57BL/6 
splenic B cells, 7 µl instead 10 µl beads per 107 cells can be used without 
reduction in cell purity.
3. PBMC and B cell isolation should be performed preferably directly after 
blood draw. In addition, it is recommended to use fresh B cells and not live 
cryopreserved PBMC or B cells, because the B cell cytokine responses are 
diminished after freezing and thawing. 
4. Before applying these assays, the number of cells in the culture and the 
duration of TLR ligation should be considered. We have established that 
higher cell numbers of human B cells are needed to evaluate secreted 
cytokine levels in response to weak TLR ligands, such as LPS. A minimum 
of 3.0 x 106 B cells/ml (3.0 x 105/well) showed detectable levels of secreted 
IL-10 and IL-6 (approx. 30 pg/ml IL-10 and 612 pg/ml IL-6 above medium) in 
response to 100 ng/ml LPS and therefore this cell number was used in further 
experiments (data not shown).
5. Kinetic experiments showed that cytokine production by human B cells 
reached its maximum after two days of TLR exposure and longer incubations 
even seemed to reduce the concentration in the supernatant, which may 
be explained by the assumption that cytokines in the supernatant will be 
consumed; for example, IL-10 acts as an autocrine factor promoting expansion 
of IL-10-producing B cells or differentiation of B cells into plasma cells (45;46). 
Although in murine B cells the TLR4 expression is more abundant compared 
to human B cells, a minimum of 3.0 x 106 cells/ml stimulation of five days 
resulted in the most optimal cytokine detection (data not shown). Therefore, 
it is recommended to apply the cell numbers and time points described above 
to allow detecting of cytokines in response to ‘weak’ TLR ligands, like LPS. 
In case the strength of the stimulus of interest or combinations of stimuli is 
unknown, additional kinetic or dose range studies are recommended. 
6. For flow cytometric analysis of B cell IL-10 expression, a two (human) to three 
(mouse) days stimulation is recommended instead of five days, because of a 
better cell viability.
7. Stimulation of cells should be performed at least in duplicates in order to 
increase the accuracy of the ELISA results.
8. Flow cytometry and ELISA may not be fully comparable because for intracellular 
cytokine visualization by flow cytometry, an additional restimulation, such as 
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PMA/ ionomycin/ BrefeldinA (PIB) is needed (see section 3.3.1). An example 
was represented in Figure 2, showing that applying intracellular cytokine 
staining, both TLR1/2 ligand Pam3CysK and TLR2/6 ligand FSL-1 induced 
more B cell IL-10 compared to peptidoglycan (PGN, TLR2/CD36) in human 
B cells (Fig. 2A), while surprisingly, PGN induced the highest IL-10 secretion 
as measured by ELISA (Fig. 2B). To sort out whether the second stimulation 
(PMA/ionomycin) changes the B cell response, TLR2 primed B cells were 
stimulated either for two hours with PMA/ionomycin (regular protocol for 
intracellular cytokine staining) or for 24 hours with a CD40L expressing cell 
line J558 to mimic B and T cell interaction in a more physiological manner 
(Fig. 2C). Both after PMA/ionomycin stimulation and after CD40 ligation, a 
higher IL-10 secretion was detected in FSL-1- and Pam3CysK- primed B cells 
in the supernatant, but not for the PGN-primed B cells. This indicates that 
in this example the second (putative T cell mediated) stimulation acts as an 
amplifying signal for B cell IL-10 production for certain TLR2 ligands (but not for 
all), and which is mimicked by PIB restimulation. Therefore, IL-10 production 
as marker for Breg cell induction by different TLR ligands should be confirmed 
both by flow cytometry and ELISA to be able to understand the role of certain 
TLR ligands for B cell activity under innate conditions and after interaction 
with T cells. Of note, the intracellular IL-10 levels measured by flow cytometry 
will be more representative for their behavior in the interaction with T cells.
9. It is important to investigate both pro- and anti-inflammatory cytokine 
responses when studying the role of TLR ligands as promoting adjuvant for 
Breg cells, and to consider species-related differences when extrapolation 
findings from disease models to human conditions. Thus, the Breg inducing 
capacity can be diverging for the same TLR ligand with different species (e.g. 
here: PGN for mouse and human B cells), as well as for different ligands 
targeting the same TLR (here: TLR2, see Fig. 2 and 3).
10. To correct for background staining of other fluorochromes in the staining 
mix, using FMOs (fluorescence minus one) for IL-10 (and other cytokines) is 
recommended. At the moment, FMOs are regarded as the best control in 
multicolor experiments and can also help to rule out problems in compensation 
or aspecific binding of the antibodies. For reference on this policy, see also 
Roederer et al. 2001 Cytometry (47), Herzenberg et al. 2006 Nature (48), 
Maecker et al. 2006 Cytometry (49) and TreeStar Daily Dongle 2011.
11. Next to the identification of IL-10 and other cytokine production, the 
functionality of the IL-10-producing B cells needs to be investigated before 
the term ‘Breg cell’ can be applied. This can be performed using memory T 
cells (Fig. 4) but also using different cell types as described by other groups 
(20;21;33) e.g. for their capacity to reduce cytokines or cell proliferation. 
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Background. Chronic schistosome infections are associated with T-cell 
hyporesponsiveness and a strong regulatory network. Murine studies have shown 
that schistosome infections can induce regulatory CD1dhi B cells, which inhibit 
inflammatory responses. Here, we evaluated the influence of regulatory B cells 
(Bregs) on T-cell cytokines in vitro in human schistosomiasis.
Methods. Gabonese young adults were recruited from areas where Schistosoma 
haematobium (S.h) infections were high or low endemic. The study participants 
were categorized as infected or uninfected from a high endemic area or uninfected 
from a low endemic (nonendemic) area. Their B cells were studied for Breg subset 
markers and cocultured with allogenic anti-CD3-stimulated CD4+ T cells, followed 
by T-cell cytokine analysis.
Results. A greater percentage of B cells from S. haematobium-infected donors 
expressed cytoplasmic interleukin(IL) 10 (IL-10) and membrane-bound latency-
associated peptide/transforming growth factor β1 (LAP/TGF-β1), compared with 
uninfected donors. T cells produced less interferon γ (IFN-γ), IL-4 and IL-17 upon 
coculture with B cells from schistosome-infected individuals only, while the 
conversion to CD25hiFoxP3+ and the percentage of IL-10+ T cells was enhanced. 
Interestingly, depletion of the prominent IL-10-producing B-cell subset, CD1dhi 
cells, resulted in less IL-10+ T cells in the S. haematobium-infected group, while 
levels of FoxP3+ regulatory T cells remained unaffected. 
Conclusions. Schistosomes can induce functional Bregs in humans that may be 
instrumental in general T-cell hyporesponsiveness and may contribute to the 
increased regulatory milieu found in schistosomiasis.
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Introduction
Helminths such as schistosomes are master regulators of host immune 
responses, characterized by polarized T-helper type 2 (Th2) cells (1;2) and a 
general T-cell hyporesponsiveness in the chronic stage of infection (3). This is 
facilitated by a number of potent regulatory cell types and increased levels of 
immunosuppressive cytokines, such as interleukin 10 (IL-10) and/or transforming 
growth factor β (TGF-β) (4-6). While B lymphocytes possess a variety of immune 
functions, more recently they were shown to be a relevant source of IL-10 and/or 
TGF-β (7;8). Such B cells were termed regulatory B cells (Bregs) as they were able 
to ameliorate various hyperinflammatory diseases (9-13). For example, IL-10-
producing B cells suppressed experimental autoimmune encephalomyelitis (EAE), 
collagen-induced arthritis (CIA), and inflammatory bowel disease (IBD) (14-17). 
Furthermore, TGF-β-producing B cells protected against acute allergic airway 
inflammation (8), and inhibited spontaneous Th1 autoimmunity in nonobese 
diabetic mice (18). Recently, Bregs have been considered relevant in infectious 
diseases, such as helminth infection. During Schistosoma mansoni infection, 
active Bregs were enriched in the splenic marginal zone, and suppressed allergic 
responses via elevated IL-10 production and/or FoxP3+ T-regulatory (Treg) cell 
induction (19;20). Likewise, during chronic Heligosomoides polygyrys infections 
CD5-CD23hi B cells from mesenteric lymph nodes also reduced allergic airway 
inflammation, but they did so independently of IL-10 (21).
 Although the majority of studies on Bregs were conducted in mouse 
models, Bregs are now also identified in humans during infectious diseases. For 
example, during chronic hepatitis B virus infection IL-10-producing CD24hiCD38hi B 
cells suppressed antigen-specific CD8+ T-cell responses (22), while in systemic lypus 
erythematosis, IL-10 production by this Breg subset was impaired compared with 
findings in healthy controls, and as a consequence Th1 cytokine production was 
not reduced (23). In human immunodeficiency virus (HIV)-infected individuals, in 
vitro depletion of CD24hiCD38hi B cells resulted in enhanced anti-HIV CD8+ T-cell 
responses, which was dependent on IL-10 (24). Furthermore, CD24hiCD27+ Bregs 
from healthy individuals reduced TNF-α production in monocytes in vitro via 
IL-10 (25), however this Breg subset is not yet studied in the context of infectious 
diseases. Lastly, during Mycobacterium tuberculosis infection CD1d+CD5+ B-cell 
numbers were increased and inhibited IL-17 production by T cells (26). Although 
active TGF-β-producing CD5+ Bregs were described in healthy individuals in 
response to milk antigens (7), the role of human TGF-β-expressing Bregs in 
infectious diseases has not yet been addressed. 
 Enhanced numbers of IL-10-producing CD1dhi B cells were first described 
in helminth-infected Argentine patients with multiple sclerosis (MS) and could 
inhibit autoreactive T-cell responses in vitro (27). We found a similarly elevated 
percentage of IL-10-producing B cells in Schistosoma haematobium-infected 
Gabonese children, which returned to baseline levels after anti-schistosome 
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treatment (20). However, the functional properties of these cells were not 
explored. In the current study, we investigated the regulatory characteristics 
of peripheral B cells of S. haematobium-infected individuals and the functional 
consequences for CD4+ T-cell activation. We observed that CD1dhi B cells and 
CD24hiCD27+ B cells of S. haematobium-infected adults express enhanced levels 
of cytoplasmic IL-10 and enhanced levels of surface latency-associated peptide 
(LAP), part of a latent TGF-β complex, respectively. In coculture with T cells, 
reduced effector T-cell cytokine responses, as well as more Tregs, were associated 
with B cells from infected individuals, compared with B cells from uninfected 
controls who resided in areas where S. haematobium is nonendemic. Depletion 
of the CD1dhi B-cell population resulted in a loss of IL-10+ T-cell induction but did 
not yield differences in the numbers of FoxP3+ Tregs, suggesting that other CD1d- 
Bregs may be important for FoxP3+ T-cell induction. Taken together, schistosome-
induced Bregs exhibit regulatory activity that may contribute to strong regulatory 
responses found during chronic schistosomiasis.
5




Heparinized venous blood was obtained from S. haematobium-uninfected 
young adults living in Lambaréné, Gabon, a semiurban municipality where S. 
haematobium is not endemic and the prevalence of S. haematobium infection is 
low; these individuals composed the "nonendemic uninfected group". Infected 
donors and additional uninfected donors were recruited from the rural village 
Bindo, where S. haematobium is endemic, residents are likely to have a history 
of S. haematobium infections, and no intervention studies have been performed 
(28); these donor groups composed the "endemic infected group" and the 
"endemic uninfected group", respectively. Current users of praziquantel were 
excluded from study participation, as were people who had lived in either region 
for <1 year before enrollment. 
 The presence of helminth and protozoan infections was determined as 
previously reported (20) (Table I). Infections with Plasmodium (P.) falciparum and 
P. malariae were determined by polymerase chain reaction (PCR) (29) and Loa 
Loa and Mansonella perstans microfilariae by microscopy (30). Written informed 
consent was obtained from all participants, and they were treated according 
to local guidelines. The study was approved by the Comité d’Ethique Regional 
Independent de Lambaréné (CERIL N°08/10) and conducted according to the 
principles expressed in the Declaration of Helsinki.
Cell isolation and characterization
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Hypaque 
density gradient centrifugation from approximately 40 ml of blood in 50 ml tubes 
(Greiner Bio-One). CD19+ B cells, untouched CD4+, and CD4+CD25- T cells were 
isolated by magnetic-bead purification (purity, >96%). For CD1dhi depletion, B 
cells were first incubated with CD1d-APC (Biolegend), washed, and incubated 
with 20 μl/107 anti-APC MicroBeads (Miltenyi Biotec). The cells were then split 
in 2 groups, CD1dhi-depleted B cells (86% depleted) and mock-depleted B cells, 
to which the eluted CD1dhi B cells were added back after depletion. Part of the B 
cells were cryopreserved in cryovials (Greiner Bio-One) and transported to Leiden 
University Medical Center, Leiden, The Netherlands.
 In PBMCs, B cells were characterized using CD1d-PE, CD19-PacificBlue, 
CD27-APCeFluor780 (all eBioscience), CD24-PeCy7 (ITK), and CD38-FITC (BD). 
For PFA-fixed PBMCs: CD1d-PE, CD20-APCeFluor780 (eBioscience), CD24-
PeCy7, CD27-Biotin (eBioscience) plus streptavidin-Qdot525 (Life Technologies), 
CD38-Horizon450 (BD), and LAP1-APC (Biolegend). For all flowcytometric 
measurements, all samples were stained in 96-well V-bottom plates (Greiner 
Bio-One), FcγR-binding inhibitor was added to the antibody mix, and FMOs were 
used for gate setting for all surface markers and cytokines.
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B-cell stimulation and intracellular staining
Freshly isolated B cells (1x105) were stimulated in medium (RPMI; Life 
Techonologies) supplemented with 10% FCS (Greiner Bio-One), 1 mM pyruvate, 
2mM Glutamate and antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin; 
all Life Technologies), in the presence of 100 ng/ml PMA, 1 μg/ml ionomycin, 
10 μg/ml BrefeldinA (all Sigma-Aldrich) and 10 μg/ml ultrapure LPS (Life 
Technologies) (25). After 5 hours, the cells were fixated with 1.9% PFA (Sigma-
Aldrich) and stained for CD1d-PE, CD20-APCeFluor780, CD24-PeCy7, CD27-APC 
(BD), CD38-FITC, IL-10-Biotin (Abd Serotec) plus streptavidin-Qdot525, and TNF-
α-eFluor450 (eBioscience). 
Functional in vitro assays
B cells (1x105) were cultured in 96-well U-bottom plates (Greiner Bio-One) 
with allogenic CD4+ T cells (1x10
5) from 1 European donor in the presence of 
1 μg/ml soluble anti-CD3 (IXE M1654, Sanquin) for 3 days or, in parallel, with 
CD4+CD25- T cells for 6 days (23). After 3 days, cells were restimulated with PIB, 
PFA-fixed and stained in 0.5% saponin buffer for IL-4-PE (BD), IL-10-Biotin plus 
streptavidin-Qdot525, IL-17-FITC (Biolegend), IFN-γ-HorizonV450 (BD), TNF-α-
PeCy7 (eBioscience), CD3-PerCPCy5.5 (BD), and CD20-APCeFluor780. After 6 
days, restimulated cells fixed with eBioscience FoxP3 fixation buffer were stained 
in permeabilization buffer for: CD1d-APC (Biolegend), CD3-PerCPeFluor710 
(eBiosience), CD20-APCeFluor780, CD25-PE (BD), IL-10-Biotin plus streptavidin-
Qdot525, TNF-α-PeCy7, FoxP3-eFluor450 (eBioscience), and Helios-FITC 
(Biolegend).
Statistical analysis
For non-parametric analysis Kruskal-Wallis, Mann-Whitney U, and Wilcoxon 
matched pairs tests were used. For categorical data, the Pearson Chi-squared 
and Fisher exact tests was used. All tests were performed used Graphad Prism. 
Correlations were analyzed using SPSS Statistics 20 (IBM). A P value <.05 was 
considered statistically significant.
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Results 
Elevated B-cell IL-10 and LAP/TGF-β1 expression in S. haematobium-infected 
subjects
Peripheral blood specimens was collected from 14 young adults in the endemic 
infected group and compared to specimens from 12 individuals in the endemic 
uninfected group and from 12 individuals from the nonendemic uninfected 
groups. As described in Table I, no significant differences were found between 
the  3 groups in the prevalence and infection intensity of other parasitic infections 
such as malaria, Ascaris lumbricoides infection, Trichuris trichiura infection, or 
hookworm infection. Furthermore, sex was equally distributed, but the age 
of the S. haematobium-infected individuals was slightly lower than that of 
uninfected individuals. Age was not regarded as a confounder, however, as the 
real age differences were very small (3-4 years). The average number of isolated 
PBMCs (1.1x106, 1.0x106, 1.0x106 cells/ml, P =.5) and the average percentage of 
isolated B cells (8.3%, 8.3%, 6.2%, P =.4) were comparable between the endemic 
infected group, endemic uninfected group, and nonendemic uninfected group, 
respectively.
 CD19+ B cells isolated from peripheral blood specimens were studied for 
the presence of IL-10-competent B cells by a short, 5-hour stimulation period 
with PMA, ionomycin, Brefeldin A and LPS (PIB+LPS) as described by Iwata et 
al. (25). TNF-α was included as an inflammatory control. The percentage of B 
cells expressing cytoplasmic IL-10 was the highest in the endemic infected group 
and lowest in the nonendemic uninfected group (Fig. 1A). TNF-α production was 
similar in all groups (Fig. 1A, Appendix S1A). The percentage of IL-10-producing 
B cells was not correlated with age, helminth burden (based on S. haematobium 
egg counts; data not shown), or Plasmodium parasites (Fig. 1C) (31). Of note, 
PIB-only stimulation also showed a greater percentage IL-10-producing B cells in 
the endemic infected group, compared to the other 2 groups, although in each 
group, levels after PIB-only stimulation were lower than those after PIB+LPS 
stimulation (data not shown). 
 We also analyzed the expression of LAP/TGF-β1. Dissociation of this 
complex results in bioactive TGF-β1. B cells from the endemic infected group 
expressed significantly more LAP, while B cells from endemic uninfected individuals 
showed an increased trend, compared with the nonendemic uninfected group 
(Fig. 1B, Appendix S1B). We did not study the coexpression of TGF-β1 and IL-10 
in B cells because this investigation requires different methods (ie, B cells need to 
be stimulated for IL-10, but not for LAP/TGF-β dectection). These results indicate 
that schistosome infections or exposure induces elevated numbers of circulating 
IL-10-producing and/or LAP/TGF-β1-expressing B cells.
Phenotypic characterization of IL-10 and LAP/TGF-β1-expressing B cells
Chapter 5
102
To determine which Breg subset was responsible for the increased IL-10 
production and/or LAP/TGF-β1 expression, PBMCs were analyzed for the 
presence of 3 different human Breg subsets: CD1dhi B cells, CD24hiCD38hi B cells 
and CD24hiCD27+ B cells (23;25;27). Only the CD1dhi subset was elevated during 
infection (from 1.9% to 2.5%), whereas the other 2 subsets were similar among 
the 3 study groups (approximately 5% CD24hiCD38hi and 21% CD24hiCD27+) (Fig. 















Mean age in yrs 
(range)
18.7 (16-23) 23 (18-28) 21.8 (18-27) 0.002#
S. haematobium 14 (100%) 0 0
Mean egg count 
(range)
165 (1-798) - -
Other helminths
Any helminths 6 (43%) 4 (33%) 3 (25%) 0.631*
Ascaris (%) 4 (29%) 2 (17%) 1 (8%) 0.407*
Trichuris (%) 4 (29%) 2 (17%) 1 (8%) 0.407*
Hookworm (%) 3 (21%) 2 (17%) 1 (8%) 0.656*
Entamoeba 
histolytica (%)
0 (0%) 0 (0%) 1 (8%) 0.329*
Malaria (PCR)
Any malaria 4 (29%) 7 (58%) 3 (25%) 0.172*
P. falciparum 4 (29%) 6 (50%) 3 (25%) 0.372*
P. malariae 0 (0%) 1 (8%) 1 (8%) 0.540*
Microfilaria
Any microfilaria 3 (21%) 5 (42%) 2 (17%) 0.332*
Loa loa 3 (21%) 2 (17%) 0 (0%) 0.248*
Mansonella 
perstans
0 (0%) 3 (25%) 2 (17%) 0.155*
The study was initiated in January 2011, and participants were from 2 villages in Gabon.
# By the Kruskal-Wallis test for age. Mann-Whitney test shows the following differences: P =.002 between 
endemic infected and -uninfected group, P =.006 between endemic infected and nonendemic uninfected 
group, and P =.255 between endemic uninfected and nonendemic uninfected groups.
* By the Pearson Chi-squared test. Because of sample size, the Fisher exact test was performed between 
the groups, and results showed no differences between the groups for all co-infections. 
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Figure 1. Intracellular interleukin 10 (IL-10) and tumor necrosis factor α (TNF-α) detection in total B cells. 1 
× 105 blood-derived B cells from Schistosoma haematobium–infected individuals from a S. haematobium–
endemic area (S.h+), uninfected individuals from a S. haematobium–endemic area (S.h−), and uninfected 
individuals from a S. haematobium–nonendemic area (S.h−) were directly stimulated for 5 hours with PMA, 
ionomycin, and brefeldinA (PIB) in combination with ultrapure lipopolysaccharide (LPS). (A) Intracellular 
IL-10 production and TNF-α production were analyzed using flow cytometry (FACS Canto II, BD Biosciences). 
(B) 1 × 106 PFA-fixed peripheral blood mononuclear cells were stained for latency-associated peptide (LAP)/
transforming growth factor β1. The geometric mean fluorescence intensity (MFI) of LAP expression on total 
B cells was determined. (C) Intracellular IL-10 in B cells after 5 hours of PIB + LPS stimulation. Donors were 
grouped according to the presence of malaria parasite infection (Mal) and/or S. haematobium infection. 
The malaria-negative S. haematobium–negative group contains 14 individuals (5 of whom were from 
Bindo), the malaria-positive S. haematobium–negative group contains 10 (7 of whom were from Bindo), the 
malaria-negative S. haematobium–positive group contains 10, and the malaria-positive S. haematobium–
positive group contains 4. Donors from Bindo are depicted in Figure 1C as half-shadowed circles or squares 
and donor from Lambaréné as open circles or squares. Each individual is represented as a separate dot, 
with a line showing the median value for the group. Data were analyzed using the Mann–Whitney U test.
2A/B, Appendix S1C). Interestingly, in the endemic infected group, the subset 
with the greatest percentage of cells producing IL-10 was the CD1dhi B cells (25 
%), and only a small percentage of CD24hiCD27+ B cells produced IL-10 (2.7 %; 
Fig. 2C). Within the IL-10-producing B-cell pool, approximately 10-20% of the B 
cells shared a CD1dhi or CD24hiCD27+ phenotype. However, only the percentage of 
CD1dhi B cells within the IL-10-producing B-cell population significantly increased 
during infection, again indicating that mostly these cells are induced during 
schistosome infections. The percentage of the different Breg subsets was not 
correlated with helminth burden (data not shown).
 Increased levels of LAP/TGF-β1 expression in total B cells from endemic 
infected individuals was mainly attributed to the CD24hiCD27hi, and partly to the 
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CD24hiCD38hi B-cell population, but not to the CD1dhi B cells (Fig. 2D). The difference 
in IL-10 expression between the endemic infected group and the uninfected 
groups was lost when CD1dhi B cells were removed from the CD24hiCD27+ B-cell 
gate, but the difference in LAP/TGF-β1 expression was maintained (Appendix S2). 
Therefore, these data suggest that the CD1dhi B cells are the dominant subset that 
increases in number and capacity to produce IL-10 during Schistosoma infection, 
while increased LAP/TGF-β1 has a stronger association with CD24hiCD27+ B cells, 
although the frequency of this subset did not change during schistosomiasis. 
Schistosome-induced B cells dampen the pro-inflammatory T-cell cytokine 
profile
We next performed in vitro CD4+ T and B cell cocultures in the presence of 
anti-CD3  to investigate whether the T-cell stimulatory activity of B cells from the 
endemic infected group is altered. Allogenic CD4+ T cells from a single donor were 
used, to prevent differences due to variation in T-cell donors. After 3 days, the 
cells were restimulated with PIB, and we observed a slight but significantly lower 
percentage of  CD4+ T cells producing IFN-γ-, IL-4- and IL-17 when stimulated in the 
presence of B cells from the endemic infected group, compared to nonendemic 
uninfected group, whereas TNF-α production was not affected (Fig. 3A-D). T 
cells stimulated with anti-CD3 only, in the absence of B cells, showed a variable 
degree of viability and were therefore excluded from the analysis. No significant 
differences were detected between endemic infected and endemic uninfected 
individuals, suggesting that past exposure to Schistosoma infections can yield 
changes in B-cell function, reflected in the slightly enhanced IL-10 and TGF-β 
expression (Fig. 2), which may be sufficient to control effector T-cell responses.
CD1dhi B cells induce IL-10-producing T cells
To investigate whether schistosome-induced B cells can prime the regulatory 
functions in T cells, either by enhancing IL-10 production (as in Tr1 cells) or by 
inducing CD25hiFoxP3hi Tregs, CD4+CD25- T cells were cocultured with B cells for 
6 days. Interestingly, the frequency of IL-10-producing T cells was significantly 
higher after coculture with B cells from the endemic infected group, compared 
with the uninfected groups (Fig. 4A). In addition, more FoxP3hi Tregs were found in 
cocultures with B cells from the endemic infected group, compared to uninfected 
groups, although the variation in FoxP3 induction was greater than the variation 
in IL-10 induction (Fig. 4B, Appendix S3). When Helios expression was analyzed 
(as an additional marker for putative functional FoxP3+ Tregs), the frequency of 
Helios+CD25hiFoxP3hi T cells still remained significantly higher in the endemic 
infected group (data not shown).
 To explore the underlying mechanism, we next focused on the dominant 
IL-10-producing B-cell subset, CD1dhi B cells, to examine the effect of helminth-
induced IL-10-producing B cells on regulatory functions of T cells (Fig. 4C). Because 
of the limited cell numbers available, we used a CD1dhi B cell depletion strategy 
instead of isolating CD1dhi B cells. Similar to findings for the total B-cell population 
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Figure 2. The frequency of different regulatory B cells in the blood specimens from Schistosoma 
haematobium-infected indviduals from a S. haematobium- endemic area (S.h+), uninfected individuals 
from a S. haematobium- endemic area (S.h-) and uninfected individuals from a S. haematobium- 
nonendemic area (S.h-). (A) Ex vivo PBMCs were gating for CD19+, following by specific Breg subset gating 
as indicated in the figure by a representative gating example involving a S. haematobium-infected donor. 
(B) The percentage of CD1dhi, CD24hiCD27+, and CD24hiCD38hi B cells. (C) IL-10 production of each B-cell 
subset after 5 hours ofstimulatuin with PIB+LPS. (D) The geometric MFI expression of LAP/TGF-β1 on the 3 
Breg subsets. For all data, the Mann-Whitney U-test was used for analysis.
from the endemic infected group, the mock-depleted B cells induced higher 
levels of IL-10 and/or CD25hiFoxP3hi T cells compared to B cells from uninfected 
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Figure 3. T-cell cytokine 
expression after coculture with 
B cells from S. haematobium-
infected (S.h+) and uninfected 
individuals (S.h-) from a S. 
haematobium-endemic area, 
and uninfected individuals 
from a S. haematobium-
nonendemic area (S.h-). 
Isolated B cells were cultured 
at a ratio of 1:1 with allogenic 
CD4+ T cells (from 1 European 
donor) in the presence of 
soluble anti-CD3 (1 µg/ml) 
for 3 days. After coculturing, 
the cells were restimulated 
with 100 μg/ml PMA and 1 
μg/ml ionomycin for 6 hours, 
in the presence of 10 μg/ml 
BrefeldinA for the last 4 hours. 
The cells were fixed with 1.9% 
PFA. Single cytokine-producing 
T cells were gated for pro-
inflammatory cytokines IFN-γ 
(A), IL-4 (B), IL-17 (C) and TNF-α 
(D). The Mann-Whitney U-test 
was used for data analysis.
groups. After the depletion of CD1dhi B cells, the percentage of T cells expressing 
IL-10 returned to levels similar to those induced by B cells from the uninfected 
groups, whereas no effect on the (elevated) level of CD25hiFoxP3hi T cells was 
observed (Fig. 4D, Appendix S3A-B). Indeed, B-cell IL-10 was also reduced to 
levels found in uninfected donors following CD1d depletion (Fig. 4D, Appendix 
S3C), suggesting that B-cell expression of IL-10 may play a role in the induction of 
IL-10-producing T cells but not the induction of FoxP3+ Tregs. TGF-β is known to 
be important for the generation of FoxP3+ Tregs (32). To investigate its role in Treg 
induction, cryopreserved Gabonese B cells were cocultured with freshly obtained 
T cells and blocking anti-TGF-β at our Dutch research institute. In contrast to  the 
culture of fresh specimens performed at the field site, isotype-cultured B cells 
from infected individuals did not enhance Treg induction, suggesting that freezing 
and thawing the cells may have affected their function, despite a good viability 
after thawing (> 94 %; data not shown). Therefore, the role of TGF-β-expressing 
B cells in the induction of FoxP3+ Tregs could not be addressed within the current 
study. Nevertheless, it is tempting to suggest that CD24hiCD27+ B cells may be 
involved in FoxP3+ Treg induction via their enhanced LAP/TGF-β1 production (Fig. 
2). Altogether, we showed in a small study set of Schistosoma-infected individuals 
that B cells not only modify effector T-cell responses by reducing their ability 
to produce pro-inflammatory cytokines, but also increase Treg functions by 
enhancing the development of FoxP3+ Tregs and IL-10-producing T cells, with the 
latter depending on the activity of CD1dhi B cells. 
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Figure 4. Induction of IL-10+ T and FoxP3+ regulatory (Tregs) cells by B cells. Isolated B cells were cultured at 
a ratio of 1:1 with allogenic CD4+CD25- T cells (from 1 European donor) in the presence of soluble anti-CD3 
(1 µg/ml) for 6 days. After coculturing, the cells were restimulated with 100 μg/ml PMA and 1 μg/ml 
ionomycin for 6 hours, in the presence of 10 μg/ml BrefeldinA for the last 4 hours. Cells were then fixed 
with FoxP3 fixation buffer (eBioscience). (A) T cells were gated for FoxP3- T cells and subsequently gated 
for IL-10+(TNF-α-) T cells (Tr1 cells). (B) The induction of CD25hiFoxP3hi T cells after coculture with B cells 
from endemic infected, endemic uninfected or nonendemic uninfected individuals. The Mann-Whitney 
U-test was used for data analysis. Median values ared denoted by horizontal lines, with dots representing 
individual donors. (C) A representative example of CD1dhi depletion, using Miltenyi Biotec isolation beads, 
is shown. In each group, total untouched B cells (total), mock-depleted total B cells (mock) and CD1dhi-
depleted B cells were cultured with CD25-CD4+ T cells (See Appendix S3 for uninfected groups). (D) The 
induction of IL-10+ T cells, FoxP3+ Tregs and IL-10 production by B cells after the depletion of CD1dhi B cells 
in Schistosoma-infected individuals. We were not able to perform CD1d depletion for all donors because of 
a limited number of B cells available. Therefore, 4 donors are missing in the S.haematobium-infected group 




In this study, we demonstrated that a greater percentage of B cells from 
schistosome-infected individuals produce IL-10 and/or LAP/TGF-β1, compared 
with B cells from uninfected individuals. In coculture with CD4+ T cells, these B cells 
reduced the production of effector T-cell cytokines and more FoxP3+ and IL-10+ T 
cells were found, compared to cultures from uninfected controls. It is suggested 
that IL-10-producing Bregs detected following in vitro stimulations may not only 
be derived from existing circulating IL-10-producing Bregs but may also be derived 
from progenitor Bregs (25;33). Indeed, it was demonstrated that these progenitor 
cells can develop into IL-10-competent Bregs during a 2-day in vitro stimulation by 
CD40 ligand and/or BCR ligation (34). Earlier studies exploring Breg frequencies 
have not investigated the presence of existing IL-10-competent Bregs, as IL-10 
production was only studied following long-term in vitro stimulation, which does 
not permit discrimination between these 2 B-cell populations (20;27). Here, we 
specifically focused on the presence of already competent IL-10 Bregs and found 
that a greater percentage of peripheral blood B cells from schistosome-infected 
individuals could readily produce cytoplasmic IL-10, without long-term in vitro 
priming or maturation of B cells. Presumably, these processes already occurred in 
vivo, indicating that schistosome infections indeed prime for the development of 
readily active IL-10-producing Bregs in humans.
 Several studies demonstrated that Bregs may simultaneously produce 
various regulatory cytokines, such as IL-10 and TGF-β. For example, LPS induced 
both IL-10 and TGF-β secretion in B cells, and these LPS-activated B cells suppressed 
the development of diabetes by promoting apoptosis of effector T cells. However, 
the responsible cytokine was not addressed in this study (18). Furthermore, 
in food-allergic mice, allergen-specific T-cell proliferation was suppressed by 
activated CD5+ B cells secreting both TGF-β and IL-10 (35). Interestingly, similar 
IL-10- and TGF-β-producing CD5+ B cells were found in healthy individuals upon 
milk antigen stimulation (7;36). Lastly, co-expression of IL-10 and TGF-β was also 
demonstrated in human CD25hiCD1dhiCD27hi B cells (37). However, other studies 
have suggested that IL-10 and TGF-β are not always expressed by the same Breg 
subset. For example, CD5+ B cells from mice chronically exposed to ovalbumin 
and tolerant for allergic airway inflammation, predominantly expressed IL-10, 
while TGF-β was not restricted to CD5+ B cells only (8). This is in agreement with 
the data presented here, as we also observed that IL-10 and LAP/TGF-β1 were 
expressed by different Breg subsets: the infected group had a greater percentage 
of CD24hiCD27+ B cells expressing LAP/TGF-β1 and had a greater percentage of 
CD1dhi B cells producing IL-10 compared with the uninfected group. This may 
suggest that helminth infections can promote the activity of 2 different B-cell 
subsets. 
 Enhanced Treg activity is one of the hallmarks of chronic Schistosoma 
infections (38). Because part of schistosome-induced Breg activity in mice is 
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centered on their capacity to induce Tregs and modulate T-cell cytokines, we 
focused on these aspects here. However, during a natural infection it is also 
possible that other cells, such as antigen-presenting cells, may also be influenced 
by Bregs (25;39). Here, we find a clear induction of FoxP3+ Tregs and IL-10+ T 
cells by schistosome-induced B cells, and we tried to identify the responsible 
Bregs. Previous studies showed that both IL-10 and TGF-β can induce FoxP3+ 
Tregs (37;40). However in our study, cocultures with B cells depleted for CD1dhi 
B cells, the main source of IL-10, mainly reduced IL-10+ T cells without affecting 
FoxP3+ T-cell levels. This suggest that the IL-10-producing B cells mainly induced 
IL-10+ T cells but not FoxP3+ Tregs, although we cannot exclude the contribution 
of other (co)factors to this process. At this stage, it is unclear which schistosome-
induced Breg subset is responsible for the enhanced Treg induction, although 
it is tempting to suggest that, given the role for TGF-β in FoxP3+ Treg induction, 
TGF-β-producing B cells (ie, the CD24hiCD27+ B cells) are involved here.
 We previously reported that 6 months after helminth treatment, B cells 
still showed increased IL-10 secretion upon in vitro stimulation with soluble 
egg antigens (SEA), suggesting the presence of a persistent pool of memory 
schistosome-specific B cells after clearance of infection (20). Our S.haematobium-
uninfected donors are coming from a schistosome-endemic area and former 
infections are likely to have occurred, which may have promoted Breg activity 
in these individuals at an earlier stage. Indeed, B cells from endemic uninfected 
group express more IL-10 and TGF-β compared to uninfected individuals from 
a close-by nonendemic area. In addition, this may explain the similar levels of 
effector T-cell cytokines found in cocultures by B cells from schistosome-infected 
and uninfected individuals from the same area. Interestingly, the Treg-inducing 
and IL-10+ T-cell-inducing capacity was not enhanced in B cells from endemic 
uninfected group, indicating that some of the activities or some of the Breg 
subsets are longer lasting after infection, while others may diminish with time. 
 Several mouse models showed that parasite products from either 
Leishmania major or Brugia malayi and the milk glycan LNFPII, containing LeX 
motifs similar to several schistosome glycoconjugates, can enhance B-cell-derived 
IL-10 via Toll-like receptor 4 ligation (41;42). Furthermore, in vitro stimulation of 
splenocytes by live schistosome worms induced IL-10-producing B cells, which 
dampened allergic airway inflammation upon transfer (19). Lastly, B cells from 
helminth-infected patients with multiple sclerosis stimulated with SEA resulted 
in a Toll-like receptor 2-mediated IL-10 production (43). These findings suggest 
that the development of Bregs, as observed in schistosome-infected individuals, 
may be specifically related to the presence and activity of certain helminth-
derived molecules. However, we cannot exclude that Breg development may 
also occur as a bystander process resulting from continuous chronic infection in 
which the immune system desperately tries to counterbalance the inflammation 
induced by the continuous presence of helminths. Indeed, also other chronic 
infections with viral or bacterial agents show enhanced IL-10-producing B cells 
(22;24;26). However, what is interesting and what may point to a helminth-
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specific Breg population, is that the affected Breg subsets in those studies were 
not characterized by CD1dhi, suggesting that this population is mostly restricted 
to helminth infections (20;27). 
 Reports on patients with autoimmune (23;44;45) or allergic diseases 
(7;36) have shown impairments in Breg frequencies or function, suggesting a 
role for Bregs in the maintenance of peripheral tolerance in healthy individuals. 
Therapies aiming to enhance Breg numbers or activity may have potential for 
future treatment of inflammatory diseases. Interestingly, upregulation of Breg 
activity was observed in patients with bee venom allergy following successful 
allergen-specific immunotherapy, reaching similar levels as found in tolerant 
beekeepers (46). As we here observed that schistosome-induced Bregs can affect 
T-cell responses (ie, reduced effector T-cell cytokines and more Treg induction), 
applying helminth-derived molecules may form an interesting novel therapy for 
hyperinflammatory disorders by driving potent Bregs. 
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Figure S1. (A) A representative gating example of intracellular IL-10 and TNF-α production upon 5 hours 
PIB+LPS stimulation in total B cells from a endemic infected (S.h+) individual. Fluorescence minus one 
(FMO) shows background levels of IL-10 and TNF-α. B, A representative gating example for LAP/TGF-β1 
expression on ex vivo total B cells from endemic infected (including FMO) and nonendemic uninfected 
(S.h-) individual. C, Intracellular IL-10 staining upon 5 hours PIB+LPS stimulation in CD1dhi, CD24hiCD27+, 
CD24hiCD38hi B cells from a endemic infected individual. Fluorescence minus one (FMO) shows background 




Figure S3. Induction of IL-10+ 
T and FoxP3+ Treg cells by B 
cells. Isolated B cells were 
cultured at a ratio of 1:1 with 
allogenic CD25-CD4+ T cells 
(from 1 European donor) in the 
presence of soluble anti-CD3 
(1 µg/ml) for 6 days. After 
coculturing, the cells were 
restimulated with 100 μg/ml 
PMA and 1 μg/ml ionomycin 
for 6 hours, in the presence 
of 10 μg/ml BrefeldinA for the 
last 4 hours. The cells were 
then fixed with FoxP3 fixation 
buffer (eBioscience). (A) The 
induction of IL-10-producing T 
cells after coculture with B cells 
from endemic uninfected and 
nonendemic uninfected donors. 
(B) The induction of FoxP3+ 
Tregs and C, IL-10 production 
by B cells. We were not able to 
perform CD1d depletion for all 
donors due to a limited number 
of B cells available. Therefore, 
the total individuals in the 
endemic uninfected group were 
n=12 (0 missing), and in the 
nonendemic uninfected group 
n=8 (4 missing). For all data, 
Wilcoxon matched pairs test 
was used for data analysis.
Figure S2. (A) IL-10 
production and (B) LAP/
TGF-β1 membrane-
bound expression of 
CD24hiCD27+ B cells after 
gating out the CD1dhi B 
cells in this population. 
The Mann-Whitney U- 
test was used for data 
analysis. 
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Background Regulatory B cells have been identified that strongly reduce allergic 
and auto-immune inflammation in experimental models by producing IL-10. 
Recently, several human regulatory B-cell subsets with an impaired function in 
auto-immunity have been described, but there is no information on regulatory B 
cells in allergic asthma. 
Objective In this study, the frequency and function of IL-10-producing B-cell 
subsets in allergic asthma were investigated. 
Methods Isolated peripheral blood B cells from 13 patients with allergic asthma 
and matched healthy controls were analyzed for the expression of different 
regulatory B-cell markers. Next, the B cells were activated by lipopolysaccharide 
(LPS), CpG or through the B-cell receptor, followed by co-culture with endogenous 
memory CD4+ T cells and house dust mite allergen Derp1. 
Results Lower number of IL-10-producing B cells were found in patients in 
response to LPS, however, this was not the case when B cells were activated 
through the B-cell receptor or by CpG. Further dissection showed that only the 
CD24hiCD27+ B-cell subset was reduced in number and IL-10 production to LPS. 
In response to Derp1, CD4+ T cells from patients co-cultured with LPS-primed 
total B cells produced less IL-10 compared to similar cultures from controls. These 
results are in line with the finding that sorted CD24hiCD27+ B cells are responsible 
for the induction of IL-10+ CD4+ T cells.
Conclusions Taken together, these data indicate that CD24hiCD27+ B cells from 
allergic asthmatic patients produce less IL-10 in response to LPS leading to a 
weaker IL-10 induction in T cells in response to Derp1, which may play a role in 
allergic asthma.
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Introduction 
Allergic asthma (AA) is a reversible obstructive lung disease, in which cross-
talk between inflammatory cells and structural lung cells is central. There is 
a negative association between reduced exposure to infectious agents and 
increased prevalence of asthma and allergy in affluent populations (1), leading 
to the hypothesis that childhood exposure to environmental microbes helps 
to prevent allergy (2). Abundant early-life microbial exposure, such as to 
farm animals, unpasteurized milk products and bacterial DNA and endotoxin 
(lipopolysaccharide, LPS), is thought to instruct a robust development of the 
regulatory arm of the immune system, preventing uncontrolled inflammatory 
responses to allergens (2-6). 
 In healthy individuals, immune responses to allergens are either absent 
or characterized by an enhanced production of IL-10. Whereas (regulatory) T cells 
are known for their capacity to produce IL-10 (7), IL-10 is also produced by other 
cell types, including B cells. Interestingly, initial studies using adoptive transfers 
in auto-immunity models have shown that IL-10-producing B cells have a strong 
potential to reduce inflammation and, therefore, are called regulatory B (Breg) 
cells (8-11). Importantly, recent mouse studies have demonstrated that Breg cells 
can reduce allergic inflammation in both anaphylactic and airway inflammation 
models by virtue of their IL-10 production and the induction of Treg cells (12-15). 
 Various Breg subsets in humans, characterized by the expression of 
CD24hiCD38hi or by CD24hiCD27+, have been described and show a reduced 
function in certain auto-immune diseases, such as systemic lupus erythematosus 
(SLE) (16;17). During chronic hepatitis B virus infection, CD24hiCD38hi B cells were 
described to produce IL-10 and thereby suppress antigen-specific CD8+ T cell 
responses (18). In addition, an enhanced CD1dhi Breg subset was described in both 
schistosome-infected Gabonese individuals (14) and in mixed helminth-infected 
Brazilian multiple sclerosis (MS) patients which could inhibit auto-reactive T cell 
responses in vitro (19). Additionally, a reduced IL-10 production of B cells from 
MS patients in response to CD40 ligation and B-cell receptor (BCR) cross-linking 
was reflected mostly in the CD27- naive B cells (20). Taken together, different 
human Breg subsets may exist and for some their function is impaired in certain 
auto-immune diseases.
  Several articles have studied the signals that control regulatory B cell 
number and/or activity, and have identified both BCR triggering and TLR ligation 
as important pathways to induce IL-10 production and functional regulatory 
activity. In this respect, TLR2 and 4 have been shown to promote IL-10-producing 
B cells in different infection models: for example, extracts from Leishmania major 
or Brugia malayi microfilaria use TLR4 (21), Helicobacter felis use TLR2 (22) and 
in Salmonella typhimurium infections MyD88-dependent signaling in B cells is 
crucial for IL-10 induction (23). 
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 So far, no information is available on the presence of regulatory B cells 
in individuals with allergic asthma (AA) or on TLR or BCR-related pathways that 
can promote their development. As abundant exposure to bacterial products in 
the farm studies (and in particular to endotoxin) is linked to protection against 
allergic inflammation and bacterial products promotes IL-10-producing B cells in 
animal models, we focused on LPS and CpG as TLR stimuli to investigate its IL-
10-inducing capacity in human B cells. Therefore, we here describe the Breg cell 
frequency in peripheral blood B cells from patients with AA compared to healthy 
controls (HC) and investigated the capacity to produce IL-10 in response to LPS, 
CpG or to BCR triggering and their ability to influence T-cell cytokine production. 
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Non-smoking (or ex-smoking for more than 1 year, less than 10 pack-years) 
AA patients with house dust mite (HDM) allergy and control (n=13; age: 19-45 
years; Table 1) were subjected to asthma control questionnaires (ACQ; based on 
(24)), spirometry, airway hyperreactivity (AHR) tests in response to metacholine 
(PC20metacholine); skin prick tests (SPT) for HDM, tree and grass pollen, cat, dog 
and Aspergillus. Nitric oxide (FeNO) levels were analyzed in exhaled breath, total 
serum IgE and allergen-specific IgE for HDM, tree and grass pollen, cat, dog, 
horse and Aspergillus (Phadiatop) were measured in serum. Inclusion criteria for 
healthy controls: PC20 >19 mg/ml, negative SPT for all antigens and total IgE <30 
IU/ml. Inclusion criteria for patients with AA: PC20 <9.6 mg/ml and a positive SPT 
for at least HDM (wheal >5 mm), total IgE ≥30 IU/ml and detectable specific IgE 
for at least HDM (> 0.7 kU/l). Patients with AA (seven out of 13) using inhaled 
corticosteroids or combination therapy were asked to cease their medication 
2 weeks before blood taking. Ten healthy control subjects donated fresh blood 
samples twice. In addition, peripheral blood from healthy laboratory donors 
were used to perform some validation experiments (secretion assays, signaling 
and ELISA). The study was approved by the Medical Ethical Committee LUMC 
(P09.170) and performed according to the declaration of Helsinki. Written 
informed consent was given by all participants.
B- and T-cell isolation and flowcytometry 
PBMCs were isolated by Ficoll-Hypaque density gradient centrifugation in 50 
ml tubes (Greiner Bio-One) from heparinized blood. B cells with a purity of 
~98% were isolated by anti-CD19 MicroBeads (Miltenyi Biotec). The remaining 
cells were collected for further isolation of memory CD45RO+CD4+ T cells 
using MicroBeads (Miltenyi Biotec). PBMCs or isolated B cells were stained in 
96-well V-bottom plates (Greiner Bio-One) for CD1d-PE (CD1d42, BD), CD5-
PercPeFluor710 (UCHT2, eBioscience), CD20-APC-eFluor780 (2H7, eBioscience), 
CD24-PeCy7 (ML5, Biolegend), CD27-APC (L128, BD), CD38-FITC (HIT2, BD), 
CD19-Pacific Blue (HIB19, Biolegend) and TLR4-biotin (HTA125, Biolegend) in 
combination with streptavidin-Qdot525 (Invitrogen) and FcγR-binding inhibitor 
(eBioscience) to define the different Breg cell subsets. CD20, which was equally 
expressed as CD19 on all B cell (subsets), was used to define B cells because of 
the MACS CD19 isolation procedure. Fluorescence minus one (FMOs) were used 
for proper gate setting for all markers.
 In a subset of healthy control donors, cells were stained for CD24-
PeCy7 (ML5, Biolegend) and CD27-APC (L128, BD Biosciences) after CD19+ B cell 




B-cell stimulation and intracellular staining for IL-10
B cells (1 x 105) were stimulated with 100 ng/ml ultra-pure LPS (Invitrogen), 5 
µg/ml CpG ODN2006 (Invitrogen) or 20 µg/ml anti-human IgG/IgM (Jackson-
ImmunoResearch) in RPMI (Invitrogen) supplemented with 10% FCS (Bodinco). 
All stimulations were tested to be optimal for IL-10 production at the given 
concentrations (data not shown). After 48 h, supernatants were taken and B cells 
were restimulated with PMA (200 ng/ml), ionomycin (2 µg/ml), and LPS (100 ng/
ml) for 6 h and the last 4 h in the presence of Brefeldin A (BrefA; 10 µg/ml; Sigma-
Aldrich), followed by fixation with 1.9% PFA. Next, the cells were permeabilized 
0.5% saponin buffer and stained for CD1d-PE (CD1d42, BD), CD5-PerCPeFluor710 
(UCHT2, eBioscience), CD20-APC-eFluor780 (2H7, eBioscience), CD24-PeCy7 
(ML5, Biolegend), CD27-APC (L128, BD), and CD38-FITC (HIT2, BD), IL-10-Biotin 
plus streptavidin-Qdot525 (JES3-12G8, Abd Serotec/Invitrogen), TNF-α-eFluor450 
(MAB11, eBioscience) and FcγR-binding inhibitor (eBioscience). FMOs were used 
for gate setting for all surface markers and cytokine expression.
B-T cell co-culture 
1 x 105 B cells were stimulated with medium, ultra-pure LPS, CpG or anti-human 
IgG/IgM for two days, followed by removal of supernatant, washed, and co-
cultured with autologous memory CD4+ T cells (ratio 1:1) in the presence of 1 
µg/ml endotoxin-free Derp1 (LoTox Derp 1, Indoor Biotechnologies) in RPMI 
supplemented with 10% FCS. CD4+ T cells were first pre-incubated with blocking 
IL-10R antibodies (2 µg/ml; R&D Systems) or IgG1 isotype control (2 µg/ml) 
for 30 min at 37 °C. After six days, supernatants were taken and the cells were 
restimulated by PMA/iono and BrefA (as indicated above) and fixated with FoxP3 
fixation/permeabilization buffer (eBioscience). The cells were stained for CD3-
PerCPCy5.5 (SK7, BD), CD20-Pacific Blue (2H7, Biolegend), CD25-PE (2A3, BD), 
IL-10-Biotin plus streptavidin-Qdot525 (JES3-12G8, Abd Serotec/Invitrogen), TNF-
α-PeCy7 (MAB11, eBioscience), FoxP3-FITC (PCH101, eBioscience), and FcγR-
binding inhibitor (eBioscience). FMOs were used for gate setting for all surface 
markers and cytokine expression.
Cytokine Secretion assay, ELISA and Luminex
From PBMC, monocytes were first depleted prior to isolation of B cells using CD14 
MicroBeads (Miltenyi Biotec). After the B-cell isolation, cells were stimulated for 
3 days (adapted from Milovanovic et al. (25)). Next, the B cells were restimulated 
with PMA and ionomycin for 2 h, washed, and incubated for1 hour with IL-10 
catch reagent according the protocol (Miltenyi Biotec). After the incubation, 
cells were stained for IL-10-PE (dilution 1:25, Miltenyi Biotec), CD20-Pacific Blue 
(2H7, BioLegend), life death marker 7-AAD-PerCP (E00031-1632, eBioscience) 
and FcγR-binding inhibitor (eBioscience). Collected supernatants collected were 
measured by Enzyme-Linked Immunosorbent Assay (ELISA) for IL-10 (Sanquin) or 
by Luminex (IL-5, IFN-γ, IgG1, IgG2, IgG4, and IgE, Invitrogen/Biorad).
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Western blot
For whole cell lysate, 1x106 B cells from 4 healthy donors from laboratory staff 
were stimulated for 5, 20, 60, 180 min with medium or LPS (100 ng/ml), washed 
and treated with a buffer containing 8% v/w glycerol, 3% SDS, and 100mM 
Tris-PO4 (EBSB) for 5 min. The lysate was heated to 95 °C for 5 min and then stored 
at -80 °C. The protein concentration of the whole cell lysates was determined 
by a bicinchoninic acid protein assay kit (Thermo Fisher Scientific). Whole cell 
lysates (10 μg/lane) were boiled in SDS sample buffer (50 mM Tris-Cl (pH 6.8), 1% 
2-ME, 2% SDS, 0.1% bromphenol blue, and 10% glycerol) for 5 min before being 
subjected to electrophoresis on 10% or 12.5% SDS-PAGE gels. After separation, 
the proteins were transferred onto nitrocellulose (Millipore). The membrane was 
incubated with primary antibodies against STAT3, and Phospho-STAT3 (Tyr 705) 
(D3A7) (all from Cell signaling Technology) and then incubated with anti-rabbit 
IgG HRP conjugated secondary antibodies (Promega). The bands were visualized 
by an enhanced chemiluminescence reagent (Thermo scientific).
Statistical analysis
For statistical analysis, Kruskal-Wallis 1-way ANOVA and the Mann-Whitney U 
tests were performed. Differences in paired conditions were analyzed by Wilcoxon 
matched pairs test. Correlations were analyzed using SPSS Statistics 20 (IBM, New 





To study the function and phenotype of peripheral blood B cells, 13 non-smoking 
patients with AA (age, 19-44 years; 7 females and 6 males) and 13 age- and sex-
matched non-smoking HC were included (age, 21-45 years). The patients with AA 
showed clinically controlled asthma without severe exacerbations for more than 
6 months (GINA guidelines). They had the following characteristics (median): an 
ACQ value of 4, a FEV1-% predicted of 101, a FEV1/FVC (as measure for obstruction) 
of 0.80, FeNO of 30 and a PC20-methacholine of 1.4 mg/ml (Table 1), which match 
values for mild to moderate bronchohyperreactivity. The HC showed no signs of 
asthma by an ACQ outcome of 0, a FEV1-% predicted of 112, a FEV1/FVC of 0.87, 
FeNO of 13 and a PC20-methacholine of >19 mg/ml.
 Positive SPT reactivity with a wheal larger than 5 mm was recorded against 
HDM in 12 patients with AA, against grass and/or tree pollen in 10 patients and 
against cat and/or dog in eight patients (Table 1). The median of total serum IgE 
levels was 108 IU/ml and the median for specific IgE for HDM was 13 IU/ml, for 
grass 0.7 IU/ml, for tree pollen 0.2 IU/ml, for cat 0.4 IU/ml and for dog 0.4 IU/
ml (Table 1). The HC group showed a negative SPT for HDM, cat, dog, tree and 
grass pollen or Aspergillus and a median total serum IgE of 7 IU/ml was recorded, 
which was significantly lower than the patients with AA. The blood of patients 
and of their matched controls was processed and analyzed simultaneously. In 
addition, the lymphocyte count (PBMC/ml blood) and the frequencies of B and 
memory CD4+ T cells were similar between the groups (data not shown).
Lower numbers of CD24hiCD27+ B cells in patients with AA
To investigate the frequency of the different Breg cell subsets, isolated peripheral 
blood CD19+ B cells were stained for CD1d, CD5, CD20, CD24, CD27 and CD38. 
Gating examples of a paired patient and healthy control are shown in Figure 1 
to define the following three different subsets: CD1dhi B cells, CD24hiCD38hi B 
cells and CD24hiCD27+ B cells. No differences were seen in frequency of CD1dhi B 
cells (average of 2%; Fig. 1A) or in the smaller subset CD1dhiCD5+ B cells (average 
of 0.3%; data not shown) between the groups. Of note, despite its confusing 
nomenclature the CD1d expression on human B cells is generally very low, but 
detectable as shown by figure 1. Although the percentage of transitional immature 
CD24hiCD38hi Breg cells was significantly increased in patients with AA (Fig. 1B), 
the absolute numbers per ml blood were not similar to that described by Blair et 
al. in SLE patients (16). Interestingly, both the percentage and absolute numbers 
per ml blood of CD24hiCD27+ B cells were significantly reduced in patients with 
AA compared to controls (Fig. 1C), while the distribution of naïve (CD27-) and 
memory B cells (CD27+) or CD24+ B cells were similar between the groups (data 
not shown). Of note, the frequency of CD24hiCD27+ B cells was the highest of 
the Breg cell subsets (~27 % CD24hiCD27+ vs. ~ 3 % CD24hiCD38hi vs. ~2% CD1dhi B 
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cells in controls). We did not detect any correlation between the percentage of 
CD24hiCD27+ B cells or any of the other Breg cells and the level of total serum IgE, 
HDM-specific serum IgE, PC20, exhaled FeNO or medication usage in the asthmatic 
patients (data not shown).
Less intracellular IL-10 in B cell from patients with AA in response to LPS
One of the hallmarks of Breg cells is their capacity to produce IL-10. To compare 
the IL-10-producing capacity of B cells from AA and HC subjects, CD19+ B cells 
were isolated from peripheral blood and stimulated for 2 days with medium 
alone, anti-IgG/IgM (general BCR trigger), LPS (TLR4 ligand) or CpG (TLR9 ligand). 
Subsequently, the cells were restimulated by PMA/ionomycin in the presence 
Table 1. Subject characteristics
AA (n=13) HC (n=13) P value
Sex (f) 7 (13) 7 (13) -
Age (yrs) 26 (19-44) 24 (21-45) 0.9379
BMI 22 (19-35) 22(18-24) 0.3517
ICS/CT 6(13) + 4(13) - -
FeNO 30 (13-80) 13 (5-21) 0.001
ACQ 4 (0-12) 0 (0-1) -
FEV1-%predicted 101 (92-118) 112 (102-128) 0.0026
FEV1/FVC 0.8 (0.64-0.91) 0.87 (0.77-0.97) 0.1637
PC20-methacholine 1.4 (0.3-9.6) >19 -
SPT (> 5mm)
HDM 12/13 - -
Grass and/or Tree 10/13 - -
Cat and/or Dog 8/13 - -
Total IgE (IU/ml) 108 (30-307) 7 (2-31) <0.0001
Spec. IgE (IU/ml)
HDM (n=9) 13 (0.11-50.6) - -
Grass (n=9) 0.7 (0.03-37.9) - -
Tree (n=9) 0.2 (0.02-10.3) - -
Cat (n=9) 0.4 (0.01-12.4) - -
Dog (n=9) 0.4 (0.1-2.7) - -
Allergic Asthma (AA); Healthy Controls (HC); female (f); years (yrs); Body mass Index (BMI); inhalation 
corticosteroids (ICS); combination therapy (CT); Exhaled nitric oxide (FeNO); Asthma Control Questionnaire 
(ACQ); Forced expiration volume in 1 second (FEV1); Forced vital capacity (FVC); provocative concentration 
of methacholine causing a 20% fall in FEV1 (PC20); Skin Prick Test (SPT); House dust mite (HDM)
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of BrefeldinA to allow intracellular cytokine detection (Fig. 2A). In medium-
conditioned B cells ~2 % IL-10 producers were found, while both BCR stimulation 
and LPS priming significantly further enhanced intracellular IL-10 levels by 
almost a two-fold (Fig. 2B). CpG showed the strongest IL-10 induction, inducing 
approximately 10%. Strikingly, only intracellular IL-10 in LPS-primed B cells of 
patients with AA was significantly lower compared to those from healthy controls 
(Fig. 2B), while equal IL-10 levels were found for medium-conditioned, BCR- 
and CpG-stimulated B cells. We analyzed the mean fluorescence intensity (MFI) 
values of the cytokine-expressing cells, demonstrating a similar MFI for IL-10+ 
cells in all conditions following background subtraction (MFI IL-10+ approx. 5200, 
data not shown) and similar between HC and patients with AA. This suggests that 
mostly the number of responding B cells varied per condition but not so much 
the quantity of IL-10 produced per B cell. No correlation was found between LPS-
induced IL-10 levels and serum IgE levels (and HDM-specific IgE), PC20, exhaled 
Figure 1. The frequency of different regulatory B cells in the blood from patients with AA and healthy 
controls. A representative gating example is depicted on the left for each Breg cell subset, showing one 
matched HC and AA donor pair. (A) CD1dhi B cells (B) CD24hiCD38hi B cells and (C) CD24hiCD27+ B cells are 
expressed as percentage or as absolute numbers (#) per ml blood.
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FeNO or medication use in patients with AA. The production of the more pro-
inflammatory cytokine TNF-α was also analyzed to exclude general increased 
cytokine levels, but no differences were found between the two groups for any of 
the stimuli. The IL-10-producing B cells did not co-produce TNF-α (Fig. 2C). 
 Secreted IL-10 levels in the supernatant of CpG-stimulated B cells 
confirmed the flowcytometry data and showed clearly detectable IL-10 levels, 
but not different between HC (210 pg/ml) and AA donors (190 pg/ml, P = 0.47). 
Unfortunately, we were unable to detect secreted IL-10 or TNF-α by ELISA in the 
supernatant of stimulated B cells in response to LPS or anti-IgG/M, due to either 
limited cell numbers (a minimum of 3 x 105 B cells is required; data not shown) or 
high background levels (caused by anti-IgG/M itself; data not shown). Therefore, 
we validated the LPS-induced IL-10 production by conducting an IL-10 secretion 
assay allowing secretion and capture of IL-10 at the B cell surface. Using this assay, 
secreted IL-10 was studied in B cells from healthy laboratory donors stimulated 
with medium, LPS, anti-IgG/M or CpG for 3 days (adapted from Milovanovic et al. 
(25). A twofold increase of B-cell IL-10 was observed for both LPS and anti-IgG/M 
Figure 2. Intracellular IL-10 detection in total B cells. B cells were stimulated for 48 h by medium, 
lipopolysaccharide (LPS) (100 ng/ml), CpG (5 µg/ml) or anti-IgG/IgM (20 µg/ml) followed by restimulation 
with PMA/Ionomycin/LPS in the presence of BrefeldinA. (A) A representative gating example of IL-10 and 
TNF-α production upon LPS stimulation of a matched healthy control (HC) and allergic asthma (AA) donor. 
Fluorescence minus one (FMO) shows background levels of IL-10 and TNF-α. (B) Intracellular IL-10 and (C) 
intracellular TNF-α production were analyzed using flowcytometry.
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stimulation, and an even higher increase for CpG, confirming the data obtained 
by intracellular cytokine staining described above (Appendix S1). 
Reduced LPS responsiveness of CD24hiCD27+ B cells in allergic asthma patients
We next questioned whether the lower LPS-induced IL-10 in B cells from patients 
with AA was the result of a selective impairment in one of the putative Breg 
subsets. Breg subset analysis showed that LPS stimulation of B cells strongly 
enhanced the number of IL-10+ cells compared to medium in all three subsets, 
i.e. CD1dhi B cells (Fig. 3A), CD24hiCD38hi (Fig. 3B) and CD24hiCD27+ B cells (Fig. 3C), 
although CD1dhi B cells tend to have a higher spontaneous production of IL-10 
(~7%) in medium conditions. When comparing patients with AA and controls, we 
found less intracellular IL-10 for CD24hiCD27+ B cells in patients with AA (Fig. 3C), 
but similar levels in the other two Breg subsets (Fig. 3A and 3B). In the remaining 
CD24+, CD27+ or CD24-CD27- B cells, the IL-10 production was not significantly 
affected in patients with AA (Appendix S2A). Despite the fact that the different 
Breg cell subsets have been analyzed separately in the previous studies, they do 
have some overlap. Interestingly, a substantial part of the CD1dhi B cells (61.7% 
for HC and 56.1% for AA; P = 0.46) can be found within the CD24hiCD27+ B cell 
subset and for both groups 17.5% of the CD24hiCD38hi are also CD24hiCD27+ (P = 
1.00). When CD1dhi B cells were removed from the analysis of the CD24hiCD27+ 
population, the decreased IL-10 production still remained in the B cells from 
patients with AA. Additionally, the exclusion of the CD24hiCD38hi B cells gave 
similar results (Appendix S2B). Altogether, these data suggest a diminished IL-10 
response of CD24hiCD27+ B cells from patients with AA compared to controls upon 
LPS stimulation. 
TLR4 expression on B cells from patients with AA compared to healthy controls
To investigate whether the differences in B cell IL-10 production between the 
groups were a consequence from differences in TLR4 expression in B cells, we 
Figure 3. Intracellular IL-10 in various B cell subsets in response to lipopolysaccharide (LPS). B cells were 
stimulated by medium or LPS and treated as described in Fig. 2. Intracellular IL-10 in CD1dhi B cells (A), in 
CD24hiCD38hi B cells (B) and in CD24hiCD27+ B cells (C) were analyzed using flowcytometry.
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evaluated the TLR4 levels by flowcytometry. Although the expression of TLR4 
on B cells is rather low compared to monocytes (data not shown, MFI of 3629 
(HC) and 3280 (AA), P = 0.10), a significant higher MFI was detected both for HC 
donors and patients with AA compared to total T cells (as a negative control) (Fig. 
4A). Nevertheless, we did observe a trend towards a decreased TLR4 expression 
in AA patients, suggesting that their lower IL-10 response to LPS might be due to 
lower TLR4 expression, however, this was not attributed to either one of the B cell 
subsets (Fig. 4B). Interestingly, we detected the highest TLR4 expression on the 
Figure 4. (A) The geometric mean fluorescence intensity of TLR4 on B cells was measured on PFA-fixed 
PBMCs from healthy controls (HC) and allergic asthma (AA) donors, using the TLR4 expression on total 
T cells as negative control. (B) TLR4 expression on the different Breg subsets. (C) 1 x 106 B cells from 
healthy laboratory donors were stimulated with medium or LPS (100 ng/ml) and incubated for 5, 20, 60 
and 180 min. At the indicated time points, cells were harvested and nuclear extracts were prepared. Equal 
concentrations of protein were subjected to electrophoresis and blots were reacted with antibodies specific 
to phospho-Tyr705 of STAT3 and total STAT3, followed by development using enhanced chemiluminescence. 
One representative blot out of n = 3-4 with similar results is shown.
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CD1dhi B cells, following by the CD24hiCD27+ B cells and very low expression on the 
CD24hiCD38hi B cells, which correlated well with their capacity to produce IL-10 in 
response to LPS (Fig. 4B).
 Furthermore, to confirm LPS-induced activation of B cells, western 
blots were performed using whole-cell extracts from primary B cells of healthy 
labdonors stimulated with LPS or medium only. We focused on signal transducer 
and activator of transcription 3 (STAT3) signaling, as in previous studies it was 
shown that LPS-induced phosphorylation of STAT3 was implicated in IL-10 
production in monocytes (26;27) and murine Breg cells (28). Here, we also 
detected strong induction of STAT3 phosphorylation after 180 min of exposure to 
LPS compared to medium (Fig. 4C), confirming that at least in healthy labdonors 
LPS induced the STAT3 signaling pathway in B cells, eventually leading to IL-10 
production. Unfortunately, due to limited cell numbers we could not study the 
LPS-induced STAT3 phosphorylation in patients with AA.
LPS-primed B cells in patients with AA induce less IL-10-producing T cells
To study whether the lower frequency of IL-10-producing B cells from patients 
with AA has any functional consequences for allergen-specific T-cell cytokine 
responses, co-cultures were set-up with primed B cells and autologous CD4+ 
memory T cells. These cells were co-cultured for 6 days in the presence of house 
Figure 5. IL-10+ T cells in co-cultures of LPS-
primed B cells and T cells. B cells were treated 
as described with Figure 2, followed by a 
1:1 co-culture with autologous CD4+ T cells 
(pre-incubated with isotype or anti-IL-10R 
antibodies; 2 µg/ml), and DerP1 (1 µg/ml). After 
6 days, cells were restimulated as in Figure 2. 
Percentage of IL-10-producing CD4+ T cells was 
determined by flowcytometry as represented in 
(A). Supernatants were taken and IL-5 and IFN-γ 
were measured using luminex (Invitrogen) (B). 
One pair was excluded as the AA patient was not 
allergic for HDM (n =12).
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dust mite allergen DerP1 to evaluate whether primed B cells could influence the 
cytokine profile of allergen-specific T cells. The induction of anti-inflammatory 
responses such as CD4+CD25hiFoxP3+ Treg cells or IL-10+ CD4+CD25hiFoxP3+ Treg 
cells was not different between the two groups (data not shown). Nevertheless, 
the intracellular IL-10 production by CD4+ T cells (putative Tr1 cells) was enhanced 
in the presence of CpG or LPS-primed B cells. Interestingly, in patients with AA, 
this induction was only observed in the condition with BCR- or CpG-stimulated 
B cells, but not with LPS-primed B cells, suggesting a specific impairment in the 
case of LPS stimulation (Fig. 5A), (Appendix S3). Remarkably, despite the higher 
IL-10 secretion in CpG-stimulated B cells, LPS-stimulated B cells from HC induced 
at least equal or even more IL-10+ T cells. The involvement of B cell derived IL-10 
in the putative Tr1 cell induction was confirmed both in the CPG and the LPS 
condition of HC where a pre-incubation of the CD4+ memory T cells with blocking 
IL-10R antibodies reduced T cell IL-10 production (Appendix S3). This was also 
observed in the condition of CpG-primed B cells of patients with AA, but not for 
the LPS-primed B cells (Appendix S3). Interestingly, blocking T cell IL-10 receptor 
in LPS-primed conditions substantially reduces the IL-10+ T cell induction in control 
subjects though not fully to levels found in medium conditions, suggesting that for 
Figure 6. (A) B cells were sorted into CD24hiCD27+B cells and remaining cells. (B) 1 x 105 CD24hiCD27+B cells 
or the remaining cells were stimulated with medium or ultra-pure LPS for two days, followed by removal of 
supernatant, washed, and co-cultured with autologous memory CD4+ T cells (ratio 1:1) in the presence of 
1 µg/ml endotoxin-free Derp1. CD4+ T cells were first pre-incubated with blocking IL-10R antibodies (2 µg/
ml) or IgG1 isotype control (2 µg/ml) for 30 min at 37 °C. After 6 days, the cells were restimulated, fixed and 
staining for IL-10 using flowcytometry. The T cells were gated for CD3+FoxP3-TNFα-.
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LPS-induced B cells also other factors than IL-10 may be involved in subsequent T 
cell IL-10 production (Fig. 5A).
 Next to IL-10, intracellular cytokine production of TNF-α and IFN-γ showed 
similar number of these cells in both groups and IL-4 was hardly detectable after 
culturing with LPS-primed B cells (data not shown). However, a higher Th2/Th1 
ratio (IL-5/IFN-γ) was found in the supernatant of B and T cell co-cultures from 
patients with AA compared to controls (Fig. 5B). Additionally, significantly more 
IgG1 and a trend for IgE production were detected in cultures of LPS-primed B cells 
and T cells from patients with AA compared to those from controls (Appendix S4), 
while IgG2 and IgG3 did not change and IgG4 levels were very low in both groups 
(data not shown) suggesting a more pro-inflammatory type 2 profile in patients 
with AA both with respect to cytokines and immunoglobulins.
CD24hiCD27+ B cells are essential for the induction of IL-10+ T cells 
We next assessed whether the induction of IL-10-producing T cells could be 
attributed to the CD24hiCD27+ B cell population (Fig. 6). To address this question, 
10 HC subjects donated blood for a second time and B cells were sorted by 
flowcytometry into two populations, CD24hiCD27+ B cells and the remaining cells 
(CD24lowCD27+ and CD24lowCD27- B cells) (Fig. 6A). Next, the cells were primed 
with medium or LPS for 2 days, followed by a co-culture with CD4+ memory T 
cells, as stated above. Interestingly, the sorted CD24hiCD27+ B cells shower similar 
inducing capacity as the total B cells, whereas the remaining B cells could not 
induce IL-10+ T cells after LPS priming (Fig. 6B). Blocking the IL-10 receptor on 
T cells significantly reduced the levels of IL-10 production to medium levels, 
confirming the exclusive role of IL-10-producing CD24hiCD27+ B cells in the 
induction of IL-10+ T cells and its dependence on B-cell-derived IL-10. 
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Discussion
Regulatory B cells have been identified that have an impaired function in auto-
immunity. Here, we demonstrated that B cells from patients with allergic asthma 
also have a lower capacity to produce IL-10 in response to LPS compared to B 
cells from controls. The CD24hiCD27+ B cell subset seems to be responsible for 
this effect. The expression of the pro-inflammatory cytokine TNF-α was similar 
in total B cells and the subsets, indicating that primarily the IL-10 response was 
specifically altered in B cells from patients with AA. Furthermore, this difference 
translates in a functional effect, namely the ability of CD24hiCD27+ B cells to induce 
IL-10+ T cells and, therefore, may point at a role for a weakened Breg function in 
patients with AA. 
 We have compared the frequency of different Breg cell membrane markers 
on peripheral blood B cells based on reports describing functional Breg cells in 
humans, i.e. CD1dhi B cells (14;19), CD24hiCD27+ B cells (17) and CD24hiCD38hi B 
cells (16). Blair et al. observed an increased frequency of CD24hiCD38hi B cells 
in SLE patients, but with an impaired capacity to inhibit IFN-γ production in 
stimulated T cells. Intracellular IL-10 production in this particular B cell subset 
were not studied (16). Interestingly, we also observed an increase in CD24hiCD38hi 
B cells in patients with AA, but with similar IL-10 frequencies between the groups. 
However, as we did not study the ability of isolated CD24hiCD38hi B cells to inhibit 
cytokine secretion by T cells, we cannot exclude functional differences for this B 
cell subset in allergic asthma, despite equal intracellular IL-10 frequencies. 
 The regulatory capacity of CD24hiCD27+ B cells was demonstrated by Iwata 
et al. by showing the ability of this B cell subset to reduce cytokine production 
by monocytes (17). Interestingly, this reduction was not IL-10-dependent and 
these cells could not reduce cytokine production by T cells. Here, we observed 
a lower LPS-induced IL-10 production by CD24hiCD27+ B cells in patients with AA 
versus controls, which upon further co-cultures with T cells, was accompanied 
by a reduced IL-10 expression in T cells. Although we only studied single sorted 
subsets in HC subjects, but given the lower IL-10 production in CD24hiCD27+ B 
cells in response to LPS in patients with AA, it is tempting to speculate that this 
subset might be responsible for the lower induction of IL-10-producing T cells 
observed in the co-cultures with total B cells.
 It was shown in several studies conducted with traditional European 
farmer families, that growing up on farms protects against the development 
of allergy and asthma and that both bacterial and fungal exposures may be 
important (4-6). Indeed, exposure to bacterial components, such as endotoxin 
(LPS) and muramic acid (component of peptidoglycan), were inversely related to 
allergic sensitization, childhood asthma or wheezing (29;30). This also accounts 
for microbial products found in floor dust from urban living rooms (31-33). Not 
only the level of microbial content but also the extent of diversity was important 
for the inverse relationship with allergies and asthma (33-35). Although there 
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is a positive correlation between the levels of bacterial DNA and the levels of 
endotoxin found in farm dust (36), suggesting that CpG and endotoxin will both 
be present to a similar extent in daily life, it is unclear whether this correlation can 
also be attributed to ‘poor’ microbe environments like urban homes. It may be 
questioned whether the in vitro stimulation conditions of B cells we have applied 
here are realistic to in vivo exposure in daily life and whether the presence of CpG 
may compensate for the defect in LPS-induced IL-10 production of B cells from 
patients with allergic asthma. Despite this assumption, it is unclear what the net 
effect is when CpG and LPS would act together on B cells, and whether a low 
concentration of CpG would still induce a similar B cell IL-10 production in both 
groups or that, like the weak B-cell activator LPS, it would also show a weaker 
response in allergic patients. Interestingly, it was showed that ‘farm’ bacterial 
DNA potentiated LPS-induced cytokine production in PBMC, while ‘urban’ 
bacterial DNA did not (36), suggesting that either the activity or the content of 
bacterial DNA versus endotoxin in dust is different between rich and poor microbe 
environments resulting in a different net effect on single cells and keeping open 
the option that the LPS conditions described in this paper may occur in vivo. 
 Also on the level of the innate receptors involved in the recognition 
of these bacterial components (CD14, TLR2 and TLR4), mRNA expression 
was shown to be increased on PBMC from farmer’s children and in particular 
exposure of pregnant mothers to stables was positively correlated with increased 
TLR expression (37;38). Although TLR4 expression on B cells is relatively low 
compared to TLR2 and TLR9, B cells are clearly able to respond to LPS (39-41). 
Furthermore, inflammatory conditions were associated with an upregulation of 
TLR4 expression on B cells (41-44). In our study, we confirmed that although TLR4 
expression on B cells is quite low, LPS was capable of inducing STAT3 signaling, 
confirming its capacity to activate human B cells of healthy controls. Because 
the phosphorylation of STAT3 was only significantly increased after 180 min, we 
cannot rule out that this effect is not a direct consequence of TLR4 signaling 
but alternatively the result of a secondary stimulation via other factors initially 
induced by LPS, but altogether still induced by LPS stimulation only. Although there 
was a trend in reduced TLR4 levels in patients with AA compared to HC subjects 
(but not in the individual Breg subsets), we cannot exclude that the lower LPS-
induced IL-10 expression in B cells of patients with AA may as well be explained 
by differences in TLR4-induced signaling pathways, as previously suggested for 
monocytes from allergic patients, which showed an impaired phosphorylation of 
MAPK pathways upon LPS stimulation (45). 
 While there is clear evidence in different animal models that enhanced 
activity of IL-10-producing Breg cells strongly suppresses allergic inflammation 
(15), there is only one study available in food allergy, studying IL-10 expression 
in B cells in patients suffering from food allergy. IL-10-expressing B cells were 
downregulated in response to milk antigens in PBMC from allergic, but not from 
healthy individuals (46). It is also still unclear whether the IL-10-producing Breg 
cells in the circulation are the ones that will migrate to the target organs, such 
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as the lung, to act in a protective way or that maybe other local Breg cell subsets 
are responsible for this. In contrast, evidence for a protective role in allergy and 
asthma of IL-10-producing T cells or FoxP3+ Treg cells is extensively reported 
in both animal models and human studies (7). In addition, IL-10 production 
plays a central role in beneficial effects of immunotherapy (47). In this study, 
we demonstrated a causal link between IL-10-producing B cell and IL-10+ T 
cells, suggesting that B cell-derived IL-10 can instruct T cells for their regulatory 
capacity. Indeed, several animal studies have demonstrated that part of the 
effect of IL-10-producing B cells is mediated by induction of IL-10-producing 
T cells or FoxP3+ Treg cells (10;15). These findings imply that targeting for 
regulatory B cells as a novel therapeutic approach may embrace two regulatory 
systems simultaneously, i.e. regulatory B cells and IL-10-producing regulatory T 
cells. New studies have to find out whether this may lead to a much more efficient 
suppression of allergen-specific immune responses in patients with AA. 
 In conclusion, further research should focus on the identification of 
pathways and molecules that enhance the number and/or activity of Breg cells, 
in which the CD24hiCD27+ B cell subset may be interesting to be targeted with 
respect to the treatment of allergic asthma. Those molecules will be interesting 
candidates to include in current immunotherapy protocols and improve their 
efficacy in establishing longer lasting protection against allergic asthma.
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 Supplementary figures
Figure S2. Intracellular IL-10 (A) in CD24lowCD27-, CD24+ or CD27+ B cells. (B) The expression of IL-10 in 
CD24hiCD27+ B cells excluded for CD1dhi and CD24hiCD38hi B cells. The B cells were treated as described in 
Figure 2.
Figure S1. B cells (3x105) from healthy laboratory donors were stimulated for 72 h with anti-IgG/M (20 
µg/ml), LPS (100 ng/ml), CpG (5 µg/ml) and medium. Medium values (~1.5%) were subtracted from the 
stimulated conditions for each individual. IL-10 secretion assay (Miltenyi Biotec) was performed and shows 
the percentage of IL-10-producing B cells. N=3.
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Figure S4. Immunoglobulin production of LPS-primed B cells in co-culture with T cells. Co-cultures were 
setup as described in Figure 4. After 6 days, supernatants were harvested and immunoglobulins (IgG1, 
IgG2, IgG4, and IgE) were measured by immunoglobuline isotyping assay (Biorad-luminex). Background 
levels of medium-primed and LPS-primed B cells are shown.
Figure S3. Co-culture of BCR- or CpG-stimulated B cells and T cells. B cells were treated as described in 
Figure 2, followed by a 6 day 1:1 co-culture with autologous CD4+ T cells CD4+ T cells (pre-incubated with 
isotype or anti-IL-10R antibodies; 2 µg/ml), and DerP1 (1 µg/ml). Cells were restimulated to determine 
intracellular cytokines by flowcytometry. Percentage in IL-10+ CD4+ T cells was calculated. One pair was 
excluded as the patient with AA was not allergic for HDM (n =12).
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Regulatory B cells: suppression of auto-immune or allergic disorders
In the past decade, convincing data have demonstrated that IL-10-producing 
B cells, termed regulatory B (Breg) cells, are induced throughout the course of 
autoimmune disease in experimental models. Fillatreau and coworkers were one 
of the first to show that these protective B cells negatively regulated experimental 
autoimmune encephalomyelitis (EAE) progression through provision of IL-10 (1). 
Additional studies by Mizoguchi, Mauri and others confirmed the presence of 
active IL-10-producing Breg cells in other autoimmune models, i.e. inflammatory 
bowel disease (IBD) or collagen-induced arthritis (CIA) (2;3). Since then, 
their function has been studied in several other immune-related diseases, 
demonstrating that IL-10-producing Breg cells were not restricted to Th1 immune 
responses associated with autoimmunity, but could be induced by extrinsic 
factors such as helminth parasites and have the capacity to protect against Th2-
skewed allergic inflammation. For example, in Heligmosomoides (H.) polygyrus-
infected mice, adoptive transfer of mesenteric lymph node (MLN) B cells 
suppressed both DerP1-specific airway inflammation and EAE (4). Furthermore, it 
has been demonstrated that B cells induced by Schistosoma (S.) mansoni worms 
protected BALB/c mice against allergic reactions in both anaphylaxis and allergic 
airway inflammation models in an IL-10 dependent manner (5). In this model 
only male parasites were used for infection, yielding infections without eggs. 
Instead, Smits et al. studied Breg cell function during different stages of natural 
S. mansoni infections, and showed the existence of active regulatory mechanisms 
during chronic, but not acute infection. Both splenic B cells and CD4+ T cells 
isolated from chronically, but not acutely, infected mice protected against allergic 
airway inflammation, revealing active roles for both B cells and CD4+ T cells (6). In 
Chapter 2, we confirmed that during a natural S. mansoni infection the induction 
of IL-10-producing Breg cells was crucial for protection against AAI using chimeric 
IL-10-/- B cell mice. 
Regulatory B cells induced by other pathogens 
Recent reports indicated that Breg cell development is not only restricted to 
helminth parasites, but can also be seen during other infections, such as infection 
by protozoan parasites Leishmania major (7) and Babesia microti (8). During 
these infections, IL-10-producing B cells were critical for the development of 
susceptibility to infection. Recently, IL-10 expression was identified in plasma 
cells during a Salmonella typhimurium infection (9). Several viruses, such as 
murine cytomegalovirus, HIV, and hepatitis B, decreased virus-specific CD8+ T 
cell responses by stimulating Breg cells (10-13). Similarly, Plasmodium berghei-
infected mice showed elevated IL-10-producing B cells, which were important 
for controlling immunopathology (14). These data indicate that the functional 
identification of IL-10-producing B cells are not restricted to helminth infections, 




inflammation induced by the presence of pathogens. What stands out, is that 
next to helminths, the viral and bacterial agents enhancing Breg cells are mostly 
inducing a chronic inflammation, suggesting that Breg cells may occur as a 
bystander process resulting from continuous chronic infection.
Identification of B cell subsets associated with a regulatory function
Regulatory B-cell subsets in models of autoimmunity
In the past few years, several studies focusing on the splenic compartment 
identified marginal zone (MZ) and transitional type 2 (T2)-MZ precursor B cells 
as B cells with a putative suppressive function. In addition, IL-10 production by 
splenic B cells has been linked to B cells expressing high levels of CD1d with or 
without the expression of CD5 (Table 1). In this respect, pioneering work has been 
performed in models of EAE (15) and oxazolone-induced contact hypersensitivity 
(CHS) (16) where an IL-10-dependent protective role for splenic CD1dhiCD5+ B 
cells was identified. This relatively rare regulatory B cell subset was termed B10 
cells (16). Further characterization revealed that approximately half of the splenic 
CD1dhiCD5+ IL-10-producing B cells expressed high levels of CD21, similar to 
marginal zone (MZ) B cells (CD21hiCD23lowIgMhi) (16). Another major contribution 
to the field was made by the use of chimeric mice lacking endogenous IL-10-
producing B cells in an arthritis model. These mice showed the exacerbation of 
the disease with a marked increase in Th1 and Th17 cells compared to WT B cell 
mice (17). Reconstitution of B-cell deficient mice showed that transitional type 
2 (T2)-MZ precursor B cells (CD21hiCD23hiIgMhi), co-expressing CD1d prevented 
disease and ameliorated established disease in mice with collagen-induced 
arthritis and lupus (17;18) (table 1). Moreover, a recent report describes another 
subset, peritoneal B1 cells, as a source for IL-10 and essential for suppressing late 
remission phase of CHS. Interestingly, they found an additional role was found for 
CD22, an sialic-binding Ig-like lectin, which was expressed on the IL-10-producing 
peritoneal B1 cells and was involved in their protective abilities (19) (Table 1).
Regulatory B cell subsets in helminth-infection models
Studies in adult stage S. mansoni-infected mice indicated that splenic CD1dhi B 
cells have a regulatory function as these cells provided protection against allergic 
airway inflammation (5). Analogous to what had been found in the models of 
autoimmunity (detailed above), the CD1dhi B cells expressed CD5, CD21hi, CD23+, 
and high levels of IgM, resembling T2-MZ precursor B cells (5) (Table 1). During 
natural infections with S. mansoni, we also found a splenic subset of IL-10-
producing B cells which protected against allergic airway disease (6), however in 
our model the regulatory B cells were identified within the MZ B-cell compartment 
(CD21hiCD23low) with a majority (> 80%) co-expressing CD1d (Chapter 2). It is not 
fully clear whether these B cell subsets form completely unique subsets because 
there is a substantial overlap between the (co-)expression of the various markers, 
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such as CD1d, CD5, CD21, CD23 and IgM. In addition, local inflammation or 
chronic infection may change the expression of individual markers complicating 
distinctions between the different proposed cell subsets. As T2-MZ precursor 
B cells can differentiate into MZ B cells, it can be speculated that the splenic 
Breg cell subsets identified by several labs are in fact all similar and simply 
represents either precursors or mature stages of the same Breg cell subset. 
Furthermore, although IL-10-producing B cells are enriched in the CD1dhi(CD5+) 
and T2-MZ precursor B cells, not all B cells within these subsets produce IL-10, 
suggesting that this set of markers is not unique to identify IL-10-producing Breg 
cells. Recently, the membrane-bound marker Tim-1 (T-cell Ig domain and mucin 
domain protein-1) was expressed on more than 70% of the IL-10-producing B 
cells. Therefore, this marker is regarded as the most specific marker yet identified 
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Abbreviations: T2 is type 2; MZ is marginal zone; Treg cell is regulatory T cells; CIA is collagen-induced arthritis; 
AAI is allergen-induced airway inflammation; EAE is experimental auto-immune encephalomyelitis; CHS is 
oxazolone-induced contact hypersensitivity; MS is multiple sclerosis; SLE is systemic lupus erythematosus 




for IL-10-producing B cells (20;21). In Chapter 3, we did find a small increase in 
Tim-1-expressing pulmonary B cells, which showed increased IL-10 production 
during schistosome infection. However, pulmonary B cells protected against 
airway inflammation in an IL-10-independent manner, suggesting that the small 
population of Tim-1-expressing pulmonary B cells were not dominant in reducing 
disease symptoms. Given that no unique marker has been identified for all Breg 
cells, multiple Breg cell subsets might occur depending on the activation state, 
inflammatory environment and the target organ involved.
Regulatory B cells located at the side of inflammation
Most studies identified regulatory B cells within the splenic compartment. 
However, a report describes another phenotype of parasite-induced Breg 
cells in the mesenteric lymph nodes (MLN) upon infection with H. polygyrus. 
These regulatory B cells expressed high levels of CD23, but no CD5 or CD1d, 
and suppressed allergic inflammation in an IL-10 independent manner (4). 
Interestingly, yet another subset with regulatory capacity, B-1a B cells, is located 
predominately in peritoneal and pleural cavity, but also in the spleen in very 
low numbers (22). Splenic CD5-expressing B-1a cells, like splenic B cells, form 
a relevant source for IL-10 and suppressed inflammation via the killing of CD4+ 
T cells by FasL/Fas-dependent mechanisms in CIA and during schistosomiasis 
(23;24). There are multiple similarities between peritoneal and splenic B-1a cells, 
suggesting that they may be related to each other or possibly even be the exact 
same cells (25). 
 In the lungs, a regulatory role for pulmonary CD5+ B-1a cells in a 
cockroach-sensitized asthma model was suggested, reducing cytokine production, 
pulmonary inflammation, and CD4+ T cell survival via increased FasL expression 
(26). Interestingly, we also found, next to splenic Breg cells, a regulatory role 
for schistosome-induced pulmonary B cells, which could transfer protection 
against AAI using adoptive transfer. However, this was not conferred by any 
CD5-expressing pulmonary B cells (Chapter 2 and 3). Characterization of these 
pulmonary cells showed that they did not share surface markers linked to Breg 
cell subsets described above. These results suggest that protection against allergic 
inflammation is not limited to one subset of regulatory B cell, and indicates that 
different effector mechanisms may work in parallel in addition to IL-10-producing 
B cells.
Regulatory B-cell effector mechanisms 
B cells as cytokine-releasing immune regulators
Breg cells can induce suppression by several effector mechanisms and by targeting 
different cell subsets. High IL-10 secretion is regarded as being prominent anti-
inflammatory effector mechanism and a marker for Breg cells as described above. 
In addition to IL-10, TGF-β is the second immunosuppressive cytokine found 
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to be secreted by some Breg cell populations to down-regulate inflammatory 
immune responses. TGF-β controls inflammation via suppression of Th1 and Th2 
inflammatory cytokine production, maintenance of Treg cells, and inhibition the 
function of antigen presenting cells (APC) (27-29). Recently, IL-35-producing plasma 
cells were identified as a complementary arm of B cell-mediated suppression to 
IL-10-producing plasma cells in EAE and during Salmonella infection (9;30;31). 
Several studies demonstrated that Breg cells may simultaneously produce 
regulatory cytokines IL-10, TGF-β and IL-35. For example, treatment of mice with 
IL-35 protected mice from experimental autoimmune uveitis via the induction 
of Breg cells producing IL-35 as well as IL-10 (32). Furthermore, LPS-activated 
B cells secreted both TGF-β and IL-10 to down-regulate inflammatory immune 
responses during diabetes (29;33). Future studies should address whether Breg 
cells producing either other suppressive cytokines, apart from IL-10, or multiple 
regulatory cytokines are present in helminth infections and how they contribute 
in the regulatory network. 
 The production of anti-inflammatory cytokines does not automatically 
define B cells as Breg cells. Even when B cells secrete elevated levels of IL-10, it is 
essential to elucidate whether the IL-10-producing B cells truly possess suppressive 
capacity and whether IL-10 is essential for this process. For example, it has been 
demonstrated that pulmonary B cells, producing elevated levels of IL-10 during 
chronic schistosome infection, can reduce AAI in an IL-10-independent manner 
(Chapter 3). Furthermore, some Toll-like receptor (TLR)-activated B cells can 
concomitantly secrete anti-inflammatory IL-10 and pro-inflammatory IL-6, two 
cytokines with opposite effects on the immune system. Importantly, B-cell derived 
IL-6 plays a prominent role in the pathogenesis of T cell–mediated autoimmune 
diseases such as EAE and MS (34). Therefore, the suppressive capacity of IL-10-
producing B cells needs to be confirmed in functional in vitro assays investigating 
e.g. the effect on T cell proliferation or T cell cytokines (Chapter 4) or in disease 
models in vivo before the term ‘Breg cell’ can be applied. 
Recruitment and/or induction of regulatory T cells
The concept that B cells can induce Treg cells was first introduced in a model of 
anterior chamber-associated immune deviation (ACAID) by Ashour and Niederkorn 
(35). A causal relationship between IL-10-producing B cells and Treg cells has 
been suggested in antigen-induced arthritis model utilizing similar chimeric mice, 
where loss of IL-10-producing B cells led to significant reduction of Treg cells in 
draining inguinal LN (17). Similar results were found in auto-immunity models, 
such as lupus where B10 cells reduce inflammation by the induction of Treg cells 
(36). Another example is shown in a model for EAE, where B cell-deficient mice 
displayed delayed emergence of Foxp3+ and IL-10+ T cells in the central nervous 
system, which was corrected by reconstitution with B cells and resulted in 
recovery from disease (37). Of note, Breg and Treg cell numbers appear to peak 
at different disease stages in EAE with enhanced Breg cell activity during early 




EAE (38). These findings can be extended to helminth infections, as schistosome-
induced CD1dhi MZ B cells promoted expansion of Foxp3+ Treg cells in the lung 
and in vitro cultures via IL-10 (5) (Chapter 2). Importantly, loss of FoxP3+ Treg 
cells via treatment with anti-CD25 antibodies during allergen challenge restored 
AAI (5). In contrast, our study showed that B cell-induced Treg cells are only 
partially involved in protection against AAI using another model to deplete Treg 
cells, namely FoxP3-DTR transgenic DEREG mice. Therefore, although Treg cell 
induction is dependent on Breg cell activity, Breg cells and Treg cells may have 
partly independent roles in controlling inflammation.
Suppression of T-cell responses 
The capacity of B cells to suppress T cell proliferation and/or T cell cytokine 
production has been studied in several disease settings. Early work showed that 
lethal Th1 responses are expanded in schistosome-infected B-cell-deficient mice, 
suggesting that in WT mice Th1 cells are suppressed by schistosome-induced 
B cells (39;40). In addition, applying different allergy models clearly indicated 
that schistosome-induced B cells can also inhibit ovalbumin (OVA)-specific Th2 
cytokine responses in an IL-10-dependent manner, resulting in reduced allergic 
symptoms (5). These findings are in line with studies in autoimmunity models, 
where IL-10-induced suppression of inflammation was found in EAE (15;38), lupus 
(41) or arthritis (18) by modulating Th cell proliferation and reducing IFN-γ, IL-2, 
IL-17 or TNF-α levels; in some studies this suppressive effect was potentiated via 
CD40 ligation (18;38;41). Furthermore, IL-10-producing B cells were described to 
inhibit type 2-mediated colitis in a T-cell receptor (TCR) alpha knock-out model by 
yet another mechanism that involves the induction of IL-12-producing B cells (42). 
Interestingly, IL-10-independent down-regulation of Th2 responses has also been 
reported by B cells from H. polygyrus infected mice (4), suggesting the involvement 
of cell-cell interaction or other soluble mediators (Table 1). Lastly, inflammation 
was controlled via apoptosis of CD4+ T cells by Fas ligand (FasL)-expressing CD5+ 
B cells from the lungs or spleen in a cockroach-based asthma model or during 
Schistosoma infection respectively (23;26). In Chapter 3, S. mansoni infection 
induced pulmonary B cells showed a reduced capacity to initiate Th2 cytokine 
responses. However, preliminary data suggested that this down-modulation is 
not related to enhanced FasL expression and the subsequent induction of T-cell 
apoptosis. Also other important signals that can influence T-cell activation and 
cytokine production, such as antigen-presentation molecule MHCII, inhibitory 
receptors PD-L1 and PD-L2, or B-cell derived cytokines IL-10, TGF-β and IL-6 did 
not play a major role in down-regulating Th2 cytokines (Chapter 3). Schistosome-
induced pulmonary B cells did express enhanced levels of CD86, which has 
been linked to protection against EAE (37). The putative role for this molecule 
and/or other yet unknown inhibitory receptors/molecules of schistosome-
induced pulmonary B cells in the down-modulation of Th2 responses remains 
to be elucidated. Altogether, these findings suggest that immune suppression by 
schistosome-induced B cells results in a number of different effector mechanisms 
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or subsets, not only involving the induction of IL-10-producing splenic Breg cells 
but also functionally impairs pulmonary B cells in their capacity to induce Th2 
cells.
Antibody-mediated regulation
Recent studies indicate that antibodies may also be involved in the suppression 
of immune responses. Potential mechanisms include suppression of dendritic cell 
(DC) activation through the binding of IgG to FcγRIIB, as well as IgG-mediated 
clearance of potentially pathogenic host apoptotic cells (43). In addition, van de 
Veen et al. have suggested that human IL-10-producing B cells are designated 
to switch to IgG4 (44). This may be potentiated by IL-10, which is an important 
switch-factor for IgG4. IgG4 belongs to the group of anti-inflammatory antibody 
isotypes as it is not able to activate complement. IgA also belongs to this 
group, and recently it was reported that microbial modulation of dendritic cell 
function was crucial to induce allergen-specific secretory IgA in the mucosa, 
which suppressed the salient features of asthma (45). Interestingly, helminths 
are strong inducers of polyclonal IgG molecules secretion and IgG4 production 
in humans (39;46;47). We reported in Chapter 3 a general elevated production 
of IgG1 and IgG2a antibodies in the BAL fluid of OVA-infected mice compared to 
OVA-uninfected mice. However, the loss of the FcγRIIB receptor did not seem to 
restore AAI upon pulmonary B cell transfer, suggesting that despite the elevated 
IgG1 and IgG2a secretion in OVA-infected mice, protection against AAI was not 
mediated via signalling through FcγRIIB. Additionally, we have some indications 
that IgA levels were not increased during S. mansoni infection in mice, suggesting 
that IgA may not contribute majorly. 
DC Impairment
It is well known that IL-10 can inhibit DC antigen-processing and -presentation 
and expression of co-stimulatory molecules, such as CD80/CD86. This has clear 
consequences for their T-cell stimulatory capacity as shown by a recent report, in 
which purified splenic DCs from mice with EAE were cultured with MOG-specific 
CD4+ T cells. Less T cell proliferation was seen when DCs were conditioned by 
CD1dhiCD5+ B cells compared to conditioning by CD1dlowCD5+ B cells. This effect 
was IL-10-dependent (38). These findings may be extended to parasite-induced 
Breg cells as L. major-exposed B cells were shown to suppress DC cytokines in 
an IL-10 dependent manner in vitro (7). Interestingly, Everts et al. observed that 
myeloid DC function was impaired in S. haematobium-infected individuals (48). 
Although not proven, it is tempting to speculate that the increased Breg activity 
during schistosome infection may contribute to the altered DC function. 
Human Breg cells – do they exist? 




The majority of the studies on regulatory B cells have been conducted in murine 
models, and only recently evidence for human Breg cells emerged. Four distinct 
human Breg cell populations, predominantly identified based on their IL-10 
secretion, have mainly been studied in conditions in auto-immunity. In 2008, 
it was first demonstrated by Correale and co-workers that CD1d+ B cells were 
present in the peripheral blood of helminth-infected patients with multiple 
sclerosis (MS), producing elevated IL-10 levels in response to CD40 ligation. B cells 
from healthy controls and infected patients with MS, but not from uninfected 
patients with MS, were able to suppress T-cell proliferation and IFN-γ production 
in an IL-10-dependent manner in vitro (49). Recently, we have established a 
causal relation between a single species of helminth, S. mansoni, and increased 
levels of IL-10-producing CD1dhi B cells, which were reduced to baseline levels 
after anti-schistosome treatment (Chapter 2). The functional capacities of those 
schistosome-induced B cells were investigated in Chapter 5. We observed an 
elevated number of CD1dhi B cells in the blood of S. haematobium-infected adults, 
which express enhanced levels of cytoplasmic IL-10. Interestingly, increased 
surface LAP(latency-associated peptide)/TGF-β1 expression was mainly attributed 
to the CD24hiCD27+ B cells (see below for details on this particular Breg subset). 
In co-culture with CD4+ T cells, B cells from schistosome-infected individuals 
reduced the production of effector T-cell cytokines while more CD25hiFoxP3+ 
and IL-10+ T cells were found compared to cultures with B cells from uninfected 
controls (Chapter 5). In search for the dominant Breg cell subset, we found a 
role for CD1dhi B cells, the main source of IL-10, in induction of IL-10+ T cells, but 
not for FoxP3+ T-cells. At this stage, it is unclear which schistosome-induced Breg 
subset is responsible for the enhanced Treg cell induction, although it is tempting 
to suggest that, given the role for TGF-β in FoxP3+ Treg cell induction, TGF-β-
producing B cells, i.e. the CD24hiCD27+ B cells, are involved here. This may suggest 
that helminth infections can promote the activity of two different B-cell subsets. 
Whether helminth-induced Breg cells in humans suppress allergic immune 
responses and participate in the maintenance of tolerance via the provision of 
IL-10, as indicated in murine models, is still unclear. However, as elevated IL-10 
levels circulating in helminth-infected individuals was negatively associated with 
the outcome of skin-test reactivity to mite, it is tempting to suggest that IL-10 
derived from B cells could have spill-over suppression effect on the immune 
responses towards allergens (50).
CD24hiCD38hi immature B cells
In peripheral blood of healthy individuals, so-called immature CD19+CD24hiCD38hi 
transitional B cells were identified by Blair and co-workers (51). Approximately 
70% of these B cells also expressed CD5 and CD1d. The CD24hiCD38hi B cell 
population was capable of suppressing IFN-γ and TNF-α secretion by anti-CD3-
stimulated T helper cells and this suppression was dependent on IL-10 and CD80/
CD86 co-stimulation. Interestingly, CD19+CD24hiCD38hi B cells isolated from SLE 
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patients were functionally impaired as they could not suppress autologous T 
helper cytokine production (51). 
CD24hiCD27+ B cells
The human equivalent of the murine competent IL-10-producing B cells was 
described within peripheral blood B cells, that either already produced IL-10 or 
first required 48 hours of priming before acquiring the ability to express IL-10 (52). 
B10 cells represented a small subset within the CD24hiCD27+ B cell population, with 
about 60% co-expressing CD38 (52). Interestingly, both stimulated CD24hiCD27+ 
and CD24lowCD27- B cells inhibited IFN-γ and TNF-α production in T helper cells 
in an IL-10-independent manner. In contrast, CD24hiCD27+ B cells inhibited TNFα 
production by monocytes via IL-10. In contradiction to what had been published 
previously (51), increased frequencies of IL-10-producing peripheral blood B 
cells were found in patients suffering from different autoimmune disorders 
(SLE, RA, Sjögren syndrome, blistering skin disease and MS compared to healthy 
controls upon stimulation with CD40 ligand and CpG motifs (52). However, these 
studies did not evaluate the functional abilities of human B10 cells from auto-
immune patients compared to those from healthy controls with respect to their 
capacity to reduce T-cell cytokines responses nor whether other cytokines were 
simultaneously expressed in the B10 cells from the patients (52). 
 As illustrated above, evidence from a few human studies points towards 
a significant role for IL-10-producing Breg cells in the modulation of pathogenic 
responses in type 1 inflammation. Although it has become clear from a number 
of reports that at least the Treg cell compartment of patients with Th2-skewed 
diseases such as allergic asthma, rhinitis or dermatitis, is impaired in number 
and activity, there are not many reports on Breg cell numbers and activity in 
these patients as yet. One report has evaluated IL-10-producing B cells in allergic 
patients and controls, describing an increased frequency of IL-10-producing 
CD5+ peripheral blood B cells from healthy individuals in response to the milk 
antigen casein, which was not observed in PBMC cultures from cow’s milk-allergic 
individuals (53). In Chapter 6, we investigated the Breg compartment in peripheral 
blood of patients with allergic asthma compared to healthy controls and identified 
a significant decrease in number of CD24hiCD27+ B cells. This population was not 
only reduced in numbers, but also showed a lower capacity to produce IL-10 in 
response to LPS. Furthermore, this impaired B-cell IL-10 production resulted in 
less IL-10+ T cells in vitro cultures from patients with allergic asthma compared 
to similar cultures from control subjects, and, therefore, may point at a role for 
a weakened Breg function in the enhanced inflammation found in patients with 
allergic asthma. 
CpG-induced CD25+CD71+CD73- B cells
In recent report of Van de Veen and co-workers, a new subset of IL-10-




CD25+CD71+CD73- population rather than in the other described Breg subsets 
(44). The IL-10-producing B cells were capable of suppressing Purified protein 
derivative (PPD)-specific proliferation of CD4+ T cells and this suppression was 
dependent on IL-10. Furthermore, prolonged culture of CD25+CD71+CD73- IL-
10-producing B cells resulted in the isotype switch to anti-inflammatory IgG4 
antibodies. Bee venom allergen phospholipase A2 (PLA)-specific B cells from 
non-allergic beekeepers mainly expressed IgG4 and showed higher IL-10 levels 
compared to non-PLA-specific B cells. Interestingly, low frequencies of IL-10+ PLA-
specific B cells detected in patients with bee venom allergy were restored to similar 
levels as found in beekeepers after successful allergen-specific immunotherapy. 
Are (defects in) specific Breg subsets associated with certain inflammatory 
diseases?
All together, these studies show that in humans different IL-10-producing Breg 
cells exist, however the question remains whether specific Breg cell subsets are 
associated to certain inflammatory milieus such as infections, auto-immunity 
or allergic disease. A drawback of most studies we have reviewed above is that 
the experiments were focused on the characteristics of one single Breg subset, 
while other Breg cell subsets where not taken into account. Nevertheless, we 
do have compared the three most studied subsets in helminth infection and 
asthma patients. What is interesting in this aspect, is that the affected regulatory 
B-cell subset in helminth infections is mostly restricted to the CD1dhi population, 
whereas defects in CD24hiCD38hi Breg cells are mostly described for auto-immunity 
and we found indications for CD24hiCD27+ Breg cell impairment to be more linked 
to allergic inflammation (Chapter 5 and 6). However, since most human studies 
are restricted to peripheral blood B cells, the results published so far may not 
fully reflect the processes in inflamed organs and B cell subsets involved there. 
In Chapter 3, we have evaluated schistosome-induced Breg cell responses in the 
lungs of allergen-sensitized mice being very different from splenic responses, 
which may better reflect the type of responses found in peripheral blood. Although 
this was studied in mice, it clearly underlines the importance of extending this to 
further studies on human B-cell biology and its activity in the inflamed organs. 
 The concept that B cells can regulate inflammation and are important in 
the maintenance of peripheral or mucosal tolerance is well conceived, but before 
manipulation of these cells can be applied in future treatment of inflammatory 
diseases, further research should focus on the identification of pathways and 
molecules that enhance the number and/or activity of Breg cells. Identifying the 
mechanisms by which helminth infection and/or their molecules influence (local) 
B cell function may be an interesting novel strategy to control or prevent allergic 
inflammatory responses at multiple sites at the same time.




In many of the above described studies applying autoimmunity models, MyD88-
dependent TLR signaling (TLR2, 4 and 9) and CD40 ligation, with or without BCR 
triggering, proved to be important for Breg development (Fig. 1, Chapter 4). 
Many of these findings have been paralleled in human in vitro studies (51;52;54). 
To integrate all the information on distinct signals required for Breg cell activation 
and development, several working models have been put forward: Mizoguchi and 
Bhan have suggested that more than one Breg cell subset exists, with different 
subsets requiring different activation signals. Innate type Breg cells are induced by 
TLR ligands while adaptive type Breg cells are induced by CD40 and (self) antigens 
that trigger BCRs (55). Instead, Fillatreau, Gray and coworkers have proposed 
that during autoimmunity, all activated B cells can become suppressors and 
that these B cell suppressive functions are acquired during a stepwise activation 
process initiated by TLR ligands followed by BCR and CD40 reinforcement (56). 
Alternatively, Tedder and coworkers have suggested a model in which immature 
progenitors cells progress into mature B10 cells following ligation by TLRs and 
CD40 (57). 
 Most studies investigating the presence and function of Breg cells 
following TLR stimulation limit their analysis to IL-10 as the major anti-
inflammatory and effector cytokine of Breg cells. However, it is often neglected 
that, next to IL-10, TLR ligation can simultaneously contribute to the development 
of inflammatory responses (58;59). For example, CpG, although a strong IL-10 
inducer, it also results in strong B cell activation, proliferation, immunoglobulin 
production and expression of pro-inflammatory cytokines such as IL-1α, IL-1β, 
IL-6 and TNF-α (60-62). Indeed, elevated numbers of IL-6-producing B cells were 
observed in MS patients after in vitro ligation with CD40 and B-cell receptor with 
CpG, which was demonstrated to have a pathogenic role in the development of 
chronic experimental autoimmune encephalomyelitis in mice (34). Because of 
Figure 1. Signals for Breg cell development. Helminth antigens support Breg cell development either 
directly via TLRs and/or BCR-crosslinking plus CD40 ligation or indirectly via BAFF, produced by stromal 
cells or local APC. Typical mouse Breg cell markers are CD1dhi, CD5, CD21 and/or CD23. Typical human Breg 




the recent interest to study the TLR-induced generation of Breg cells, it is crucial 
to investigate both pro- and anti-inflammatory cytokine responses when studying 
the role of TLR ligands as promoting adjuvant for Breg cells, and to consider 
species-related differences when extrapolation findings from disease models to 
human conditions, as described in Chapter 4.
Signals from helminth antigens – TLR, BCR and CD40 ligation
How can this information be applied to helminth-induced Breg cell activation and 
development (Fig. 1)? Several reports have suggested that S. mansoni eggs and 
adult worm antigens contain TLR ligands: lacto-N-fucopentaose-III (LNFPIII), a 
milk-derived sugar similar to those found on soluble egg antigens (SEA) interacts 
with TLR4, at least on DCs, and stimulates splenic B cells to produce IL-10 (63). 
Furthermore, lysophosphatidylserine, a lipid derived from soluble S. mansoni 
worm antigens ligated TLR2 on human monocyte-derived DCs and promoted 
Treg cell activity (64). Moreover, it was demonstrated that soluble egg antigen 
(SEA) could modify immune responses by both human B cells and DCs via TLR2 
(65). More evidence for the involvement of TLR signaling in microbial-induced 
Breg cell development comes from reports describing non-parasitic infections: 
B-cell ligation by TLR2 ligands from Helicobacter species suppressed Helicobacter-
induced immunopathology by inducing Treg cells (66). MyD88-signaling in B 
cells suppressed protective immunity during Salmonella typhimurium infections 
via IL-10 affecting neutrophils, natural killer cells and effector T cells (9). Lastly, 
Amu et al. showed that in vitro exposure of splenic B cells to live schistosome 
worms induced functional IL-10-producing Breg cells (5), supporting the notion 
that direct interactions between helminth molecules and B cells may be involved 
in the induction of Breg cells. However, in this study the involvement of TLR 
signaling was not assessed. Because peritoneal injection of schistosome egg-
derived glycans or filarial glycoproteins also induces IL-10-producing B cells 
(5;67), the exact helminth-derived molecules involved in enhancing the activity 
of Breg cells in protection against AAI might be a shared molecule present on 
both worms and deposited eggs. Therefore, further studies need to be done 
to identify the (nature of) helminth antigens and the molecular details of their 
interaction with the immune system, answering the question whether different 
B cell subsets can be stimulated, depending on the stimuli (helminth molecules), 
to secrete IL-10. In addition, a possible role for CD40 ligation either alone or 
with BCR triggering, to mediate helminth-induced Breg cell development needs 
to be clarified. Importantly, as indicated in Chapter 4, ligation of TLRs on the 
surface of B cells and interaction with T cells via CD40-CD40L interaction can even 
generate an amplifying signal for B-cell IL-10 production. Due to the dual role of 
TLR ligands, namely promoting as well as restraining inflammation, it would be 
interesting to study whether micro-environmental changes could reprogram Breg 
to inflammatory B cells and induce pro-inflammatory cytokine release or vice 
versa. This would also provide insight in the stability or flexibility of the various 
cytokine producing B cell phenotypes.
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Signals from helminth – soluble factors
Interestingly, endogenous apoptotic cells (68) or soluble factors, such as B cell-
activating factor (BAFF) (69) may also provide signals for Breg cell activation (Fig. 
1). BAFF induced IL-10-producing splenic Breg cells in vitro which were mainly 
derived from MZ B cells and had a distinct CD1dhiCD5+ phenotype. In addition, 
intraperitoneal injection of BAFF increased IL-10-producing B cells in the MZ 
areas (69). As BAFF can be produced by local dendritic cells or stromal cells, it 
is possible that both direct effects of helminth-derived antigens on B cells and 
indirect signals, such as helminth infection-induced APC production of BAFF, form 
an important stimulus for the development of Breg cells. As this point of view 
may open a totally new area of research, it is worth noting that a recent study 
by Phythian-Adams et al., in which depletion of CD11c-expressing cells during 
natural schistosome infections, completely abolished infection-induced changes 
in the frequency of MZ B cells, but not other B cell subsets (70). Although these 
findings suggest that splenic CD11c+ cells can strongly affect MZ B cells, it is still 
unclear whether this has any consequences for the induction of IL-10-producing 
(MZ) Breg cells by schistosomes.
 Recently, injections with recombinant IL-33, an innate type 2 cytokine 
(71), protected mice from IBD induction and protection was closely associated 
with the induction of IL-10-producing CD23- B cells in the circulation (72). 
Interestingly, during helminth infections or exposure to allergens also enhanced 
IL-33 levels have been reported in the lungs (73-75). However, whether this IL-33 
response is associated with the induction and/or migration of Breg cells into the 
mucosal tissues and may give rise to pulmonary B cells as described in Chapter 
3 remains to be clarified. Another set of recent studies focused on the role of 
a novel anti-inflammatory cytokine IL-35. Treatment with IL-35 protected mice 
from experimental autoimmune uveitis via the induction of mostly plasma B 
cells producing IL-35 and/or IL-10 (32). Mice in which B cells are deficient for one 
of the subunits of IL-35, i.e. p35 or EBI3, displayed an enhanced APC function, 
suggesting that IL-35 can regulate the APC function of B cells in an autocrine 
fashion (30). It would be interesting to study the role of IL-35-producing plasma/B 
cells in our asthma model and investigate whether these processes contribute to 
the schistosome-induced protection against AAI (Chapter 3).
Application of Breg cells for the treatment of allergy and asthma?
At the moment, treatment of allergic diseases is mostly centered on the alleviation 
of symptoms though the use of drugs such as anti-histamine, glucocorticoids and 
bronchodilators. These treatments are nonspecific, could induce serious side 
effects, and require lifelong applications. Therefore, it is warranted to search for 
other therapies, such as allergen-specific immunotherapy, that can target allergen-
specific cells and have the possibility to induce longer lasting protective immunity. 




Tr1 and FoxP3+ Treg cells together with increased IgG4 and IgA responses and 
simultaneous decreased IgE levels (76). Recently, an increase in IL-10-producing 
allergen-specific B cells was demonstrated in allergic patients receiving allergen-
specific immunotherapy (44). Furthermore, it has become clear from our report 
(Chapter 6) that a part of the Breg cell compartment of patients with allergic 
asthma is impaired in number and activity. Therefore, the restoration of impaired 
Breg function may hold promise as a novel therapeutic strategy. Studies on Breg 
cells described in this thesis, show particularly that IL-10-producing B cells are 
of interest because of their ability to induce/recruit Treg cells, even further 
amplifying regulatory responses, and their capacity to strongly reduce allergic 
airway inflammation, at least in mice (Fig. 2). This emphasizes that targeting for 
regulatory B cells may offer superior immunosuppression when compared to Treg 
alone. However, before therapeutic application can be evaluated in patients a 
number of issues first need to be addressed. Firstly, although most studies have 
mainly studied the potency of Breg cells in preventing onset of disease, there are 
only a few reports that describe the capacity of Breg cells to reverse established 
disease. For example, schistosome-induced CD1dhi B cells could reverse asthma-
like AAI in a mouse model (5), while IL-35-induced B cells could ameliorate 
autoimmune uveitis even when the disease was established (32). Clearly, more 
studies are needed evaluating immunosuppressive B cells for the treatment of 
established diseases. 
 Another open question is whether it is necessary to generate antigen- or 
allergen-specific Breg cells within novel treatment approaches. Applying non-
specific immune suppressive B cells for treatment could lead to undesired side 
effects, such as general immune suppression promoting of tumor progression 
demonstrated in mouse models (77) and might prolong the course of infection 
as shown for chronic salmonella infection and HIV (78-80). Therefore, we 
would argue that the induction of allergen-specific Breg cells is mostly desired, 
if possible. Promising in this respect is a recent study describing an enhanced 
population of bee venom allergen-specific IL-10-producing Breg cells in patients 
following successful allergen-specific immunotherapy, reaching similar levels as 
found in tolerant beekeepers (44). Interestingly, these IL-10-producing B cells 
later developed into IgG4-producing B cells, a phenomenon that is also highly 
present in helminth-infected individuals. Therefore, it is tempting to suggest 
IL-10-producing B cells induced by helminths may develop into IgG4-producing 
B cells and thereby may contribute to protective mechanisms against allergic 
symptoms. 
 Lastly, it is unclear in this stage what is the best application form of 
helminth-based therapy for the treatment of respiratory diseases. Treatment 
options range from controlled natural infection with certain species of helminths, 
mixtures of helminth-derived products or even with single immunosuppressive 
helminth-derived molecules. However, the identification of the most potent 
immunosuppressive molecules is an elaborative process and may take a long 
time before application is possible in clinical studies. Therefore, several research 
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groups have taken up the approach using Trichuris (T.) suis eggs or Necator 
(N.) americanus larvae as a basis for helminth therapy. Treatment of T. suis 
eggs appeared to be beneficial for the clinical outcome of patients with MS 
or inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis 
(81-83), suggesting that this approach may be successfull in treating these 
specific types of inflammatory diseases. However, since most studies have only 
applied a follow-up time of less than 24 weeks, more studies are needed to 
confirm whether this protection can sustain for a longer period of time. What is 
in contrast to these studies is that clinical trials with T. suis eggs in allergic rhinitis 
or N. americanus larvae in allergic rhinitis, asthma and coeliac disease did not 
show any beneficial effect with respect to clinical symptoms, medication use or 
skin-prick test reactivity (84-89). It remains to be established whether different 
types of helminths, e.g. schistosomes, would be more effective in generating 
protective effects in the treatment of atopic diseases (90). Furthermore, recent 
evidence has suggested that primarily early-life exposure is of most importance 
for the development of the immune system, and treatment at young age might 
be an decisive element in the efficacy of the treatment (91;92). Moreover, the 
development of immunomodulatory effects might take months or even years 
to be established. Currently, long-term treatment or the administration of high 
doses have not been assessed using helminth-based therapy, due to a greater 
risk of developing pathogenic effects. In order to improve the efficacy of the 
treatment but not run into the risk of more severe side-effects, it seems a more 
likely strategy to treat patients with a single parasite-derived molecule or mixture 
Figure 2. Breg cell-induced protection against allergic airway inflammation. In non-infected individuals, 
allergic sensitization leads to allergen-loaded airway DCs, driving polarized Th2 cells (1-3). These Th2 cells 
will subsequently drive the allergic effector cascade in the lung (4a,5a). In helminth-infected individuals, 
steps 1 till 3 are similar. At the same time however, helminth antigens will prime Breg cells (4b) secreting 
IL-10 and suppressing DCs and Th2 cells (5b). In addition, Breg cells will induce/recruit Treg cells(6), further 




of molecules that targets regulatory cells instead. In a murine model of colitis, 
excreted-secreted products from Ankylostoma, Acanthocheilonema vitae, and 
extracts from S. mansoni adult worms improved the clinical score or diminished 
local inflammation, respectively (93;94). The filarial-derived glycoprotein ES-62 
has been shown to improved arthritis in mice, and reduced the production of 
pro-inflammatory cytokines in synovial cells from patients with rheumatoid 
arthritis (95;96). Furthermore, molecules derived from helminths including adult 
worms, eggs, and isolated protein, or extracts were described to suppress airway 
inflammation in a murine model of allergic asthma (97-104). Making full benefit 
from Breg cells actively induced during helminth infection (this thesis), the next 
step in this line of research would be to identify the dominant schistosome 
molecules or pathways driving those Breg cells and explore their beneficial effects 
in allergic patients. 
Concluding remarks 
The underlying mechanisms leading to inflammatory conditions such as 
autoimmune diseases and allergies are diverse and far from being fully 
understood. However, it has become obvious that a balance between effector and 
regulatory functions of different subsets of immune cells is critically important in 
the maintenance of a balanced steady-state condition. Under those conditions, 
Breg cells can be an important player to help to control effector cell activation, by 
releasing immunosuppressive cytokines and inducing target cell apoptosis. The 
broad target cell range of their cytokines allows them to inhibit pro-inflammatory 
functions of both innate immune cells, such as DC and macrophages as well as 
cells of the adaptive immune system, such as effector T cells of both the Th1 
and Th2 lineage. Furthermore, they also further amplify the regulatory arm of 
immune responses by inducing regulatory T cells. Impaired regulatory capacity 
of Breg cells might play a role in the development of inflammatory diseases. 
Uncontrolled effector T and B cell activation can ultimately lead to inflammation 
and tissue damage in various target organs. Correspondingly, several treatments 
demonstrated to be beneficial in autoimmune and allergic diseases seem to affect 
the immune system at the level of B cells by amplifying their regulatory capacity. 
Therefore, adding Breg cells to the spectrum of regulatory cells such tolerogenic 
DCs and Tregs, may be of particular interest to treat a range of diseases. For this, 
helminth infections may be of particular value, as helminths appear to be potent 
inducers of Breg cells. In addition, to further characterization of Breg subtypes 
and their mode of action, it would be important to unravel the mechanisms 
underlying Breg cell induction by helminths, and to identify the helminth-derived 
molecules involved, as this may open novel avenues for the treatment of hyper-
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Afweerreacties in allergisch astma
Het afweersysteem, ook wel het immuunsysteem genoemd, heeft als doel 
mensen te beschermen tegen schadelijke indringers zoals bacteriën, virussen 
en wormen. Het afweersysteem kan worden onderverdeeld in een aspecifiek 
(aangeboren) en adaptief (verworven) deel. Het aspecifiek afweersysteem 
bestaat uit een eerstelijnsafweer van huid en slijmvliezen die een mechanische 
barrière vormen om het binnendringen van ziekteverwekkers tegen te gaan. 
Mocht een ziekteverwekker toch het lichaam binnendringen, dan stuit deze 
op een tweedelijnsafweer die bestaat uit witte bloedcellen. Deze afweercellen 
kunnen ziekteverwekkers opnemen en verteren. Hierna worden de kleine 
stukjes (antigeen) van de indringer gepresenteerd aan witte bloedcellen van het 
adaptieve immuunsysteem, zoals T cellen en B cellen. Het type afweerreactie 
dat geactiveerd wordt, hangt af van de binnendringende ziekteverwekker. 
Zo ontwikkelen T cellen zich tot T helper (Th) 1 cellen tijdens virale infecties 
en worden juist Th2 cellen gevormd tijdens worminfecties. De belangrijkste 
functie van B cellen in het afweersysteem is de productie van antistoffen, ook 
wel immuunglobulinen genoemd. Deze antistoffen herkennen heel specifiek een 
bepaald antigeen afkomstig van een ziekteverwekker en zullen vervolgens na 
binding aan het antigeen een reactie starten die uiteindelijk leidt tot de opruiming 
van deze ziekteverwekker. Aangezien dit soort afweerreacties ontstekingen 
bevorderen, kan het ook schade aanrichten aan de omliggende weefsels. Een 
goed functionerend afweersysteem zal er naar streven om de schade aan het 
lichaam zelf, als gevolg van heftige afweerreacties, in zekere mate af te remmen. 
Deze tak van het afweersysteem wordt het ‘regulatoire afweersysteem’ genoemd 
en bestaat uit verschillende regulatoire witte bloedcellen die signaalstoffen 
uitscheiden en zorgen voor tolerantie. 
 Als de verschillende componenten van het afweersysteem uit balans zijn, 
worden afweerreacties tegen een onschuldig antigeen of een antigeen afkomstig 
van het eigen lichaam niet afgeremd en kunnen ontstekingsziekten ontstaan 
zoals allergieën en auto-immuunziekten. Allergie is een complexe ziekte die 
wordt veroorzaakt door een combinatie van erfelijke aanleg die iemand heeft 
om allergie te ontwikkelen en omgevingsfactoren. Voorbeelden van allergische 
ziekten zijn eczeem, hooikoorts en astma. In dit proefschrift richten we ons op 
allergisch astma. Allergisch astma is een chronische longaandoening die ontstaat 
doordat het afweersysteem een hevige Th2-specifieke reactie ontketent tegen 
ingeademde onschuldige stoffen zoals huisstofmijtdeeltjes, kattenhuidschilfers 
of boom- en graspollen, terwijl gezonde mensen daar niet of nauwelijks op 
reageren. Deze onschuldige stoffen worden allergenen genoemd. Tijdens een 
Th2 afweerreactie komen mediatoren, zoals histamine vrij die zorgen dat de 
gladde spiercellen van de luchtwegen samentrekken en de bloedvaten zich 
verwijden. Verder zorgt een verhoogde slijmproductie en activatie van andere 
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ontstekingscellen voor irritatie van het weefsel en vernauwing van de luchtwegen. 
Als gevolg treedt er weefselschade op waardoor de luchtwegwand stugger wordt 
en de spierlaag verdikt. Dit leidt uiteindelijk tot symptomen zoals benauwdheid, 
kortademigheid, hoesten en piepende ademhaling in astmapatiënten. Tot op 
heden is astma niet te genezen, wel te onderdrukken met luchtwegverwijdende 
en ontstekingsremmende medicatie. 
Parasitaire wormen beschermen tegen allergie
In de afgelopen decennia, vooral vanaf begin jaren ’70, zijn allergisch ziekten bij 
kinderen sterk toegenomen in de geïndustrialiseerde landen. Deze bevinding kon 
niet verklaard worden vanuit een verandering in erfelijke aanleg, maar leidden tot 
de zogenaamde ‘hygiënehypothese’ die een verband trok tussen het elimineren 
van infecties en infectiebronnen door veranderingen in levensstijl en een 
verbeterde hygiëne, en de forse toename van allergieën in de geïndustrialiseerde 
landen. Epidemiologisch onderzoek toonde aan dat in ontwikkelingsgebieden, 
waar veel chronisch worminfecties voorkomen, allergisch aandoeningen veel 
zeldzamer waren en de prevalentie in de afgelopen decennia nauwelijks gestegen 
was. Behandeling gericht op de verwijdering van deze worminfecties resulteerde 
juist in een toename van prevalentie van allergieën. Verder bleek dat allergie 
en astma ook minder voorkwam bij kinderen die tijdens hun jeugd opgegroeid 
waren in een omgeving die rijk was aan micro-organismen, zoals bacteriën en 
schimmels. Voorbeelden zijn kinderen die opgroeiden op een boerderij, met 
meerdere broers en zussen, of die regelmatig in een kinderdagverblijf verbleven. 
Dit leidde tot de veronderstelling dat juist de micro-organismen waarmee wij 
tezamen zijn geëvolueerd zoals huid- en darmbacteriën en indringers die chronisch 
in het lichaam verblijven zoals parasitaire wormen, invloed hebben op een 
evenwichtige uitrijping van ons afweersysteem. Door de eliminatie of veranderde 
samenstelling van deze micro-organismen in onze omgeving wordt verondersteld 
dat het regulatoire afweersysteem minder hard hoeft te werken waardoor de 
balans doorslaat naar een ontstekingsbevorderende afweersysteem. Als gevolg 
hiervan kunnen overdreven ontstekingsreacties ontstaan tegen onschuldige 
stoffen. Uit verschillende onderzoeken is inderdaad gebleken dat bepaalde witte 
bloedcellen van het regulatoire afweersysteem, waaronder de regulatoire T (Treg) 
cellen, verminderd zijn in aantallen in mensen met allergisch aandoeningen en 
auto-immuunziekten.
Regulatoire netwerk tijdens worminfecties
Uit verscheidene muismodellen en humaan onderzoek is aangetoond dat een 
langdurige infectie met parasitaire wormen, zoals met de platworm van het geslacht 
Schistosoma, leidt tot een versterking van het regulatoire immuunsysteem. Men 
veronderstelt dat deze opgewekte onderdrukking van het afweersysteem gunstig 
is voor de worm omdat het de wormen beschermt tegen uitroeiing, maar ook 
gunstig voor de geïnfecteerde gastheer omdat die dan beschermd wordt tegen al 




zou naast de worm-specifieke afweer, ook tegelijkertijd reacties tegen andere 
moleculen, zoals allergenen, kunnen worden onderdrukt. Een belangrijke en 
centrale speler in het door wormen opgewekte regulatoire afweersysteem bleek 
het ontstekingsremmende signaalmolecuul interleukine-10 (IL-10) te zijn dat 
onder anderen geproduceerd wordt door T cellen. Tevens werden tijdens infectie 
meer Treg cellen aangemaakt die met behulp van signaalstoffen, maar ook via 
directe interactie met andere afweercellen, de sterkte van een opkomende 
immuunrespons verder konden matigen. 
 Muismodellen van auto-immuunziekten toonden aan dat naast T of Treg 
cellen, ook B cellen een belangrijke bron van IL-10 konden zijn. B cellen staan 
eigenlijk meer bekend om hun versterkende functie binnen afweerreacties, maar 
onderzoek heeft aangetoond dat B cellen wel degelijk ook een regulerende en 
onderdrukkende functie kunnen hebben. Zij doen dit door de productie van 
veel IL-10 en deze cellen worden dan ook regulatoire B (Breg) cellen genoemd. 
Al snel werd duidelijk dat Breg cellen naast de productie van IL-10 ook op 
andere manieren deze rol kon uitoefenen, bijvoorbeeld door de productie van 
ontstekingsremmende signaalmolecuul TGF-β en/of het remmen van celdeling 
en signaalstofproductie van Th cellen. Verder kunnen Breg cellen het regulatoire 
netwerk versterken door het opwekken van meer Treg cellen. In muizen zijn 
verscheidene Breg celpopulaties aangetoond die gekenmerkt worden door 
hoge expressie van moleculen op het oppervlakte zoals CD1d, CD5 en/of CD23 
en die zich voornamelijk in de milt, buikholte en in de lymfeklieren bevinden. 
Onlangs zijn er in het bloed van mensen ook verschillende IL-10 producerende 
Breg celpopulaties geconstateerd. Tevens is aangetoond dat bepaalde Breg 
celpopulaties in patiënten met auto-immune ziekten verminderd zijn in aantallen 
en/of activiteit in vergelijking met Breg cellen van gezonde mensen. In analogie 
met hun rol in bescherming tegen auto-immuniteit, is er wellicht ook een functie 
voor Breg cellen weggelegd in de bescherming tegen allergische astma tijdens 
chronische worminfecties. 
Onderzoek beschreven in dit proefschrift
Het doel van het onderzoek beschreven in dit proefschrift is om beter inzicht 
te krijgen hoe chronische worminfecties bescherming kunnen bieden tegen 
allergisch astma en wat de rol van regulatoire B cellen hierin is. In Hoofdstuk 2 
hebben wij gebruik gemaakt van een gecombineerd muizenmodel voor astma 
en de parasitaire worm Schistosoma (S.) mansoni. Experimenten toonden aan 
dat ook in de longen van muizen een verminderde allergische ontstekingsreactie 
plaats vond tijdens een chronische worminfectie. Met behulp van muizen die 
geen IL-10 producerende B cellen konden aanmaken, bleek dat de aanwezigheid 
van IL-10 producerende B cellen essentieel was voor bescherming tegen allergie 
tijdens infectie. Wanneer B cellen van worm-geïnfecteerde dieren afkomstig van 
de milt of de longen werden overgebracht naar allergische ontvangstmuizen, 
resulteerde dit in bescherming tegen allergisch astma. Vervolgens werd het 
mechanisme waarmee deze B cellen bescherming boden onderzocht. B cellen uit 
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de milt beschermden tegen allergisch astma via IL-10 productie en de aanmaak 
van Treg cellen in de longen. Daarentegen, experimenten met beschermende B 
cellen uit de longen toonden aan dat ze ontsteking onderdrukten onafhankelijk 
van IL-10 of Treg cellen. Verder onderzoek liet zien dat de verantwoordelijke 
Breg celpopulatie in de milt gekenmerkt werd door de expressie van moleculen 
CD21+CD23-CD1d++, dat sterk overeenkomt met de marginale zone B celpopulatie. 
Om een beter beeld te krijgen of Schistosoma infecties in mensen ook Breg cellen 
aanmaken, hebben we een veldstudie uitgevoerd in Gabon (centraal Afrika), waar 
S. haematobium infecties endemisch voorkomt. In het bloed van schoolkinderen 
met worminfecties werden verhoogde aantallen IL-10 producerende B cellen 
met een hoge CD1d expressie gevonden in vergelijking met niet-geïnfecteerde 
kinderen. Na een behandeling tegen worminfecties daalden het aantal IL-10 
producerende B cellen weer naar aantallen die ook in niet-geïnfecteerde kinderen 
waren aangetoond. Hiermee hebben we een directe relatie tussen Schistosoma 
en Breg celaanmaak aangetoond zowel in de muis als in de mens. 
 In Hoofdstuk 3 hebben wij de beschermende functie van de B cellen uit 
de longen verder onderzocht. De B cellen uit de longen bleken geen kenmerken 
of functies te delen die tot nu toe aan Breg cellen waren toegekend. In celkweken 
met T cellen bleek dat B cellen uit geïnfecteerde dieren een verminderde capaciteit 
hadden om T celdeling en Th2 cellen aan te maken in vergelijking met B cellen 
uit allergische controle dieren. Dit suggereert dat B cellen via dit mechanisme 
zou kunnen bijdragen aan de bescherming tegen allergisch ontsteking tijdens 
een worminfectie. Het is nog onduidelijk via welk mechanisme de B cellen uit de 
longen dit bewerkstelligen en hiervoor is nog verder onderzoek nodig.  
 Met oog op een eventuele therapeutische toepassing van Breg cellen 
in de bescherming of genezing van allergische aandoeningen, is het belangrijk 
om te identificeren onder invloed van welke prikkels de Breg cellen worden 
geactiveerd of aangemaakt. Wormmoleculen of andere moleculaire structuren 
van micro-organismen kunnen herkend worden door receptoren, waarvan de 
“Toll-like” receptoren (TLR) een van de meest bekende receptoren zijn. Naast 
de ontstekingsreactie die opgewekt wordt na TLR herkenning, wordt de laatste 
jaren ook onderzoek gedaan naar de ontstekingsremmende reacties van TLR. Uit 
onderzoek blijkt dat activatie van B cellen via bepaalde TLR receptoren leidt tot het 
aanmaken of activeren van Breg cellen. Daarom hebben wij in Hoofdstuk 4 in detail 
beschreven hoe B cellen afkomstig van mens of muis in reactie op verschillende 
TLR receptoren geanalyseerd en gevalideerd kunnen worden in kweekmodellen. 
Het is belangrijk om verschillende kweekmodellen te gebruiken om te bepalen of 
de gestimuleerde B cellen wel ontstekingsremmende signaalstoffen maken en of 
de cellen zich wel gedragen als functionele Breg cellen.  
 Met behulp van de informatie uit de voorgaande hoofdstukken wilden 
we bestuderen of het verhoogde aantal IL-10 producerende B cellen in mensen 
met S. haematobium infecties ook een functionele invloed had op T cellen 
(Hoofdstuk 5). In Gabon werd het bloed van jonge volwassenen met en zonder 




bleken geïnfecteerde personen meer B cellen te hebben die IL-10, maar ook 
TGF-β tot expressie brachten in vergelijking met B cellen van niet-geïnfecteerde 
personen. De celpopulatie CD1d++ B cellen bleek verantwoordelijk te zijn voor 
meer IL-10 expressie, terwijl een andere celpopulatie, de CD24++CD27+ B cellen, 
meer TGF-β op hun oppervlakte lieten zien tijdens infectie. Vervolgens hebben 
we onderzocht wat het effect was van deze verschillende Breg celpopulaties 
op de functie van T cellen. B cellen van geïnfecteerde donoren remden het 
uitscheiden van signaalstoffen door T cellen in vergelijking met B cellen van niet-
geïnfecteerde donoren. Bovendien bleken de B cellen meer Treg cellen en IL-10 
producerende T cellen te kunnen opwekken. Wanneer wij de CD1d++ populatie 
uit de totale B cel pool verwijderden, werd het percentage IL-10 producerende T 
cellen weer vergelijkbaar met die van mensen zonder infectie terwijl nog steeds 
verhoogde aantallen Treg cellen werden opgewekt. Dit betekent dat CD1d++ Breg 
cellen belangrijk zijn voor het versterken van het regulatoire afweersysteem door 
het vermeerderen van het aantal IL-10 producerende T cellen, terwijl een andere, 
nog onbekende Breg celpopulatie meer Treg cellen weet op te wekken. 
 Ten slotte is bestudeerd of de frequentie van regulatoire B cellen en 
de aanmaak van IL-10 afwijkt in patiënten met allergisch astma in vergelijking 
met gezonde individuen (Hoofdstuk 6). Wij vonden dat juist de CD24++CD27+ B 
cellen verminderd waren in aantal en in hun capaciteit om IL-10 te maken na 
blootstelling aan TLR-4 ligand LPS. Vervolgens bleek de vermindering in IL-10 
producerende B cellen te leiden tot een functioneel defect in geheugen T cellen 
in de aanwezigheid van huisstofmijt allergenen: de T cellen maakten namelijk 
minder IL-10. Deze data impliceren dat een verminderde productie van IL-10 door 
B cellen, vooral de CD24++CD27+ populatie, kan leiden tot een verzwakte IL-10 
productie in T cellen. Een verzwakte Breg celfunctie zou daardoor een mogelijk 
bijdrage kunnen leveren aan een verzwakte onderdrukking van overdreven 
allergische reacties zoals die in allergisch astma patiënten gevonden worden. 
Conclusie
Het onderzoek beschreven in dit proefschrift heeft geleid tot een beter begrip hoe 
wormen het afweersysteem beïnvloeden en hoe zij via een verhoogde aanmaak 
van Breg cellen bescherming kunnen bieden tegen de ontwikkeling van astma in 
muizen. Momenteel bestaat er nog geen afdoende therapie voor allergisch astma. 
Wel is duidelijk dat verschillende witte bloedcellen die deel uitmaken van het 
ontstekingsremmende deel van het afweersysteem, waaronder de Breg cellen, 
verminderd voorkomen en hun functie verzwakt is in patiënten met allergische 
astma. Een nieuwe therapeutische strategie gericht op het versterken van het 
regulatoire deel van het afweersysteem via Breg cellen zou hoopgevend kunnen 
zijn om allergieën en astma te genezen of te voorkomen (Hoofdstuk 7). Daarom 
is het belangrijk om verder onderzoek te verrichten naar moleculen van wormen 
of signaaltransductieroutes die specifiek Breg cellen kunnen vermeerderen 
of activeren om zo een centrale plaats te kunnen innemen in een toekomstige 
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